

EU

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06274 A1

(51) International Patent Classification⁷: C07D 401/12,
211/58, 401/14, 417/14, A61P 3/10, 13/00, 13/00, 29/00,
A61K 31/4545

(21) International Application Number: PCT/US01/22379

(22) International Filing Date: 16 July 2001 (16.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/218,589 17 July 2000 (17.07.2000) US

(71) Applicant: AMERICAN HOME PRODUCTS COR-
PORATION [US/US]; Five Giralda Farms, Madsion, NJ
07940-0874 (US).

(72) Inventors: SUM, Fuk-Wah; 16 Chamberlain Court,
Pomona, NY 10970 (US). MALAMAS, Michael,
Sotirios; 2443 Oleander Circle, Jamison, PA 18929 (US).

(74) Agents: ECK, Steven, R.; American Home Products
Corporation, Patent Law Department, Five Giralda Farms,
Madison, NJ 07940 et al. (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS



(57) Abstract: The invention provides compounds of Formula I having the structure (I), wherein R₁, R₂, R₃, R₄, W, X, and Y are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

WO 02/06274 A1

**N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES
AS BETA-3 ADRENERGIC RECEPTOR AGONISTS**

This invention relates to N-(4-sulfonylaryl)cyclylamine 2-hydroxyethylamine derivatives which are β_3 adrenergic receptor agonists useful for the treatment of metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension, and frequent urination, and are particularly useful in the treatment or inhibition of type II diabetes.

The subdivision of β adrenergic receptors (β -AR) into β_1 - and β_2 -AR has led to the development of β_1 - and β_2 - antagonists and/or agonists which have been useful for the treatment of cardiovascular disease and asthma. The recent discovery of "atypical" receptors, later called β_3 -AR, has led to the development of β_3 -AR agonists which may be potentially useful as antiobesity and antidiabetic agents. For recent reviews on β_3 -AR agonists, see: 1. A. D. Strosberg, *Annu. Rev. Pharmacol. Toxicol.* **1997**, *37*, 421; 2. A. E. Weber, *Ann. Rep. Med. Chem.* **1998**, *33*, 193; 3. C. P. Kordik and A. B. Reitz, *J. Med. Chem.* **1999**, *42*, 181; 4. C. Weyer, J. F. Gautier and E. Danforth, *Diabetes and Metabolism*, **1999**, *25*, 11.

Compounds that are potent and selective β_3 agonists, may be potentially useful antiobesity agents. Low levels or lack of β_1 and β_2 -agonistic properties will minimize or eliminate the adverse side effects that are associated with β_1 and β_2 agonistic activities, i.e. increased heart rate, and muscle tremor, respectively.

Early developments in the β_3 -agonist field are described in European patent 427480, US patents 4396627, 4478849, 4999377, 5153210. Although the early developments purport to claim compounds with greater β_3 -AR selectivity over the β_1 - and β_2 -AR. However, clinical trials in humans with those early developed β_3 -agonists have, so far, not been successful.

More recently, potent and selective human β_3 agonists have been described in several patents and published applications: WO 98/32753, WO 97/46556, WO 97/37646,

WO 97/15549, WO 97/25311, WO 96/16938, WO 95/29159, European Patents 659737, 801060, 714883, 764640, 827746, and US Patents 5561142, 5705515, 5436257, and 5578620. These compounds were evaluated in Chinese hamster ovary (CHO) cells test procedures, expressing cloned human β_3 receptors, which predict the effects that can be expected in humans (Granneman et al., *Mol Pharmacol.*, 1992, 42, 964; Emorine et al., *Science*, 1989, 245, 1118; Liggett *Mol. Pharmacol.*, 1992, 42, 634).

β_3 -Adrenergic agonists also are useful in controlling the frequent urge of urination. It has been known that relaxation of the bladder detrusor is under beta adrenergic control (LI JH, Yasay GD and Kau ST *Pharmacology* 1992; 44: 13-18). Beta-adrenoceptor subtypes are in the detrusor of guinea-pig urinary bladder. Recently, a number of laboratories have provided experimental evidence of β_3 adrenergic receptors in a number of animal species including human (Yamazaki Y, Takeda H, Akahane M, Igawa Y, et al. *Br. J. Pharmacol.* 1998; 124: 593-599), and that activation of the β_3 receptor subtype by norepinephrine is responsible for relaxation of the urinary bladder.

Urge urinary incontinence is characterized by abnormal spontaneous bladder contractions that can be unrelated to bladder urine volume. Urge urinary incontinence is often referred to hyperactive or unstable bladder. Several etiologies exist and fall into two major categories, myogenic and neurogenic. The myogenic bladder is usually associated with detrusor hypertrophy secondary to bladder outlet obstruction, or with chronic urinary tract infection. Neurogenic bladders are associated with an uninhibited micturition reflex. An upper motor neuron disease is usually the underlying cause. In either case, the disease is characterized by abnormal spontaneous contractions that result in an abnormal sense of urinary urgency and involuntary urine loss. At present, the most common therapy for hyperactive bladder includes the use of antimuscarinic agents to block the action of the excitatory neurotransmitter acetylcholine. While effective in neurogenic bladders, their utility in myogenic bladders is questionable. In addition, due to severe dry mouth side-effects associated with antimuscarinic therapy, the patient compliance with these agents is only approximately 30%.

In the bladder, β_3 adrenergic receptor agonists activate adenylyl cyclase and generate cAMP through the G-protein coupled β_3 receptor. The resulting phosphorylation of phospholamban/calcium ATPase enhances uptake of calcium into the


sarcoplasmic reticulum. The decrease in intracellular calcium inhibits bladder smooth muscle contractility.

It is suggested therefore, that activation of the β_3 adrenergic receptor in the urinary bladder will inhibit abnormal spontaneous bladder contractions and be useful for the treatment of bladder hyperactivity. Note, that unlike the antimuscarinics, β_3 adrenergic receptor agonists would be expected to be active against both neurogenic and myogenic etiologies.

Despite all these recent developments there is still no single therapy available for the treatment of type II diabetes (NIDDM), obesity, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, frequent urination and related diseases. A potent and selective β_3 adrenergic receptor agonist is therefore highly desirable for the potential treatment of such disease states.

DESCRIPTION OF THE INVENTION

This invention provides compounds of Formula I having the structure



wherein:

W is $(CH_2)_m$;

X is $(CH_2)_n$;

Y is OCH_2 , SCH_2 , or a bond;

R_1 is phenyl substituted with R_5 and R_6 , or Het substituted with R_5 and R_6 ;

R_2 is hydrogen, trifluoromethyl, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, or alkynyl of 2-7 carbon atoms;

R_4 is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, hydroxy, aryl substituted with R_5 and R_6 , Het substituted with R_5 and R_6 , aryloxy, $-NHCOR_7$, $-NR_8R_8$, $-CR_3R_5R_6$, arylamino, Het-amino, arylalkylamino having 1-6 carbon atoms in the alkyl chain,

Het-alkylamino having 1-6 carbon atoms in the alkyl chain, alkoxycarbonylalkyl of 3-13 carbon atoms, carboxyalkyl of 2-7 carbon atoms, alkylcarbonylalkyl of 3-13 carbon atoms, arylcarbonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-carbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminocarbonylalkyl of 2-7 carbon atoms, alkylaminocarbonylalkyl of 3-13 carbon atoms, arylaminocarbonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-aminocarbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminosulfonylalkyl of 1-6 carbon atoms, alkylsulfonylalkyl of 2-12 carbon atoms, arylsulfonylalkyl having 1-6 carbon atoms in the alkyl chain, alkylaminosulfonylalkyl of 2-12 carbon atoms, arylaminosulfonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-aminosulfonylalkyl having 1-6 carbon atoms in the alkyl chain, phosphonylalkyl of 1-6 carbon atoms, or phosphorylalkyl of 1-6 carbon atoms;

R₃, R₅, and R₆, are each, independently, hydrogen, trifluoromethyl, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl, Het, arylalkyl having 1-6 carbon atoms in the alkyl chain, Het-alkyl having 1-6 carbon atoms in the alkyl chain, halogen, cyano, nitro, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy, arylalkyloxy having 1-6 carbon atoms in the alkyl chain, alkylthio 1-6 carbon atoms, arylthio, arylamino, Het-amino, arylalkylamino of 1-6 carbons in the alkyl chain, Het-alkylamino having 1-6 carbon atoms in the alkyl chain, hydroxyamino, -NHCOR₇, -NH₂SO₂R₇, -NHP(O)(R₇)₂, -COR₈, -SO₂R₈, -NR₈R₈, carboxy, alkylcarbonyl of 2-7 carbon atoms, formyl-alkyl of 2-7 carbon atoms, phosphoryl, alkoxycarbonylalkyl of 3-13 carbon atoms, carboxyalkyl of 2-7 carbon atoms, alkylcarbonylalkyl of 2-13 carbon atoms, arylcarbonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-carbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminocarbonylalkyl of 2-7 carbon atoms, alkylaminocarbonylalkyl of 3-13 carbon atoms, arylaminocarbonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-aminocarbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminosulfonylalkyl of 1-6 carbon atoms, alkylsulfonylalkyl of 2-12 carbon atoms, arylsulfonylalkyl having 1-6 carbon atoms in the alkyl chain, alkylaminosulfonylalkyl of 2-12 carbon atoms, arylaminosulfonylalkyl of 1-6 carbon atoms, Het-aminosulfonylalkyl of 1-6 carbon atoms, phosphonylalkyl of 1-6 carbon atoms, or phosphorylalkyl of 1-6 carbon atoms; or R₅ and R₆ may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R₅ and R₆ are attached to a common carbon atom;

R₇ is hydrogen, trifluoromethyl, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, aryl, alkoxy of 1-6 carbon atoms, -NR₈R₉, or -NR₉(CH₂)_p-R₈

5 R₈ is hydrogen, alkoxy of 1-6 carbon atoms, alkyl of 1-6 carbon atoms, hydroxy, aryl substituted with R₅ and R₆, arylalkoxy having 1-6 carbon atoms in the alkyl chain, -CR₃R₅R₆, -(CH₂)_p-COR₉, or -(CH₂)_p-R₉;

R₉ is hydrogen, hydroxy, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, alkoxy of 1-6 carbon atoms, aryl substituted with R₅ and R₆, Het substituted with R₅ and R₆, arylalkoxy having 1-6 carbon atoms in the alkyl chain, or -NR₁₀R₁₀;

10 R₁₀ is hydrogen, alkyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, hydroxy, aryl substituted with R₅ and R₆, or Het substituted with R₅ and R₆;

Het is a monocyclic or bicyclic heterocycle of 5-10 ring atoms, having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur; wherein the heterocycle may be saturated, unsaturated, or partially unsaturated; and may be optionally fused to a phenyl ring; wherein one or more of the ring carbon atoms of Het may be a carbonyl moiety, where the ring does not contain a double bond in the position corresponding to that carbon atom;

m is 1-3;

n is 1-3;

20 p is 0-6;

or a pharmaceutically acceptable salt thereof, which are selective agonists at human β_3 adrenergic receptors and are useful as antidiabetic, antihyperglycemic, and antiobesity agents.

25 Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic, camphor-sulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety. Salts may also be formed from organic and inorganic bases, such as alkali metal salts (for example, sodium, lithium, or potassium) alkaline earth metal salts, ammonium salts, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, and trialkyl-

ammonium salts containing 1-6 carbon atoms in each alkyl group, when a compound of this invention contains an acidic moiety.

Alkyl as a group or part of a group includes both straight chain as well as
5 branched moieties, eg alkyl of 1-6 carbon atoms such as methyl, ethyl propyl and butyl. By definition alkyl also includes alkyl moieties which are optionally mono- or poly substituted with groups such as halogen, hydroxy, cyano, alkoxy, aryloxy, arylalkyl, alkylthio, arylthio, amino, alkylamino, and dialkylamino. Aryl as a group or part of a group means carbocyclic aromatic ring systems of 6-10 carbon atoms. Halogen means
10 bromine, chlorine, fluorine, and iodine. Where a substituent contains one or more moieties which have the same designation (i.e., -NR₈R₈), each of the moieties can be the same or different.

Preferred aryl moieties include phenyl or naphthyl. Preferred Het moieties
15 include: (a) 6-membered saturated, partially unsaturated, or unsaturated heterocycles containing 1-2 nitrogens, optionally fused to a phenyl ring; (b) 5-membered saturated, partially saturated, or unsaturated heterocycles containing 1-3 nitrogen, oxygen, or sulfur atoms, optionally fused to a phenyl ring; (c) saturated, partially unsaturated, or unsaturated bicyclic heterocycles containing 1-4 nitrogen, oxygen, or sulfur atoms; (d)
20 carbazole, dibenzofuran, and dibenzothiophene. In the Het of categories (a), (b), and (c), ring carbon atoms may be carbonyl moieties, where the ring does not contain a double bond in that position (for example, thiazolidine-2,4-dione).

More preferred Het rings include pyridine, pyrimidine, furan, imidazolyl, thiazole,
25 oxazole, isoxazole, pyrazole, triazole, tetrazole, carbazole, pyrrole, thiophene, imidazole, imidazol-2-one, imidazole-2-thione, imidazolidine-2,4-dione, pyrazoline, triazole, tetrazole, oxazolone, oxadiazole, imidazolone, thiazole, thiazolone, thiadiazole, thiadiazolone, thiazolidine-2,4-dione, pyridine, pyrimidine, piperazine, pyrazine, pyrrolidine, piperidine, morpholine, benzofuran, dibenzofuran, dibenzothiophene, iso-
30 benzofuran, indole, isoindole, benzothiophene, 1,3-dihydrobenzoimidazol-2-one, benzo-[1,2,5]thiadoazole, 2-oxo-2,3-dihydro-1H-benzoimidazole, quinoline and isoquinoline. Particularly preferred Het include pyrrolidine, piperazine, piperidine, thiazole, imidazolidine-2,4-dione, carbazole, and 2-oxo-2,3-dihydro-1H-benzoimidazole. It is understood that Het do not contain heteroatoms in arrangements which would make
35 them inherently unstable. For example, the term Het does not include ring systems containing O-O bonds in the ring backbone.

The compounds of the present invention contain at least one asymmetric center. Additional asymmetric centers may exist on the molecule depending upon the structure of the substituents on the molecule. The compounds may be prepared as a racemic mixture and can be used as such, or may be resolved into the individual isomers. In addition to covering the racemic compounds, this invention also covers all individual isomers, enantiomers, diastereomers or mixtures thereof, regardless of whether the structural representations of the compounds indicate such stereochemistry.

10 R_2 may be for example hydrogen.

R_3 may be hydrogen or COR_8 , preferably R_3 is hydrogen.

An example of m is 2.

An example of n is 2.

R_4 may be aryl substituted with R_5 and R_6 , Het substituted with R_5 and R_6 , $-NHCOR_7$,

15 $-NR_8R_9$, or $-CR_3R_5R_6$.

R_5 , and R_6 may be each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, alkoxy of 1-6 carbon atoms, arylalkoxy having 1-6 carbon atoms in the alkyl chain, $-COR_8$, alkoxy carbonylalkyl of 3-13 carbon atoms, or carboxyalkyl of 2-7 carbon atoms, or R_5 and R_6 may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R_5 and R_6 are attached to a common carbon atom.

R_7 may be NR_8R_9 .

R_8 may be hydrogen, alkoxy of 1-6 carbon atoms, alkyl of 1-6 carbon atoms, hydroxy, aryl substituted with R_5 and R_6 , arylalkoxy having 1-6 carbon atoms in the alkyl chain, $-CR_3R_5R_6$, $-(CH_2)_p-COR_9$, or $-(CH_2)_p-R_9$;

25

R_9 may be hydroxy, alkoxy of 1-6 carbon atoms, aryl substituted with R_5 and R_6 , or arylalkoxy having 1-6 carbon atoms in the alkyl chain.

30 Preferred compounds of Formula I are those having one or more (eg all) of the following values:

R_2 is hydrogen;

R₄ is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl substituted with R₅ and R₆, Het substituted with R₅ and R₆, -NHCOR₇, -NR₈R₈, or -CR₃R₅R₆;

5 R₃, R₅, and R₆ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, hydroxy, alkoxy of 1-6 carbon atoms, arylalkoxy having 1-6 carbon atoms in the alkyl chain, hydroxyamino, arylalkyl having 1-6 carbon atoms in the alkyl chain, Het-alkyl having 1-6 carbon atoms in the alkyl chain, -NHCOR₇, -NHSO₂R₇, -NR₈R₈, -COR₈, formylalkyl of 2-7 carbon atoms, alkoxycarbonylalkyl of 3-13 carbon atoms, or carboxyalkyl of 2-7 carbon atoms, or R₅ and R₆ may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R₅ and R₆ are attached to a common carbon atom;

15 Het is (a) a 6-membered saturated, partially unsaturated, or unsaturated heterocycle containing 1-2 nitrogens, optionally fused to a phenyl ring; (b) a 5-membered saturated, partially saturated, or unsaturated heterocycle containing 1-3 nitrogen, oxygen, or sulfur atoms, optionally fused to a phenyl ring; (c) a saturated, partially unsaturated, or unsaturated bicyclic heterocycle containing 1-4 nitrogen, oxygen, or sulfur atoms; (d) carbazole, dibenzofuran, and dibenzothiophene; wherein one or more of the ring carbon atoms of Het as described in (a), (b), or (c) may be a carbonyl moiety, where the ring does not contain a double bond in the position corresponding to that carbon atom;

20 or a pharmaceutically acceptable salt thereof.

25 More preferred compounds of Formula I are those having one or more (eg all) of the following values:

Y is OCH₂ or a bond;

R₂ is hydrogen;

R₄ is aryl substituted with R₅ and R₆, Het substituted with R₅ and R₆, -NHCOR₇, -NR₈R₈, or -CR₃R₅R₆;

30 R₃, R₅, and R₆ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, hydroxy, alkoxy of 1-6 carbon atoms, arylalkoxy having 1-6 carbon atoms in the alkyl chain, hydroxyamino, -NHSO₂R₇, -NR₈R₈, -COR₈, formylalkyl of 2-7 carbon atoms,

alkoxycarbonylalkyl of 3-13 carbon atoms, or carboxyalkyl of 2-7 carbon atoms, or R₅ and R₆ may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R₅ and R₆ are attached to a common carbon atom;

5 Het is pyridine, pyrimidine, furan, imidazolyl, thiazole, oxazole, isoxazole, pyrazole, triazole, tetrazole, carbazole, pyrrole, thiophene, imidazole, imidazol-2-one, imidazole-2-thione, imidazolidine-2,4-dione, pyrazoline, triazole, tetrazole, oxazolone, oxadiazole, imidazolone, thiazole, thiazolone, thiadiazole, thiadiazol-
 10 one, thiazolidine-2,4-dione, pyridine, pyrimidine, piperazine, pyrazine, pyrrolidine, piperidine, morpholine, benzofuran, dibenzofuran, dibenzothiophene, isobenzofuran, indole, isoindole, benzothiophene, 1,3,-dihydrobenzoimidazol-2-one, benzo[1,2,5]thiadiazole, 2-oxo-2,3-dihydro-1H-benzoimidazole, quinoline, or isoquinoline;

or a pharmaceutically acceptable salt thereof.

15

Specifically preferred compounds of this invention are:

- a) N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-{4-[2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- b) N-Benzyl-N-butyl-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide ;
- 20 c) N-Benzyl-N-butyl-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- d) N-Benzyl-4-{4-[2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- 25 e) N-Benzyl-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- f) N-Benzyl-4-{4-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- g) N-(3,4-Dimethoxy-phenyl)-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- 30 h) N-(3,4-Dimethoxy-phenyl)-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- i) 4-{4-[(2S)-3-(4-Benzoyloxy-phenoxy)-2-hydroxy-propylamino]-piperidin-1-yl}-N-(3,4-dimethoxy-phenyl)-benzenesulfonamide;

- j) 4-{4-[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxy-propylamino]-piperidin-1-yl}-N-(3,4-dimethoxy-phenyl)-benzenesulfonamide;
- k) N-(3,4-Dimethoxy-phenyl)-4-{4-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propyl-amino]-piperidin-1-yl}-benzenesulfonamide;
- 5 l) N-Butyl-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- m) N-Butyl-4-{4-[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxy-propylamino]piperidin-1-yl}-benzenesulfonamide;
- n) N-Butyl-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonamide;
- 10 o) 1-(4-{4-[2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester;
- p) 1-(4-{4-[2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)propylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester;
- 15 q) 1-(4-{4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)propyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid methylamide;
- r) 1-(4-{4-[2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid;
- s) [Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid benzyl ester;
- 20 t) [Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid;
- u) (2R)-1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester;
- 25 v) (2S)-1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester;
- w) [Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester-1-yl)-phenyl)-amino]-acetic acid;
- 30 x) N-(2-Hydroxyethyl)-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- y) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-methyl-amino]-acetic acid ethyl ester;
- 35 z) N-Cyclopropylmethyl-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;


- aa) 4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-N-isobutyl-benzenesulfonamide;
- bb) [Cyclopropylmethyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester;
- 5 cc) 4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-N-isopropyl-benzenesulfonamide;
- dd) 1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid ethyl ester;
- ee) [Cyclopropylmethyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid;
- 10 ff) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-isobutyl-amino]-acetic acid ethyl ester;
- gg) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-methyl-amino]-acetic acid;
- 15 hh) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-isobutyl-amino]-acetic acid;
- ii) 1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid;
- jj) ethyl(2S)-1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethylamino]-1-piperidinyl}phenyl)sulfonyl]-2-pyrrolidinecarboxylate;
- 20 kk) ethyl(2S)-2-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]-phenyl)ethylamino]-1-piperidinyl}phenyl)sulfonyl]amino)-4-methylpentanoate;
- ll) ethyl(2S)-2-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]-phenyl)ethylamino]-1-piperidinyl}phenyl)sulfonyl]amino)-3-methylbutanoate;
- 25 mm) (2S)-1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethylamino]-1-piperidinyl}phenyl)sulfonyl]-2-pyrrolidinecarboxylic acid;
- nn) ethyl 1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-nyl)phenyl)sulfonyl]amino)-cyclopentanecarboxylate];
- oo) N-{2-hydroxy-5-[(1R)-1-hydroxy-2-[(1-{4-(1-pyrrolidinylsulfonyl)phenyl}-4-piperidinyl)amino)ethyl]phenyl}methanesulfonamide;
- 30 pp) N-{2-hydroxy-5-[(1R)-1-hydroxy-2-[(1-{4-(1-piperidinylsulfonyl)phenyl}-4-piperidinyl)amino)ethyl]phenyl}methanesulfonamide;
- qq) Ethyl 1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-nyl)phenyl)sulfonyl]amino)cyclohexanecarboxylate];
- 35 rr) Ethyl [(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-idinyl)phenyl)sulfonyl](isopropyl)-amino]acetate;

- ss) N-[2-Hydroxy-5-(1-hydroxy-2-{1-[4-(toluene-4-sulfonyl)phenyl]piperidin-4-ylamino}-ethyl)-phenyl]-methanesulfonamide;
- tt) 4-((2S)-2-Hydroxy-3-{1-[4-(toluene-4-sulfonyl)-phenyl]-piperidin-4-ylamino}-propoxy)-1,3-dihydro-benzoimidazol-2-one;
- 5 uu) 2-(2-butynyl)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-4-hexynoic acid tert-butyl ester;
- vv) 2-(2-butynyl)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-4-hexynoic acid;
- ww) 1-(4-{4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yl)oxy]propyl-amino]-piperidin-1-yl)-benzenesulfonyl)-imidazolidine-2,4-dione;
- 10 xx) N-[5-((1R)-2-{1-[4-(2,4-Dioxo-imidazolidine-1-sulfonyl)-phenyl]piperidin-4-yl-amino}-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide;
- yy) 1-(4-{4-[(2S)-2-Hydroxy-2-(2-trifluoromethyl-thiazol-4-yl)-ethylamino]-piperidin-1-yl)-benzenesulfonyl)-imidazolidine-2,4-dione;
- 15 zz) *tert*-Butyl 2-[[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino]acetate;
- aaa) 2-[[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)-amino]-1-piperidinyl}phenyl)sulfonyl]amino]acetic acid;
- bbb) *tert*-Butyl 2-[[2-(*tert*-butoxy)-2-oxoethyl][[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino]-acetate;
- 20 ccc) 2-[(Carboxymethyl)[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino]acetic acid;
- ddd) Ethyl 2-[[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino]acetate;
- 25 eee) Methyl 2-[[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino]acetate;
- fff) Ethyl 2-[[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino]piperidin-1-yl}phenyl)sulfonyl]amino]acetylcarbamate;
- 30 ggg) *tert*-Butyl [[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino] piperidin-1-yl}phenyl)sulfonyl](methoxycarbonyl)amino]acetate;
- hhh) [[[4-{4-[(2R)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)-amino]piperidin-1-yl}phenyl)sulfonyl](methoxycarbonyl)amino]acetic acid;
- iii) Ethyl {(2,5-difluorobenzyl)[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]phenyl}ethyl)amino]piperidin-1-yl}phenyl)sulfonyl]amino]acetate;
- 35

- jij) 1-[4-(((Butylamino)carbonyl)amino)sulfonyl]phenyl]-4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)piperidine ;
 kkk) 2-((2,5-Difluorobenzyl)[(4-{4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-1-piperidinyl)phenyl)sulfonyl]amino)acetic acid;
 5 lll) Ethyl {4-[(4-{4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)piperidin-1-yl)phenyl)sulfonyl]piperazin-1-yl}acetate;
 mmm) {4-[(4-{4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)piperidin-1-yl)phenyl)sulfonyl]piperazin-1-yl}acetic acid;
 nnn) N-(2-Hydroxy-5-((1*R*)-1-hydroxy-2-[(1-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl)-piperidin-4-yl]amino)ethyl)phenyl)methanesulfonamide;
 10 ooo) tert-Butyl ((2,5-difluorobenzyl)[(4-{4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)piperidin-1-yl)phenyl)sulfonyl]amino)acetate;
 or a pharmaceutically acceptable salt thereof; and
 {4-[(4-{4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-piperidin-1-yl)phenyl)sulfonyl]piperazin-1-yl}acetic acid, sodium salt.
 15


This invention also provides processes for preparing compounds of formula I which processes comprise one of the following:

- a) reductively aminating a compound of formula



20


wherein W, X, R₃ and R₄ are as defined herein with a compound of formula



wherein R₁ and Y are as defined in herein to give a compound of formula I as defined in Claim 1 wherein R₂ is hydrogen;

25


- or
b) reacting a compound of formula




wherein R_1 , Y, W, X, R_3 and R_4 are as defined herein with an organometallic agent, e.g. of formula R_2M where M is an alkali metal, MgBr, ZnCl to give a compound of formula I wherein R_2 is trifluoromethyl, alkyl of 1-6 carbons, alkenyl of 2-7 carbons, alkynyl of 2-7

5 carbons or cycloalkyl of 4-8 carbons; or

c) reacting a compound of formula



wherein R_1 and Y are as defined in Claim 1 with a compound of formula



10 wherein W, X, Z and R_3 are as defined herein to give a compound of formula I wherein R_2 is hydrogen; or

d) removing a protecting group from a compound of formula I in which at least one substituent carries a protecting group to give a compound of formula I;

or

15 e) converting a basic compound of formula I to a salt thereof by reaction with a pharmaceutically acceptable acid;

or

f) converting a compound of formula I having one or more reactive substituent groups to a different compound of formula I;

20 or

g) isolating an isomer of a compound of formula I from a mixture thereof.

An example of converting one compound of formula I to another is de-esterification of an ester function to give a carboxy function eg wherein R_5 is $-COR_8$


25 where R_8 is alkoxy or arylalkoxy to give a compound of formula I wherein R_5 is carboxy.

If necessary in the reactions described reactive substituent groups may be protected during the reaction and removed thereafter.


The compounds of this invention may be prepared for example according to the following schemes from commercially available starting materials or starting materials which can be prepared using literature procedures. These schemes show the preparation of representative compounds of this invention.

5

Scheme 1




Scheme 2




10

Scheme 3




15


Scheme 4




Scheme 5



Scheme 6




Scheme 7



In general, as shown in Scheme 1, compounds of the present invention are prepared by reductive amination of N-(4-sulfonylaryl)-substituted oxo-cyclylamines with the appropriate aryl-substituted ethanolamines. Various oxo-cyclamine derivatives can be prepared according to one of the synthetic Schemes 2 to 7.


Many of the aryloxypropanolamines and aryloethanolamines used in Scheme 1 are commercially available or readily prepared by known methods [e.g., 1. A. Guy, *Synthesis*, 1992, 821; 2. A. A. Asselin, *J. Med. Chem.*, 1986, 1009; 3. M.S. Berridge et al., *Nucl. Med. Biol.*, 19, 1992, 563; 4. C. D. Jesudason, et al., EP0764640; 5. EP0659737.]. In one method (Scheme 8), equimolar amounts of a substituted phenol and (2S) or (2R)-glycidyl 3-nitrobenzenesulfonate are dissolved in an organic solvent such as acetone or dimethylformamide and treated with a base such as sodium hydride or potassium carbonate for 0.5 to 24 hours at temperatures of 20 to 100 °C to provide the corresponding aryloxyoxiranes. The aryloxyoxiranes are converted to the ethanolamines by regioselective ring opening of the oxirane with lithium azide in a solvent such as hexamethylphosphoramide, followed by reduction with triphenylphosphine or hydrogenation with 10% Pd/C as catalyst. Alternatively, the aryloxyoxiranes can be converted to the ethanolamines by regioselective ring opening of the oxirane with dibenzylamine, followed by hydrogenation with 10% Pd/C as catalyst.

Scheme 8



The arylethanolamines used in Scheme 1 can be prepared according to the
 5 methods shown in Scheme 9. Arylmethylketones are converted to the corresponding α -
 haloketones using known methods [J. March, Advanced Organic Chemistry, 3rd Ed.,
 John Wiley and Sons, New York:1985, p529 and references cited therein]. The
 haloketones are reduced to the corresponding alcohol which can be protected as the
 triethylsilyl ether, or converted directly to the ethanolamine by treatment with ammonia or
 10 sodium azide followed by reduction. Treatment of the halo silyl ether with benzylamine
 followed by desilylation and hydrogenation also gives the corresponding
 arylethanolamine.

Scheme 9



The compounds of this invention are useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance. The compounds of this invention are therefore, particularly useful in the treatment or inhibition of type II diabetes. The compounds of this invention are also useful in modulating glucose levels in disorders such as type I diabetes.

The ability of compounds of this invention to treat or inhibit disorders related to insulin resistance or hyperglycemia was established with representative compounds of this invention in the following standard pharmacological test procedures, which measured the binding selectivity to the β_1 , β_2 , and β_3 adrenergic receptors. Binding to the receptors was measured in Chinese Hamster ovary (CHO) cells that were transfected with adrenergic receptors. The following briefly summarizes the procedures used and results obtained.

Transfection of CHO cells with β_1 and β_2 adrenergic receptors: CHO cells were transfected with human β_1 - or β_2 -adrenergic receptors as described in Tate, K.M., , *Eur. J. Biochem.*, 196:357-361 (1991).

Cloning of Human β_3 -AR Genomic DNA: cDNA was constructed by ligating four polymerase chain reaction (PCR) products using the following primers: an ATG-NarI fragment, sense primer 5'-CTTCCCTACCGCCCCACGCGCGATC3' and anti-sense primer 5'CTGGCGCCCAACGGCCAGTGGCCAGTC3'; a NarI-AccI fragment, 5'TTGGCGCTGATGGCCACTGGCCGTTTG3' as sense and 5'GCGCGTAGACGAAGAGCATCACGAG3' as anti-sense primer; an AccI-StyI fragment, sense primer 5'CTCGTGATGCTCTTCGTCTCACGCGC3' and anti-sense primer 5'GTGAAGGTGCCCATGATGAGACCCAAGG3' and a StyI-TAG fragment, with sense primer 5'CCCTGTGCACCTTGGGTCTCATCATGG3' and anti-sense primer 5'CCTCTGCCCCGGTTACCTACCC3'. The corresponding primer sequences are described in Mantzoros, C.S., et.al., *Diabetes* 45: 909-914 (1996). The four fragments are ligated into a pUC 18 plasmid (Gibco-BRL) and sequenced. Full length β_3 AR clones (402 amino acids) containing the last 6 amino acids of h β_3 -AR are prepared with the β_3 -BARpcDNA3 from ATTC.

15

Binding Procedure: Clones expressing receptor levels of 70 to 110 fmoles/mg protein were used in the test procedures. CHO cells were grown in 24-well tissue culture plates in Dulbecco's Modified Eagle Media with 10% fetal bovine serum, MEM non-essential amino acids, Penicillin-Streptomycin and Geneticin. On the day of test procedure, growth medium was replaced with preincubation media (Dulbecco's Modified Eagle Media and incubated for 30 minutes at 37° C. Preincubation medium was replaced with 0.2 ml treatment medium containing DMEM media containing 250 μ M IBMX (isobutyl-1-methylxanthine) plus 1 mM ascorbic acid with test compound dissolved in DMSO. Test compounds were tested over a concentration range of 10^{-9} M to 10^{-5} M for β_3 cells and 10^{-8} to 10^{-4} M for β_1 and β_2 transfected cells. Isoproterenol (10^{-5} M) was used as an internal standard for comparison of activity. Cells were incubated at 37° C. on a rocker for 30 min with the β_3 cells and 15 min for β_1 and β_2 cells. Incubation was stopped with the addition of 0.2N HCl and neutralized with 2.5N NaOH. The plates, containing the cells and neutralized media, were stored at -20 degrees celsius until ready to test for cAMP using the SPA test kit (Amersham).

30

Data Analysis and Results: Data collected from the SPA test procedure were analyzed as per cent of the maximal isoproterenol response at 10^{-5} M. Activity curves were plotted using the SAS statistical and graphics software. EC₅₀ values were generated for each compound and the maximal response (IA) developed for each

35

compound is compared to the maximal response of isoproterenol at 10^{-5} M from the following formula:

$$IA = \frac{\% \text{ activity compound}}{\% \text{ activity isoproterenol}}$$

Table I shows the EC_{50} and IA values for the representative compounds of this invention that were evaluated in this standard pharmacological test procedure that measured binding selectivity at that β -adrenergic receptors.

Table I

Example	beta-3 EC_{50} μ M (IA)	beta-2 EC_{50} μ M(IA)	beta-1 EC_{50} μ M (IA)
1	0.017 (0.92)	(0)	(0.09)
2	0.094 (1.1)	(0.03)	(0.16)
3	0.015 (1.1)	0.31 (0.59)	2.1 (0.66)
4	0.021 (0.78)	(0)	(0.17)
5	0.016 (0.98)	(0.07)	2.2 (0.59)
6	0.2 (0.76)		
7	0.02 (0.8)	(0.01)	0.6 (0.15)
8	0.016 (0.91)	0.61 (0.28)	3.6 (0.41)
10	0.1 (0.45)		
11	0.33 (0.83)		
12	0.01 (1)		
13	0.05 (0.7)		
14	0.001 (1.3)	0.17 (0.53)	0.64 (1)
15	0.001 (1)	0.16 (0.37)	13 (0.23)
16	0.003 (0.86)		
17	0.028 (0.81)		
18	0.041 (0.99)	1 (0.55)	(0.29)
19	0.007 (1)	(0.2)	0.79 (0.54)
20	0.01 (1)	10 (0.3)	10 (0.4)
21	0.001 (1)	0.64 (0.82)	0.06 (0.88)
22	0.002 (1)	0.04 (0.63)	0.2 (1.08)

Example	beta-3 EC ₅₀ μ M (IA)	beta-2 EC ₅₀ μ M(IA)	beta-1 EC ₅₀ μ M (IA)
23	0.016 (1)	1.67 (0.89)	1.32 (0.68)
24	0.033 (0.88)	1 (0.68)	1 (0.35)
25	0.052 (1)	1.43 (0.37)	1 (0.63)
26	0.023 (0.98)	0.27 (0.29)	0.24 (0.41)
27	0.002 (1)	0.54 (0.29)	0.42 (0.22)
28	0.002 (0.94)	6.6 (0.85)	(0.24)
29	0.007 (1.3)	2.9 (0.48)	2.0 (0.57)
30	0.004 (1.2)	3.6 (0.36)	9.8 (1.1)
31	0.007 (1.2)	12 (0.33)	20 (0.96)
32	0.004 (1)	10 (0.57)	6.7 (0.48)
33	0.018 (1)	(0.15)	25 (0.66)
34	0.006 (1.1)	(0.14)	10 (0.49)
35	0.011 (1.1)	(0.04)	49 (0.66)
36	0.009 (1)	0.72 (0.19)	4.8 (0.85)
37	0.016 (0.89)	0.9 (0.42)	5.6 (0.43)
38	0.032 (1.1)	0.38 (0.32)	1.1 (0.5)
39	0.03 (1)	(0.23)	10 (0.42)
40	0.004 (1.2)	0.04 (0.31)	1.9 (0.45)
41	0.002 (1)	2 (0.24)	0.8 (0.58)
42	0.001 (1)	0.37 (0.35)	1.32 (0.69)
43	0.001 (1)	0.09 (0.68)	1.28 (0.58)
44	0.003 (0.95)	2 (0.43)	12 (0.71)
45	0.001 (1)	0.7 (0.63)	0.02 (0.74)
46	0.009 (1.1)		
47	0.006 (0.93)	3.2 (0.46)	1 (0.47)
48	0.59 (1)	10 (0.54)	10 (0.26)
49	0.009 (0.96)		
50	0.01 (1)	7 (0.35)	2.6 (0.72)
52	0.006 (1)	0.48 (0.65)	0.96 (0.48)
53	0.034 (1.2)	(0.23)	(0.24)
54	0.014 (1.2)	12 (0.42)	2.3 (0.33)
55	0.41 (0.94)		

Example	beta-3 EC ₅₀ μ M (IA)	beta-2 EC ₅₀ μ M (IA)	beta-1 EC ₅₀ μ M (IA)
56	0.014 (1)	1.6 (0.27)	9.5 (0.31)
57	0.006 (0.85)	(0.18)	(0.18)
58	0.011 (1)	3.9 (0.31)	3.6 (0.65)
59	0.015 (0.98)	12 (0.2)	7.8 (0.52)
60	0.021 (1.1)	10 (0.21)	10 (0.18)
61	0.001 (1.1)	(0.2)	1.9 (0.3)
62	0.009 (1)	5 (0.31)	5 (0.32)
63	0.005 (0.91)	(0.15)	10 (0.88)
64	0.004 (1.1)	5.9 (0.22)	(0.11)
65	0.16 (0.93)	16 (0.67)	(0.23)
66	0.025 (0.95)	(0.17)	2.7 (0.44)
67	0.005 (0.96)	(0.17)	1 (0.48)

Based on the results obtained in these standard pharmacological test procedures, representative compounds of this invention have been shown to be selective β_3 adrenergic receptor agonists and are therefore useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance. More particularly, the compounds of this invention are useful in the treatment or inhibition of type II diabetes, and in modulating glucose levels in disorders such as type I diabetes. As used herein, the term modulating means maintaining glucose levels within clinically normal ranges.

As used in accordance with this invention, the term providing an effective amount means either directly administering such a compound of this invention, or administering a prodrug, derivative, or analog which will form an effective amount of the compound of this invention within the body.

It is understood that the effective dosage of the active compounds of this invention may vary depending upon the particular compound utilized, the mode of administration, the condition, and severity thereof, of the condition being treated, as well as the various physical factors related to the individual being treated. For treating treating metabolic disorders related to insulin resistance or hyperglycemia generally

satisfactory results may be obtained when the compounds of this invention are administered to the individual in need at a daily dosage of from about 0.1 mg to about 1 mg per kilogram of body weight, preferably administered in divided doses two to six times per day, or in a sustained release form. For most large mammals, the total daily dosage is from about 3.5 mg to about 140 mg. It is preferred that the administration of one or more of the compounds herein begin at a low dose and be increased until the desired effects are achieved.

Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, intranasally, vaginally, and transdermally. For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).

Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, , xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s).

35

In some cases it may be desirable to administer the compounds directly to the airways in the form of an aerosol.

5 The compounds of this invention may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparation contain a preservative to prevent the growth of
10 microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must
15 be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

20

Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used.

25

The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving lean meat to fat ratio in edible animals, i.e. ungulate animals and poultry.

30

Animal feed compositions effective for increasing lean meat deposition and for improving lean meat to fat ratio in poultry, swine, sheep, goats, and cattle are generally prepared by mixing the compounds of the present invention with a sufficient amount of animal feed to provide from about 1 to 1000 ppm of the compound in the feed. Animal feed supplements can be prepared by admixing about 75% to 95% by weight of a
35 compound of the present invention with about 5% to about 25% by weight of a suitable carrier or diluent. Carriers suitable for use to make up the feed supplement compositions

include the following: alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, sodium chloride, cornmeal, cane molasses, urea, bone meal, corncob meal and the like. The carrier promotes a uniform distribution of the active ingredients in the finished feed into which the supplement is blended. It thus performs an important function by ensuring proper distribution of the active ingredient throughout the feed. The supplement is used as a top dressing for the feed, it likewise helps to ensure uniformity of distribution of the active material across the top of the dressed feed.

The preferred medicated swine, cattle, sheep and goat feed generally contain from 0.01 to 400 grams of active ingredient per ton of feed, the optimum amount for these animals usually being about 50 to 300 grams per ton of feed. The preferred poultry and domestic pet feed usually contain about 0.01 to 400 grams and preferably 10 to 400 grams of active ingredient per ton of feed.

For parenteral administration the compounds of the present invention may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal in which increase in lean meat deposition and improvement in lean meat to fat ratio is sought. In general, parenteral administration involves injection of a sufficient amount of the compounds of the present invention to provide the animal with 0.001 to 100 mg/kg/day of body weight of the active ingredient. The preferred dosage for swine, cattle, sheep and goats is in the range of from 0.001 to 50 mg/kg/day of body weight of active ingredient; whereas, the preferred dose level for poultry and domestic pets is usually in the range of from 0.001 to 35 mg/kg/day of body weight.

Paste formulations can be prepared by dispersing the active compounds in a pharmaceutically acceptable oil such as peanut oil, sesame oil, corn oil or the like. Pellets containing an effective amount of the compounds of the present invention can be prepared by admixing the compounds of the present invention with a diluent such as carbowax, carnuba wax, and the like, and a lubricant, such as magnesium or calcium stearate, can be added to improve the pelleting process. It is, of course, recognized that more than one pellet may be administered to an animal to achieve the desired dose level which will provide the increase in lean meat deposition and improvement in lean meat to fat ratio desired. Moreover, it has been found that implants may also be made periodically during the animal treatment period in order to maintain the proper drug level

in the animal's body. For the poultry and swine raisers, using the method of the present invention yields leaner animals.

5 Additionally, the compounds of this invention are useful in increasing the lean mass to fat ratio in domestic pets, for the pet owner or veterinarian who wishes to increase leanness and trim unwanted fat from pet animals, the present invention provides the means by which this can be accomplished.

10 The following procedures describe the preparation of representative aryloxypropanolamines and arylethanolamines used in the preparation of compounds of this invention.

(1R)-2-Amino-1-(3-chloro-phenyl)-ethanol:

15 Lithium azide (7.5 g, 150 mmol) was added to a solution of (1R)-1-(3-chloro-phenyl)oxirane (15.5 g, 100 mmol) in hexamethylphosphoramide (70 mL). After being stirred at room temperature for 16 hours the suspension was poured into ice-water and the mixture was extracted with diethyl ether. The combined extracts were dried (MgSO_4) and concentrated. The residue was dissolved in 550 mL of THF/ H_2O (10 : 1) and triphenylphosphine (30 g, 114 mmol) was added. After overnight stirring at room
20 temperature, the solvents were removed and the residue was purified by column chromatography on silica gel using triethylamine-methanol-methylene chloride (1 : 1 : 8) as the eluent to give the title compound as a free base. The free base was then dissolved in diethyl ether and slowly treated with HCl gas. The precipitate was collected by filtration to yield 15 g (72%) of the title compound as a white powder; ^1H NMR (300
25 MHz, DMSO-d_6) δ 2.83 (dd, $J = 12.8, 9.5$ Hz, 1 H), 3.06 (dd, $J = 12.8, 3.2$ Hz, 1 H), 4.80-4.90 (m, 1 H), 6.22 (d, $J = 4.0$ Hz, 1 H), 7.10-7.75 (m, 4 H), 8.08 (brs, 2); MS (ES) m/z : 171.7, 173.7 ($\text{M}^+ + \text{H}$); HRMS Calcd. for $\text{C}_8\text{H}_9\text{ClNO}$ (M^+): 172.0529. Found: 172.0531.

(2S)-1-Amino-3-(4-benzyloxy-phenoxy)-propan-2-ol:

30 The title compound was prepared from (2S)-2-(4-benzyloxy-phenoxy)methyl-oxirane (EP 0 714 883) according to the procedure described above as a white solid; ^1H NMR (300 MHz, CDCl_3) δ 2.50-2.70 (m, 2 H), 3.33 (brs, 2 H), 3.60-3.90 (m, 3 H), 5.02 (s, 2 H), 6.90 (d, $J = 6.7$ Hz, 2 H), 6.93 (d, $J = 6.7$ Hz, 2 H), 7.25-7.50 (m, 5 H); MS (ES) m/z : 274.1 ($\text{M}^+ + \text{H}$); HRMS Calcd. for $\text{C}_{16}\text{H}_{19}\text{NO}_3$ (M^+): 273.1365. Found: 273.1347.

Anal. Calcd. for $C_{16}H_{19}NO_3$: C, 70.31; H, 7.01; N, 5.12. Found: C, 70.39; H, 6.80; N, 5.23.

(2S)-1-Amino-3-(4-hydroxy-phenoxy)-propan-2-ol:

5 A mixture of (2S)-1-amino-3-(4-benzyloxy-phenoxy)-propan-2-ol (0.9 g, 3.3 mmol) 0.2 mL of acetic acid and 10% Pd/C (0.3 g) in 70 mL of ethanol was pressurized with 20 psi hydrogen and shaken over 2 hours. The catalyst was then removed by filtering through a short pad of silica gel and the solvent was removed to give the title compound as an off-white solid; 1H NMR (300 MHz, DMSO- d_6) δ 1.86 (s, 1 H),
10 2.66 (dd, $J = 12.8, 5.3$ Hz, 1H), 2.85 (dd, $J = 12.8, 3.5$ Hz, 1H), 3.79-3.95 (m, 3 H), 6.67 (d, $J = 6.6$ Hz, 2H), 6.75 (d, $J = 6.6$ Hz, 2 H); MS (ES) m/z : 183.1 ($M^+ + H$); HRMS Calcd. for $C_9H_{13}NO_3(M^+ + H)$: 183.0895. Found: 183.0892.

N-[2-Benzyloxy-5-(2-dibenzylamino-1-oxo-ethyl)-phenyl]-methanesulfonamide:

15 N-[2-Benzyloxy-5-(2-chloro-1-oxo-ethyl)-phenyl]-methanesulfonamide (EP 0 659 737) (17.0 g, 42.8 mmol) was dissolved in 200 mL of dimethylformamide and treated with dibenzylamine (22.0 g, 110 mmol). The mixture was stirred at room temperature overnight and then the solvent was removed. The residue was purified by silica gel chromatography using 20-50% ethyl acetate/hexanes as elute to give the title compound
20 as a white solid; 1H NMR (300 MHz, $CDCl_3$) δ 2.94 (s, 3 H), 3.77 (s, 2 H), 3.82 (s, 2 H), 5.16 (s, 2 H), 6.75 (brs, 1 H), 6.96 (d, $J = 8.7$ Hz, 1 H), 7.20-7.50 (m, 15 H), 7.67 (dd, $J = 8.7, 2.1$ Hz, 1 H), 8.10 (d, $J = 2.1$ Hz, 1 H); MS (ES) m/z : 515.2 ($M^+ + H$); HRMS Calcd. for $C_{30}H_{30}N_2O_4S(M^+)$: 514.1926. Found: 514.1927.

25 **N-[2-Benzyloxy-5-(2-dibenzylamino-1-hydroxy-ethyl)-phenyl]-methanesulfonamide:**

 Sodium borohydride (0.37 g, 9.7 mmol) was added in portions to a stirred solution of N-[2-benzyloxy-5-(2-dibenzylamino-1-oxo-ethyl)-phenyl]-methanesulfonamide (1.0 g, 1.9 mmol) in 20 mL of methanol/tetrahydrofuran (5 : 2) at room temperature and the resulting solution was stirred for 2 hours. Methylene chloride was added and the
30 resulting solution was washed with aqueous sodium bicarbonate, dried over $MgSO_4$ and the solvent was removed. Recrystallization from methylene chloride/hexanes gave the title compound as a crystalline solid; 1H NMR (300 MHz, $CDCl_3$) δ 2.58 (d, $J = 6.7$ Hz, 2 H), 2.86 (s, 2 H), 2.92 (s, 2 H), 3.55 (d, $J = 13.5$ Hz, 2 H), 3.70 (d, $J = 13.5$ Hz, 2 H), 4.11 (s, 1 H), 4.64 (t, $J = 6.7$ Hz, 1 H), 5.10 (s, 2 H), 6.92 (d, $J = 8.5$ Hz, 1 H), 7.00 (dd, J

= 8.5, 2.0 Hz, 1 H), 7.20-7.50 (m, 16 H), 7.89 (brs, 1 H); MS (ES) m/z : 517.1 (M⁺+H); HRMS Calcd. for C₃₀H₃₂N₂O₄S(M⁺): 516.2083. Found: 516.2074.

N-[2-Benzyloxy-5-(2-amino-(1R)-1-hydroxy-ethyl)-phenyl]-methanesulfonamide:

5 A mixture of N-[2-benzyloxy-5-(2-iodo-(1R)-1-[(triethylsilyl)oxy]-ethyl)-phenyl]-methanesulfonamide (EP 0 659 737) (4.48 g, 8 mmol) and sodium azide (0.65 g, 10 mmol) in 100 mL of hexamethylphosphoramide was stirred at 60°C overnight. After cooling to room temperature the mixture was diluted with diethyl ether, washed with water, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was
10 dissolved in 200 mL of THF/H₂O (10 : 1) and triphenylphosphine (2.62 g, 10 mmol) was added. After overnight stirring at room temperature, the solvents were removed and the residue was partitioned between ethyl acetate and water. The organic layers were combined and dried over MgSO₄ and concentrated. The residue was redissolved in 100 mL of THF and tetrabutylammonium fluoride (10 mL, 1 M solution in THF) was added.
15 The reaction was stirred for 2 hours then the solvent was removed in vacuo. The residue was purified by column chromatography on silica gel using triethylamine-methanol-methylene chloride (1 : 1 : 3) to give the title compound as a white solid; MS (ES) m/z : 337.4 (M⁺+H).

20 N-[5-(2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide:

To a stirred suspension of N-[2-benzyloxy-5-(2-dibenzylamino-1-hydroxy-ethyl)-phenyl]-methanesulfonamide (1.03g, 2 mmol) and 10% Pd/C (0.4 g) in methanol (100 mL) at room temperature is added anhydrous HCO₂NH₄ (1.26 g, 20 mmol) under a nitrogen atmosphere. The resulting mixture is refluxed for 2 hours. After cooling to room
25 temperature the catalyst is removed by filtration through a celite pad and washed with methanol. The filtrate is evaporated under reduced pressure to give the titled compound as a pale yellowish solid; ¹H NMR (300 MHz, DMSO-d₆) δ 2.62 (dd, J = 12.6, 8.7 Hz, 1 H), 2.75 (dd, J = 12.6, 3.7 Hz, 1 H), 2.90 (s, 3 H), 4.47 (dd, J = 8.7, 3.7 Hz, 1 H), 6.84 (d, J = 9.1 Hz, 1 H), 6.96 (dd, J = 9.1, 2.0 Hz, 1 H), 7.16 (d, J = 2.1 Hz, 1 H), 8.44 (s,
30 1 H); MS (ES) m/z : 246.7 (M⁺+H); HRMS Calcd. for C₉H₁₄N₂O₄S(M⁺): 246.0674. Found: 246.0672.

N-[5-(2-Amino-(1R)-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide:

Method A: A mixture of N-[2-benzyloxy-5-(2-iodo-(1R)-1-[(triethylsilyl)oxy]ethyl)-phenyl]-methanesulfonamide (EP 0 659 737) (8.60 g, 15.3 mmol) and benzylamine (21.4 g, 200 mmol) was heated at 60°C for 24 hours. The reaction mixture was cooled, diluted with hexanes (500 mL), and the residue was washed with diethyl ether. The combined solvents were removed and the residue was purified by silica gel column eluting with 30 to 100% Et₂O/hexanes. The fractions with molecular weight of 540 were concentrated and re-dissolved in 200 mL of THF and TBAF (20 mL, 1.0 M solution in THF) was added. After stirring at room temperature for 4 hours the reaction mixture was then poured into water and extracted with CH₂Cl₂. The organic layers were passed through a short pad of silica gel eluting with 10% methanol/CH₂Cl₂. The solvents were removed and the residue were dissolved in methanol (200 mL). 10% Pd/C (0.6 g) and anhydrous HCO₂NH₄ (6.3 g, 100 mmol) were added. The resulting mixture was refluxed under a nitrogen atmosphere for 2 hours. After cooling to room temperature the catalyst was removed by filtration through a celite pad and washed with methanol. The filtrate is evaporated under reduced pressure to give the title compound as an off-white solid; ¹H NMR (300 MHz, MeOH-d₄) δ 2.95 (s, 3 H), 2.99 (dd, J = 9.7, 9.2 Hz, 1 H), 3.07 (dd, J = 9.7, 3.6 Hz, 1 H), 4.75 (dd, J = 9.2, 3.6 Hz, 1 H), 6.90 (d, J = 8.3 Hz, 1 H), 7.12 (dd, J = 8.3, 2.1 Hz, 1 H), 7.38 (d, J = 2.1 Hz, 1 H), 8.44 (s, 1 H); MS (ES) m/z : 246.7 (M⁺+H)⁺; HRMS Calcd. for C₉H₁₄N₂O₄S: 246.0674. Found: 246.0672.

Method B: To a stirred solution of N-[2-benzyloxy-5-(2-Bromo-1-hydroxy-ethyl)-phenyl]-methanesulfonamide (EP 0 659 737) (15.05 g, 0.376 mol) in DMSO (150 ml) was added sodium iodide (3.76 g, 0.376 mol) and sodium azide (9.48 g, 0.150 mol). The mixture was stirred for 5 days under Nitrogen atmosphere. The reaction mixture was poured onto water and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated. The residue was triturated with water and hexanes. Recovered yellow solid as of N-[5-((1R)-2-azido-1-hydroxy-ethyl)-2-benzyloxy-phenyl]-methanesulfonamide (12.85 g, 94%): ¹H NMR (300 MHz, CDCl₃): δ 2.93(s, 3 H), 3.45(d, J = 9.0 Hz, 2 H), 3.46(m, 1 H), 5.11(s, 2 H), 6.80(s, 1 H), 6.99(d, J = 8.4 Hz, 1 H), 7.15(dd, J = 6 Hz, 2.1 Hz, 1H), 7.26(s, 1 H), 7.39(s, 5 H), 7.53(d, J = 2.1 Hz, 1 H); MS (ES) m/z 361.4 (M⁺-H, 70%). A mixture of N-[5-((1R)-2-Azido-1-hydroxy-ethyl)-2-benzyloxy-phenyl]-methanesulfonamide (12.85 g, 0.037 mol) and 10% Palladium on carbon (2.75 g) in ethanol (100 ml) was hydrogenated under 45 PSI for two days. The reaction mixture was filtered through celite and concentrated. The title compound was

recovered as a tan solid (6.08 g, 66%): ^1H NMR (300 MHz, DMSO-d_6): δ 2.60(m, 2 H), 2.87(s, 3 H), 4.34(m, 1 H), 6.79(d, $J = 9.0$ Hz, 1 H), 6.89(d, $J = 9.0$ Hz, 2 H).

5 The following procedures describe the preparation of intermediates useful in the preparation of compounds of this invention.

INTERMEDIATE 1

N-(3,4-Dimethoxy-phenyl)-4-fluoro-benzenesulfonamide

3,4-Dimethoxyaniline(1.01g, 6.99mM) was added to a solution of 4-Fluoro-benzenesulfonyl chloride (1.50g, 7.69mM) in anhydrous pyridine(10ml). The reaction
10 was stirred overnight. The reaction was quenched with 1N HCl_{aq} (20ml) and washed with ethyl acetate(3x20ml). The organic extracts were combined, dried(sodium sulfate), solids filtered off and concentrated. The desired product was isolated using silica gel flash chromatography of 1.30g as a yellow solid. ^1H NMR(CDCl_3) δ 3.79(s, 3H), 3.86(s, 3H),
15 6.50(d, 1H, $J=4.71\text{Hz}$), 6.68(d, 1H, $J=2.64\text{Hz}$), 6.71(d, 1H, $J=2.76\text{Hz}$), 7.11(d, 2H, $J=8.67\text{Hz}$), 7.75(m, 2H). MS(ES) m/z 328.9; ($\text{M}+\text{NH}_4^+$); HRMS for (MH^+) $\text{C}_{14}\text{H}_{14}\text{SFNO}_4$: 260.1511.

INTERMEDIATE 2

N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-fluoro-benzenesulfonamide

N-(3,4-Dimethoxy-phenyl)-4-fluoro-benzenesulfonamide (0.51g, 1.61mM) was added to a solution of benzyl bromide (0.57g, 4.82mM) and potassium carbonate (0.66g, 4.82mM) in anhyrous acetone (10ml). The reaction was stirred overnight. The undissolved solids were removed by filtration and the mother liquor was concentrated.
25 This gum was triturated with hexanes to afford 0.52g of the desired product as an off-white solid. ^1H NMR(CDCl_3) δ 3.66(s, 3H), 3.81(s, 3H), 6.42(m, 2H), 6.66(d, 1H, $J=8.70\text{Hz}$), 7.23(m, 7H), 7.71(m, 2H). MS(ES) m/z 401.9; (MH^+); HRMS for $\text{C}_{21}\text{H}_{20}\text{SFNO}_4$: 401.1094.

30 INTERMEDIATE 3

N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonamide

1,4-Dioxa-8-azaspiro[4.5]decane (0.14ml, 0.95mM) was added to a solution of N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-fluoro-benzenesulfonamide (0.19g, 0.47mM) and
35 potassium carbonate (0.66g, 4.82mM) in anhyrous 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-

pyrimidinone(5ml). The reaction was stirred at 70°C for two days. The reaction was quenched with water(50ml). The precipitate was washed with water and dried under reduced pressure to afford 0.15g of the desired product as a tan solid. ^1H NMR(CDCl_3) δ 1.81(t, 4H, J=5.67Hz), 3.50(t, 4H, J=5.97Hz), 3.65(s, 3H), 3.81(s, 3H), 4.01(s, 4H), 4.66(s, 2H), 6.43(d, 1H, J=2.34Hz), 6.53(m, 1H), 6.66(d, 1H, J=8.58Hz), 6.90(d, 1H, J=9.03Hz), 7.19(m, 6H), 7.53(d, 2H, J=9.00Hz). MS(ES) m/z 525.0; (MH^+); HRMS for $\text{C}_{26}\text{H}_{32}\text{N}_2\text{O}_6$: 525.2049.

INTERMEDIATE 4

10 N-Benzyl-4-fluoro-benzenesulfonamide

The title compound was prepared according to the procedure of Intermediate 1 as a yellow solid. ^1H NMR(CDCl_3) δ 4.17(d, 2H, J=6.06Hz), 4.81(t, 1H, J=5.82Hz), 7.19(m, 4H), 7.27(m, 3H), 7.88(m, 2H). MS(ES) m/z 265.9; (MH^+); HRMS for $\text{C}_{13}\text{H}_{12}\text{S F NO}_2$: 266.0625.

15

INTERMEDIATE 5

N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide

N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonamide(0.10g, 0.19mM) was stirred in 6M HCl (2ml) and acetone(5ml) at 60°C overnight. The reaction mixture was basified with 5N NaOH_{aq} (until pH>7) and washed with ethyl acetate (3x10ml). The organic extracts were dried with sodium sulfate, passed through a plug of magnesol, concentrated and triturated with hexanes to afford 0.65g of the desired product as a white solid. ^1H NMR(CDCl_3) δ 2.58(t, 4H, J=6.06Hz), 3.67(s, 3H), 3.74(t, 4H, J=6.12Hz), 3.81(s, 3H), 4.71(s, 2H), 6.48(m, 3H), 6.67(d, 1H, J=8.46Hz), 6.93(d, 2H, J=9.9Hz), 7.20(m, 4H), 7.59(d, 2H, J=4.71Hz). MS(ES) m/z 481.0; (MH^+); HRMS for $\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}_5$: 481.1778.

25

INTERMEDIATE 6

N-Benzyl-N-(tert-butylcarbonyl)-4-fluoro-benzenesulfonamide

t-Boc-Anhydride(0.18g, 0.83mM) was added to N-Benzyl-4-fluoro-benzenesulfonamide (0.2g, 0.75mM) and 4-dimethylaminopyridine (scoopful) in anhydrous methylene chloride (5ml). The reaction was stirred for two hours at room temperature. The reaction was quenched with 1N HCl(20ml) and washed with methylene chloride (3x10ml). The organic extracts were combined, dried with sodium sulfate and passed through a plug of magnesol and concentrated to afford an oil. The oil was triturated with hexanes to afford

35

0.22g of the desired product as a white solid. ^1H NMR(CDCl_3) δ 1.34(s, 9H), 5.11(s, 2H), 7.08(t, 2H, $J=3.42\text{Hz}$), 7.34(m, 5H), 7.66(m, 2H). MS(ES) m/z 383.1; ($\text{M}+\text{NH}_4^+$); HRMS for $\text{C}_{26}\text{H}_{28}\text{SN}_2\text{O}_5$: 366.1179.

5

INTERMEDIATE 7**N-Benzyl-N-butyl-4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)benzenesulfonamide**

The title compound was prepared according to the procedure of Intermediate 3 as a yellow solid. ^1H NMR(CDCl_3) δ 0.74(t, 3H, $J=7.26\text{Hz}$), 1.08(m, 2H), 1.29(m, 2H), 1.79(t, 4H, $J=5.70\text{Hz}$), 3.05(t, 2H, $J=7.74\text{Hz}$), 3.50(t, 4H, $J=5.76\text{Hz}$), 4.01(s, 4H), 4.27(s, 2H), 6.93(d, 2H, $J=5.31\text{Hz}$), 7.28(m, 5H), 7.66(d, 2H, $J=5.41\text{Hz}$). MS(ES) m/z 445.3; (MH^+); HRMS for $\text{C}_{24}\text{H}_{32}\text{SN}_2\text{O}_4$: 444.2082.

10

INTERMEDIATE 8**N-Benzyl-N-(tert-butylcarbonyl)-4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)benzenesulfonamide**

15

The title compound was prepared according to the procedure of Intermediate 3 as a yellow solid. ^1H NMR(CDCl_3) δ 1.34(s, 9H), 1.78(t, 4H, $J=5.82\text{Hz}$), 3.48(t, 4H, $J=5.82\text{Hz}$), 3.99(s, 4H), 5.09(s, 2H), 6.81(t, 2H, $J=4.83\text{Hz}$), 7.35(m, 5H), 7.50(d, 2H, $J=4.97\text{Hz}$). MS(ES) m/z 489.0; (MH^+); HRMS for $\text{C}_{25}\text{H}_{32}\text{SN}_2\text{O}_6$: 488.1977.

20

INTERMEDIATE 9**N-Benzyl-N-butyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide**

The title compound was prepared from Intermediate 7 according to the procedure of Intermediate 5 as a yellow solid. ^1H NMR(CDCl_3) δ 0.75(t, 3H, $J=7.26\text{Hz}$), 1.12(m, 2H), 1.32(m, 2H), 2.59(t, 4H, $J=6.09\text{Hz}$), 3.08(t, 2H, $J=7.77\text{Hz}$), 3.76(t, 4H, $J=6.18\text{Hz}$), 4.32(s, 2H), 6.94(d, 2H, $J=5.31\text{Hz}$), 7.31(m, 5H), 7.72(d, 2H, $J=5.41\text{Hz}$). MS(ES) m/z 401.5; (MH^+); HRMS for $\text{C}_{22}\text{H}_{28}\text{SN}_2\text{O}_3$:

25

INTERMEDIATE 10**N-Butyl-4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonamide**

30

The title compound was prepared from N-butyl-4-fluoro-benzenesulfonamide) according to the procedure of Intermediate 3 as a white solid; mp 122-124°C; ^1H NMR (CDCl_3) δ 0.85 (t, $J=7.23\text{ Hz}$, 3H), 1.21-1.30 (m, 2H), 1.32-1.49 (m, 2H), 1.65 (s, 1H),

1.80 (t, J=5.79 Hz, 4H), 2.90 (q, J=6.75 Hz, 2H), 3.48 (t, J=5.7 Hz, 4H), 4.00 (s, 4H), 6.88-6.93 (m, 2H), 7.67-7.77 (m, 2H); MS (ES) m/z 355.0 (MH⁺); C₁₇H₂₆N₂O₄S

INTERMEDIATE 11

5 N-Butyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide

The title compound was prepared from N-butyl-4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonamide according to the procedure of Intermediate 5 as an off-white solid; mp 79-82 °C; ¹H NMR (CDCl₃) δ 0.85 (t, J=7.26 Hz, 3H), 1.23-1.37 (m, 2H), 1.40-1.50 (m, 2H), 1.65 (s, 1H), 2.59 (t, J= 6.12 Hz, 4H), 2.92 (q, J= 6.69 Hz, 2H), 3.75 (t, J=6.09 Hz, 4H), 6.92-6.97 (m, 2H), 7.70-7.80 (m, 2H); MS (ES) m/z 311.0 (MH⁺); HRMS for C₁₅H₂₂N₂O₃S: 310.1349

INTERMEDIATE 12

15 1-(4-Fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester

The title compound was prepared from DL-proline, isopropanol, and 4-fluorobenzenesulfonyl chloride according to the procedure of Intermediate 48 as a clear oil; ¹H NMR (CDCl₃) δ 1.21-1.28 (m, 6H), 1.80-1.85 (m, 1H), 1.95-2.10 (m, 3H), 3.31-3.49 (m, 2H), 4.26-4.36 (m, 1H), 4.95-5.08 (m, 1H), 7.15-7.23 (m, 2H), 7.89-8.08 (m, 2H); MS (ES) m/z 315.8 (MH⁺); HRMS for C₁₄H₁₈FNO₄S: 338.0830 (M+ Na)

INTERMEDIATE 13

20 1-[4-(1,4-Dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid isopropyl ester

The title compound was prepared with 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester according to the procedure of Intermediate 3 as a clear oil; ¹H NMR (CDCl₃) δ 1.23-1.28 (m, 6H), 1.80-1.85 (t, J=5.82 Hz, 4H), 1.91-2.05 (m, 3H), 3.24-3.29 (m, 2H), 3.42-3.51 (m, 4H), 4.00 (s, 4H), 4.19-4.25 (m, 1H), 4.96-5.09 (m, 2H), 6.88-6.93 (m, 2H), 7.66-7.74 (m, 2H); MS (ES) m/z 438.9 (MH⁺); HRMS for C₂₁H₃₀N₂O₆S: 439.1896 (MH⁺)

30

INTERMEDIATE 14**1-[4-(4-Oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid isopropyl ester**

The title compound was prepared with 1-[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid isopropyl ester according to the procedure of Intermediate 5 as a white solid; mp 97-101 °C; ¹H NMR (CDCl₃) δ 1.23-1.28 (m, 6H), 1.75-1.80 (m, 1H), 1.94-2.07 (m, 3H), 2.58 (t, J=6.3 Hz, 4H), 3.27-3.36 (m, 1H), 3.42-3.51 (m, 1H), 3.75 (t, 6.09 Hz, 4H), 4.23-4.28 (m, 1H), 4.97-5.10 (m, 1H), 6.91-6.96 (m, 2H), 7.70-7.84 (m, 2H); MS (ES) m/z 394.9 (MH⁺); HRMS for C₁₉H₂₆N₂O₅S: 395.1631 (MH⁺)

INTERMEDIATE 15**1-(4-Fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid**

To a stirred solution of 2.06 g (6.5 mmol) of 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester in 10 mL of methanol was added 2.3 mL (13 mmol) of 5N NaOH. After 2 hours, the solvent was removed in vacuo and the aqueous residue was acidified with 1N HCl and then extracted twice with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated in vacuo to afford 1.69 g of the title compound as a white solid; mp 145-148 °C; ¹H NMR (DMSO) δ 1.56-1.63 (m, 1H), 1.78-2.05 (m, 4H), 3.13-3.21 (m, 1H), 4.10-4.15 (m, 1H), 7.42-7.50 (m, 2H), 7.88-7.95 (m, 2H), 12.75 (bs, 1H); MS (ES) m/z 271.9 (MH⁺); HRMS for C₁₁H₁₂N₂FO₄S: 274.0543 (MH⁺)

INTERMEDIATE 16**1-(4-Fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester**

HCl gas was bubbled into a solution of 1.49 g of 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid and 6 mL of benzyl alcohol for 15 minutes and the resulting mixture was allowed to stir overnight. 10 mL of 2,3-butanediol and a catalytic amount of DMAP was then added and stirred for 2 days. The solvent was removed in vacuo and the residue was purified by flash column chromatography (3:1 Hexanes:Ethyl Acetate) to give 1.01 g of the title compound as a clear gum; ¹H NMR (CDCl₃) δ 1.74-1.85 (m, 1H), 1.95-2.18 (m, 3H), 3.32-3.58 (m, 2H), 4.40-4.44 (m, 1H), 5.15 (s, 2H), 7.11-7.17 (m, 2H),

7.33-7.41 (m, 5H), 7.84-7.90 (m, 2H); MS (ES) m/z 363.9 (MH⁺); HRMS for C₁₈H₁₈FNO₄S: 364.1012 (MH⁺)

INTERMEDIATE 17

5 **1-[4-(1,4-Dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester**

The title compound was prepared from 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester according to the procedure of Intermediate 3 as a gum; ¹H NMR (CDCl₃) δ 1.54-1.62 (m, 1H), 1.67 (t, J=5.64 Hz, 4H), 1.69-1.90 (m, 4H), 3.07-3.15 (m, 1H), 3.35-3.48 (m, 4H), 3.92 (s, 4H), 4.15-4.20 (m, 1H), 5.14 (s, 2H), 7.05 (d, J=9.09 Hz, 2H), 7.22-7.43 (m 5H), 7.58 (d, J=9.00 Hz, 2H); MS (ES) m/z 487.0 (MH⁺); HRMS for C₂₅H₃₀N₂O₆S: 487.1890 (MH⁺)

INTERMEDIATE 18

15 **{Butyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid benzyl ester**

The title compound was prepared from N-butyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide and benzyl bromoacetate according to the procedure of Intermediate 2 as a gum; ¹H NMR (CDCl₃) δ 0.85 (t, J=7.23 Hz, 3H), 1.19-1.32 (m, 2H), 1.43-1.53 (m, 2H), 2.56 (t, J=6.12 Hz, 4H), 3.19 (t, J=7.47 Hz, 2H), 3.72 (t, J=6.06 Hz, 4H), 4.09 (s, 2H), 5.10 (s, 2H), 6.84-6.89 (m, 2H), 7.29-7.40 (m, 5H), 7.69-7.74 (m, 2H); MS (ES) m/z 459.4 (MH⁺); HRMS for C₂₅H₃₀N₂O₆S: 459.1945 (MH⁺)

INTERMEDIATE 19

25 **(2S)-1-4-Fluoro-benzenesulfonyl-pyrrolidine-2-carboxylic acid benzyl ester**

The title compound was prepared from L-proline, benzyl alcohol, and 4-fluorobenzenesulfonyl chloride according to the procedure of Intermediate 48 as a gum; ¹H NMR (CDCl₃) δ 1.80-1.85 (m, 1H), 1.94-2.30 (m, 3H), 3.31-3.51 (m, 2H), 4.42 (dd, J=3.57 Hz, 8.13 Hz, 1H), 5.14 (s, 2H), 6.91-7.17 (m, 2H), 7.32-7.40 (m, 5H), 7.84-7.90 (m, 2H); MS (ES) m/z 363.8 (MH⁺); HRMS for C₁₈H₁₈FNO₄S: 364.1011

INTERMEDIATE 20**1-[4-(1,4-Dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid methylamide**

0.57 g of 1-[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid isopropyl ester was stirred in 20 mL methyl amine (40% wt in water) at 100 °C in a sealed tube for 5 days. The methyl amine was allowed to evaporate and the residual aqueous solution was left to stand overnight uncapped. The following morning, a white precipitate was present, which was collected by vacuum filtration. The precipitate was washed with water and hexanes. The original aqueous solution was then extracted twice with ethyl acetate. The organic layer was then dried over sodium sulfate and concentrated in vacuo to afford more product. 0.31 g of the title compound was collected as a white solid; mp 137-139 °C; ¹H NMR (CDCl₃) δ 1.52-1.72 (m, 5H), 1.81 (t, J=5.82 Hz, 4H), 2.15-2.20 (m, 1H), 2.86 (d, J=4.95 Hz, 3H), 3.08-3.55 (m, 1H), 3.49-3.55 (m, 4H), 4.00 (s, 4H), 6.89-6.94 (m, 2H), 6.99-7.01 (m, 1H), 7.61-7.73 (m, 2H); MS (ES) m/z 410.0 (MH⁺); HRMS for C₁₉H₂₇N₃O₅S: 410.1740

INTERMEDIATE 21**(2S)-1-[4-(1,4-Dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester**

The title compound was prepared with 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester according to the procedure of Intermediate 3 as a colorless gum; ¹H NMR (CDCl₃) δ 1.67-1.82 (m, 4H), 1.92-2.03 (m, 3H), 3.17-3.36 (m, 3H), 3.42-3.64 (m, 4H), 4.00 (s, 4H), 4.24-4.47 (m, 1H), 5.16 (s, 2H), 6.62-6.91 (m, 2H), 7.29-7.42 (m, 5H), 7.66-7.72 (m, 2H); MS (ES) m/z 487.0 (MH⁺); HRMS for C₂₅H₃₀N₂O₆S: 487.1893

INTERMEDIATE 22**(2S)-1-[4-(4-Oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester**

The title compound was prepared with (2S)-1-[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester according to the procedure of Intermediate 5 as a gum; ¹H NMR (CDCl₃) δ 1.65-1.82 (m, 1H), 1.90-2.17 (m, 3H), 2.57 (t, J=6.09 Hz, 4H), 3.28-3.34 (m, 1H), 3.42-3.49 (m, 1H), 3.73 (t, J=6.09 Hz, 4H),

4.35-4.39 (m, 1H), 5.16 (s, 2H), 6.87-6.92 (m, 2H), 7.29-7.40 (m, 5H), 7.73-7.79 (m, 2H); MS (ES) m/z 442.9 (MH⁺); HRMS for C₂₃H₂₆N₂O₅S: 443.1631 (MH⁺)

INTERMEDIATE 23

5 (2R)-1-[4-(4-Oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester

The title compound was prepared with (2R)-1-[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester according to the procedure of Intermediate 5 as a gum; ¹H NMR (CDCl₃) δ 1.61-1.82 (m, 1H), 1.92-2.06 (m, 3H), 2.58 (t, J=6.18 Hz, 4H), 3.27-3.35 (m, 1H), 3.42-3.52 (m, 1H), 3.73 (t, J=6.06 Hz, 4H), 4.35-4.39 (dd, J=3.87 Hz, 7.98 Hz, 1H), 5.17 (s, 2H), 6.85-6.92 (m, 2H), 7.29-7.41 (m, 5H), 7.73-7.88 (m, 2H); MS (ES) m/z 442.9 (MH⁺); HRMS for C₂₃H₂₆N₂O₅S: 443.1632 (MH⁺)

15 INTERMEDIATE 24

8-[4-(Toluene-4-sulfonyl)-phenyl]-1,4-dioxo-8-aza-spiro[4.5]decane

To a solution of 4-fluorophenyl-4-tolylsulfone (1.25 g, 5 mmol) in N,N'-dimethyl-propyleneurea (5 ml) was added 1,4-dioxo-8-aza-spiro[4.5]decane (0.88 g, 6 mmol), and potassium carbonate (0.83 g, 6 mmol). The mixture was stirred at room temperature for 4 h and then heated at 70°C for 18 h. An additional 0.22 g of 1,4-dioxo-8-aza-spiro[4.5]-decane was added, and the reaction was continued for 1 day. The mixture was cooled to room temperature, and treated with water. The resulting suspension was filtered, and the precipitate washed with water and methanol, and dried in vacuo to give 1.80 g of a white solid; m.p. 164-165 °C; MS (ES) m/z 373.9 (MH⁺); HRMS (EI) Calcd. for C₂₀H₂₃NO₄S (M⁺): 373.1348, Found: 373.1342.

INTERMEDIATE 25

1-[4-(Toluene-4-sulfonyl)-phenyl]-piperidin-4-one

The title compound was prepared according to the procedure of Intermediate 40 from 2.0 g (4.7 mmol) of 8-[4-(toluene-4-sulfonyl)-phenyl]-1,4-dioxo-8-aza-spiro[4.5]-decane, yielding 1.42 g of a white solid; m.p. 159-160 °C; MS (ES) m/z 329.9 (MH⁺); HRMS (EI) Calcd. for C₁₈H₁₉NO₃S (M⁺): 329.1086, Found: 329.1073.

INTERMEDIATE 26**2-But-2-ynyl-2-[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-hex-4-ynoic acid tert-butyl ester**

The title compound was prepared according to the procedure of Intermediate 24 from 0.53 g (3.6 mmol) of 1,4-dioxo-8-aza-spiro[4.5]decane and 1.13 g (3.0 mmol) of 2-but-2-ynyl-2-[4-fluorobenzenesulfonyl]-hex-4-ynoic acid tert-butyl ester, yielding 1.52 g of a colorless foam; MS (ES) m/z 502.3 (MH^+); HRMS (EI) Calcd. for $C_{27}H_{35}NO_6S$ (M^+): 501.2185, Found: 501.2177.

INTERMEDIATE 27**2-But-2-ynyl-2-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-hex-4-ynoic acid tert-butyl ester**

The title compound was prepared according to the procedure of Intermediate 40 from 1.40 g (2.8 mmol) of 2-but-2-ynyl-2-[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-hex-4-ynoic acid tert-butyl ester, yielding 1.19 g of a white solid; m.p. 128–130°C; MS (ES) m/z 458.2 (MH^+); HRMS (EI) Calcd. for $C_{25}H_{31}NO_5S$ (M^+): 457.1923, Found: 457.1919.

INTERMEDIATE 28**4-Fluoro-N-(2-hydroxyethyl)-benzenesulfonamide**

The title compound was prepared according to the procedure of Intermediate 33 from 3.97 g (20 mmol) of 4-fluorobenzenesulfonyl chloride and 3.11 g (50 mmol) of ethanolamine, yielding 3.0 g of a white solid; m.p. 77–78 °C; MS (ES) m/z 219.8 (MH^+); HRMS (EI) Calcd. for $C_8H_{10}FNO_3S$ (M^+): 219.0366, Found: 219.0369.

INTERMEDIATE 29**4-(1,4-Dioxo-8-aza-spiro[4.5]dec-8-yl)-N-(2-hydroxyethyl)-benzenesulfonamide**

The title compound was prepared according to the procedure of Intermediate 24 from 2.28 g (15.6 mmol) of 1,4-dioxo-8-aza-spiro[4.5]decane and 2.85 g (13.0 mmol) of 4-fluoro-N-(2-hydroxyethyl)-benzenesulfonamide, yielding 3.0 g of a colorless gum; MS (ES) m/z 343.2 (MH^+); HRMS (EI) Calcd. for $C_{15}H_{22}N_2O_5S$ (M^+): 342.1249, Found: 342.1235.

INTERMEDIATE 30**N-(2-Hydroxyethyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide**

The title compound was prepared according to the procedure of Intermediate 40 from 2.23 g (6.5 mmol) of 4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-N-(2-hydroxyethyl)-benzenesulfonamide, yielding 1.88 g of a colorless gum; MS (ES) m/z 299.1 (MH⁺); HRMS (EI) Calcd. for C₁₃H₁₈N₂O₄S (M⁺): 298.0988, Found: 298.0974.

INTERMEDIATE 31**8-[4-(Piperidine-1-sulfonyl)-phenyl]-1,4-dioxo-8-aza-spiro[4.5]decane**

The title compound was prepared with N-piperidine-4-fluoro-benzenesulfonamide according to the procedure of Intermediate 37 as a white solid; ¹H NMR (CDCl₃) δ 1.36-1.44 (m, 2H), 1.59-1.67 (m, 4H), 1.81 (t, J=5.79 Hz, 4H), 2.95 (t, J=5.37 Hz, 4H), 3.49 (t, J=5.7 Hz, 4H), 4.00 (s, 4H), 6.89-6.93 (m, 2H), 7.56-7.61 (m, 2H); MS (ES) m/z 367.32 (MH⁺); HRMS for C₁₈H₂₆N₂O₄S: 367.1683

INTERMEDIATE 32**8-[4-(Pyrrolidine-1-sulfonyl)-phenyl]-1,4-dioxo-8-aza-spiro[4.5]decane**

The title compound was prepared with N-pyrrolidine-4-fluoro-benzenesulfonamide according to the procedure of Intermediate 37 as a white needles; ¹H NMR (CDCl₃) δ 1.72-1.77 (m, 4H), 1.79-1.83 (m, 4H), 3.14-3.23 (m, 4H), 3.47-3.51 (m, 4H), 4.00 (s, 4H), 6.89-6.95 (m, 2H), 7.61-7.72 (m, 2H); MS (ES) m/z 353.29 (MH⁺); HRMS for C₁₇H₂₄N₂O₄S: 353.1527

INTERMEDIATE 33**N-Cyclopropylmethyl-4-fluoro-benzenesulfonamide**

To a stirred solution of 2 mL (23 mmol) of aminomethyl cyclopropane in 25 mL methylene chloride was added 4.8 mL (28 mmol) of diisopropylethyl amine. After 10 minutes of stirring, 4.49 g (23 mmol) of 4-fluorobenzene sulfonyl chloride was added and the mixture was allowed to stir for 4 hours. The reaction mixture was quenched with water and the organic layer was washed twice with 1N HCl, twice with water, dried over magnesium sulfate and then concentrated in vacuo. Then the solid was dried under vacuum to give 4.65 g of the title compounds as an off white solid; ¹H NMR (CDCl₃) δ 0.08-0.13 (m, 2H), 0.45-0.51 (m, 2H), 0.83-0.94 (m, 1H), 2.86 (t, J=6.9 Hz, 2H), 4.66-

4.71 (m, 1H), 7.12-7.23 (m, 2H), 7.85-7.92 (m, 2H); MS (ES) m/z 218.23 (MH⁺); HRMS for C₁₀H₁₂FNO₂S: 218.0637

INTERMEDIATE 34

5 1-[4-(Pyrrolidine-1-sulfonyl)-phenyl]-piperidin-4-one

The title compound was prepared with 8-[4-(pyrrolidine-1-sulfonyl)-phenyl]-1,4-dioxo-8-aza-spiro[4.5]decane according to the procedure of Intermediate 40 as a fluffy beige solid; ¹H NMR (CDCl₃) δ 1.70-1.79 (m, 4H), 2.59 (t, J=6.18 Hz, 4H), 3.20-3.29 (m, 4H), 3.75 (t, J=6.09 Hz, 4H), 6.86-6.97 (m, 2H), 7.70-7.76 (m, 2H); MS (ES) m/z 230.2 (MH⁺); HRMS for C₁₅H₂₀N₂O₃S: 230.0645

INTERMEDIATE 35

1-[4-(Piperidine-1-sulfonyl)-phenyl]-piperidin-4-one

The title compound was prepared with 8-[4-(piperidine-1-sulfonyl)-phenyl]-1,4-dioxo-8-aza-spiro[4.5]decane according to the procedure of Intermediate 40 as an off white solid; ¹H NMR (CDCl₃) δ 1.37-1.45 (m, 2H), 1.60-1.68 (m, 4H), 2.59 (t, J=6.18 Hz, 4H), 2.97 (t, J=5.4 Hz, 4H), 3.75 (t, J=6.09 Hz, 4H), 6.90-6.97 (m, 2H), 7.61-7.68 (m, 2H); MS (ES) m/z 323.3 (MH⁺); HRMS for C₁₆H₂₂N₂O₃S: 323.1398

INTERMEDIATE 36

4-(1,4-Dioxo-8-aza-spiro[4.5]dec-8-yl)-N-isobutyl-benzenesulfonamide

The title compound was prepared with 4-fluoro-n-isobutyl-benzenesulfonamide according to the procedure of Intermediate 37 as a light yellow solid; ¹H NMR (CDCl₃) δ 0.86-0.89 (m, 6H), 1.78 (t, J=5.76 Hz, 4H), 2.69-2.82 (m, 3H), 2.95 (s, 1H), 3.49 (t, J=5.79 Hz, 4H), 4.00 (s, 4H), 6.88-6.94 (m, 2H), 7.66-7.71 (m, 2H); MS (ES) m/z 355.3 (MH⁺)

INTERMEDIATE 37

N-Cyclopropylmethyl-4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonamide

A mixture of 2.5 g (11 mmol) N-cyclopropylmethyl-4-fluoro-benzene-sulfonamide, 1.87 g (13 mmol) 1,4-dioxo-8-azaspiro[4.5]decane and 1.81 g (13 mmol) potassium carbonate was heated at 65°C in 6 mL 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidin-one and 3 mL acetonitrile overnight. The reaction mixture was quenched with water and

extracted twice with ethyl acetate. The organic layer was then washed twice with 1N HCl, twice with water, dried over sodium sulfate and then concentrated in vacuo. After drying overnight on a vacuum line, 3.33 g of the title compound was isolated as a yellow solid; ¹H NMR (CDCl₃) δ 0.51 (m, 2H), 0.81-0.94 (m, 2H), 1.80 (t, J=5.85 Hz, 4H), 2.77-2.84 (m, 2H), 2.92 (s, 1H), 3.48 (t, J=5.76 Hz, 4H), 4.00 (s, 4H), 4.32-4.37 (m, 1H), 6.88-6.93 (m, 2H), 7.66-7.71 (m, 2H); MS (ES) m/z 353.3 (MH⁺); HRMS for C₁₇H₂₄N₂O₄S: 353.1539

INTERMEDIATE 38

10 **{[4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-methyl-amino}-acetic acid ethyl ester**

The title compound was prepared with [(4-fluoro-benzenesulfonyl)-methyl-amino]-acetic acid ethyl ester according to the procedure of Intermediate 37 as a red oil; ¹H NMR (CDCl₃) δ 1.25 (t, J=5.58 Hz, 3H), 1.80 (t, J=5.85 Hz, 3H), 2.84 (s, 1H), 2.92 (s, 15 1H), 3.53 (m, 4H), 3.92 (s, 3H), 4.00 (s, 4H), 4.13 (q, J=5.22 Hz, 2H), 6.88-6.95 (m, 2H), 7.58-7.67 (m, 2H); MS (ES) m/z 399.2 (MH⁺); HRMS for C₁₈H₂₆N₂O₆S: 399.1585

INTERMEDIATE 39

N-Isobutyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide

20 The title compound was prepared with 4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-N-isobutyl-benzenesulfonamide according to the procedure of Intermediate 40 as a beige solid; ¹H NMR (CDCl₃) δ 0.87 (d, J=6.72 Hz, 6H), 1.63-1.81 (m, 1H), 2.59 (t, J=6.15 Hz, 4H), 2.75 (q, J=6.75 Hz, 2H), 2.92 (s, 1H), 3.75 (t, J=6.09 Hz, 4H), 6.86-6.97 (m, 2H), 7.70-7.78 (m, 2H); MS (ES) m/z 311.3 (MH⁺); HRMS for C₁₅H₂₂N₂O₃S: 311.1420

25

INTERMEDIATE 40

N-Cyclopropylmethyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide

30 A solution of 3 g (8.5 mmol) n-cyclopropylmethyl-4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonamide in 40 mL acetone and 40 mL 10% sulfuric acid in water was stirred for 3 days. The solvent was removed in vacuo and the resulting mix was quenched with water and neutralized with 10% sodium carbonate. The aqueous mixture was extracted twice with methylene chloride. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The resulting solid was then triturated

with hexanes and ether. After drying via high vacuum, 2.56 g of the title compound was isolated as a beige solid; ^1H NMR (CDCl_3) δ 0.81-0.97 (m, 2H), 1.26 (s, 1H), 2.59 (t, $J=6.15$ Hz, 4H), 2.77-2.87 (m, 4H), 2.92 (s, 1H), 3.75 (t, $J=6.06$ Hz, 4H), 6.89-6.96 (m, 2H), 7.73-7.78 (m, 2H); MS (ES) m/z 309.3 (MH^+); HRMS for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_3\text{S}$: 309.1251

5

INTERMEDIATE 41

{Methyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid

The title compound was prepared with {[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-methyl-amino}-acetic acid ethyl ester according to the procedure of Intermediate 40 as a red gum; ^1H NMR (CDCl_3) δ 2.61 (t, $J=6.12$ Hz, 4H), 2.87 (s, 1H), 2.92 (s, 1H), 3.77 (t, $J=6.09$ Hz, 4H), 3.97 (s, 2H), 6.91-6.99 (m, 2H), 7.69-7.73 (m, 2H); MS (ES) m/z 327.2 (MH^+); HRMS for $\text{C}_{14}\text{H}_{18}\text{N}_2\text{O}_5\text{S}$: 327.1019

INTERMEDIATE 42

{Methyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid ethyl ester

A solution of 0.53 g (1.6 mmol) {methyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid in 8 mL anhydrous tetrahydrofuran was treated with 0.32 g (2.0 mmol) 1,1'-carbonyl-diimidazole. After stirring for 45 minutes, 1 mL of ethanol was added. The resulting mixture was then permitted to stir overnight. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The organics were washed twice with saturated sodium bicarbonate, twice with water, dried over sodium sulfate and concentrated in vacuo. After drying via high vacuum overnight, 0.76 g of the title compound was isolated as a red solid; ^1H NMR (CDCl_3) δ 1.23-1.29 (m, 3H), 2.59 (t, $J=6.15$ Hz, 4H), 2.87 (s, 1H), 3.76 (t, $J=6.09$ Hz, 4H), 3.96 (s, 2H), 4.11-4.18 (m, 2H), 6.89-6.96 (m, 2H), 7.67-7.75 (m, 2H); MS (ES) m/z 355.3 (MH^+); HRMS for $\text{C}_{16}\text{H}_{22}\text{N}_2\text{O}_5\text{S}$: 355.1332

INTERMEDIATE 43

{Butyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid ethyl ester

The title compound was prepared with N-butyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide and ethyl bromoacetate according to the procedure of Intermediate 2 as a yellow oil; ^1H NMR (CDCl_3) δ 0.88 (t, $J=7.29$ Hz, 3H), 1.23 (t, $J=7.11$ Hz, 3H), 1.19-1.35 (m, 2H), 1.48-1.56 (m, 2H), 2.58 (t, $J=6.18$ Hz, 4H), 3.20 (t, $J=7.47$ Hz, 2H),

3.74 (t, J=6.09 Hz, 4H), 4.03 (s, 2H), 4.13 (q, J=7.14 Hz, 2H), 6.89-6.95 (m, 2H), 7.72-7.78 (m, 2H); MS (ES) m/z 397.2 (MH⁺); HRMS for C₁₉H₂₈N₂O₅S: 397.1791

INTERMEDIATE 44

5 4-(1,4-Dioxo-8-aza-spiro[4.5]dec-8-yl)-N-isopropyl-benzenesulfonamide

The title compound was prepared with 4-fluoro-N-isopropyl-benzenesulfonamide according to the procedure of Intermediate 37 as a colorless oil; ¹H NMR (CDCl₃) δ 1.06 (d, J=6.54 Hz, 6H), 1.81 (t, J=5.85 Hz, 4H), 1.92-2.01 (m, 1H), 2.92 (s, 1H), 3.25 (t, J=5.94 Hz, 4H), 4.00 (s, 4H), 6.89-6.94 (m, 2H), 7.68-7.72 (m, 2H); MS (ES) m/z 341.2 (MH⁺); HRMS for C₁₆H₂₄N₂O₄S: 341.1526

INTERMEDIATE 45

{Cyclopropylmethyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid ethyl ester

15 The title compound was prepared with n-cyclopropylmethyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide and ethyl bromoacetate according to the procedure of Intermediate 2 as a yellow oil; ¹H NMR (CDCl₃) δ 0.10 (m, 2H), 0.50-0.54 (m, 2H), 0.82-0.94 (m, 1H), 1.23 (t, J=7.14 Hz, 3H), 2.58 (t, J=6.18 Hz, 4H), 3.13 (d, J=6.96 Hz, 2H), 3.74 (t, J=6.09 Hz, 4H), 4.13 (q, J=7.14 Hz, 2H), 4.21 (s, 2H), 6.89-6.94 (m, 2H), 7.73-7.78 (m, 2H); MS (ES) m/z 395.5 (MH⁺); HRMS for C₁₉H₂₆N₂O₅S: 395.1578

INTERMEDIATE 46

{Isobutyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid ethyl ester

25 The title compound was prepared with N-isobutyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide and ethyl bromoacetate according to the procedure of Intermediate 2 as a yellow oil; ¹H NMR (CDCl₃) δ 0.90 (d, J=7.29 Hz, 6H), 1.22 (t, J=7.11 Hz, 3H), 1.72-1.89 (m, 1H), 2.58 (t, J=6.12 Hz, 4H), 3.02 (d, J=7.53 Hz, 2H), 3.74 (t, J=6.06 Hz, 4H), 4.00 (s, 4H), 4.11 (q, J=7.14 Hz, 2H), 6.89-6.96 (m, 2H), 7.70-7.76 (m, 2H); MS (ES) m/z 397.2 (MH⁺); HRMS for C₁₉H₂₆N₂O₅S: 397.1702

30

INTERMEDIATE 47**N-Isopropyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide**

The title compound was prepared with 4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-N-isopropyl-benzenesulfonamide according to the procedure of Intermediate 40 as a white solid; mp 103-105 °C; ¹H NMR (CDCl₃) δ 1.09 (d, J=6.48 Hz, 6H), 2.59 (t, J=6.18 Hz, 4H), 3.36-3.43 (m, 1H), 3.47-3.54 (m, 1H), 3.75 (t, J=6.09 Hz, 4H), 6.89-6.96 (m, 2H), 7.71-7.79 (m, 2H); MS (ES) m/z 297.2 (MH⁺); HRMS for C₁₄H₂₀N₂O₃S: 296.1196

INTERMEDIATE 48**1-(4-Fluoro-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid ethyl ester**

To 5 g (43 mmol) of D-proline in 20 g (434 mmol) ethanol was added 100 mL 1N HCl in ether. (mixture should become homogenous over time) After stirring for 3 days, the solvent was removed in vacuo. The residue was then dissolved in methylene chloride, which was then treated with 12 mL (86 mmol) of triethylamine. After 15 minutes, 8.45 g (43 mmol) of 4-fluoro-benzenesulfonyl chloride was added and the resulting mixture was stirred overnight. The reaction mixture was quenched with water and the organic layer was washed twice with saturated sodium carbonate, twice with 1N HCl and twice with water. After drying over magnesium sulfate, the organics were concentrated in vacuo and dried via high vacuum to give 11.56 g of the title compound as a white solid; mp 62-63 °C; ¹H NMR (CDCl₃) δ 1.26 (t, J=7.11 Hz, 3H), 1.81-1.86 (m, 1H), 1.95-2.17 (m, 2H), 3.32-3.48 (m, 2H), 4.08-4.24 (m, 2H), 4.37 (q, J=3.99 Hz, 2H), 7.15-7.23 (m, 2H), 7.88-7.98 (m, 2H); MS (ES) m/z 302.3 (MH⁺); HRMS for C₁₃H₁₆FNO₄S: 302.2934

INTERMEDIATE 49**1-(4-Fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid ethyl ester**

The title compound was prepared with DL-proline according to the procedure of Intermediate 48 as a white semi-solid; ¹H NMR (CDCl₃) δ 1.26 (t, J=7.11 Hz, 3H), 1.81-1.85 (m, 1H), 1.95-2.13 (m, 2H), 3.32-3.48 (m, 2H), 4.08-4.24 (m, 2H), 4.34 (q, J=4.47 Hz, 2H), 7.15-7.23 (m, 2H), 7.89-7.96 (m, 2H); MS (ES) m/z 302.3 (MH⁺); HRMS for C₁₃H₁₆FNO₄S: 302.0830

INTERMEDIATE 50**1-(4-Fluoro-benzenesulfonyl)-pyrrolidine-(2S)-2-carboxylic acid ethyl ester**

The title compound was prepared with L-proline according to the procedure of Intermediate 48 as a white solid; mp 58-59 °C; ¹H NMR (CDCl₃) δ 1.26 (t, J=7.14 Hz, 3H), 1.81-1.85 (m, 1H), 1.95-2.11 (m, 2H), 3.31-3.48 (m, 2H), 4.09-4.24 (m, 2H), 4.34 (q, J=4.41 Hz, 2H), 7.15-7.23 (m, 2H), 7.88-7.98 (m, 2H); MS (ES) m/z 302.3 (MH⁺); HRMS for C₁₃H₁₆FNO₄S: 302.0855

INTERMEDIATE 51**1-[4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-(2R)-2-carboxylic acid ethyl ester**

The title compound was prepared with 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid ethyl ester according to the procedure of Intermediate 37 as a yellow oil; ¹H NMR (CDCl₃) δ 1.27 (t, J=7.14 Hz, 3H), 1.76-1.81 (m, 4H), 1.92-1.99 (m, 4H), 3.22-3.31 (m, 3H), 3.42-3.51 (m, 4H), 4.00 (s, 4H), 4.18 (q, J=4.80 Hz, 2H), 6.91 (d, J=9.03 Hz, 2H), 7.68-7.74 (m, 2H); MS (ES) m/z 425.3 (MH⁺); HRMS for C₂₀H₂₈N₂O₆S: 425.1685

INTERMEDIATE 52**1-[4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid ethyl ester**

The title compound was prepared with 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-2-carboxylic acid ethyl ester according to the procedure of Intermediate 37 as a yellow oil; ¹H NMR (CDCl₃) δ 1.23-1.29 (m, 3H), 1.78-1.83 (m, 4H), 1.92-2.06 (m, 4H), 3.22-3.32 (m, 3H), 3.44-3.50 (m, 4H), 4.00 (s, 4H), 4.16-4.20 (m, 2H), 6.88-6.94 (m, 2H), 7.68-7.75 (m, 2H); MS (ES) m/z 425.2 (MH⁺); HRMS for C₂₀H₂₈N₂O₆S: 425.1661

INTERMEDIATE 53**1-[4-(4-Oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-(2R)-2-carboxylic acid ethyl ester**

The title compound was prepared with 1-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-(2R)-2-carboxylic acid ethyl ester according to the procedure of Intermediate 40 as a yellow oil; ¹H NMR (CDCl₃) δ 1.27 (t, J=7.14 Hz, 3H), 1.76-1.81

(m, 1H), 1.94-2.10 (m, 2H), 2.61 (t, J=7.44 Hz, 4H), 3.23-3.36 (m, 2H), 3.44-3.49 (m, 2H), 4.17-4.22 (m, 2H), 6.91-6.96 (m, 2H), 7.75-7.81 (m, 2H); MS (ES) m/z 381.2 (MH⁺); HRMS for C₁₈H₂₄N₂O₅S: 380.1398

5

INTERMEDIATE 54**1-[4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-(2S)-2-carboxylic acid ethyl ester**

The title compound was prepared with 1-(4-fluoro-benzenesulfonyl)-pyrrolidine-(2S)-2-carboxylic acid ethyl ester according to the procedure of Intermediate 37 as a
10 light yellow semi-solid; ¹H NMR (CDCl₃) δ 1.26 (t, J=7.11 Hz, 3H), 1.83 (t, J=5.76 Hz, 4H), 1.92-2.01 (m, 3H), 3.25 (t, J=5.94, 4H), 3.42-3.51 (m, 2H), 4.00 (s, 4H), 4.14-4.21 (m, 4H), 6.94 (d, J=8.97 Hz, 2H), 7.71 (d, J=11.94 Hz, 2H); MS (ES) m/z 425.2 (MH⁺); HRMS for C₂₀H₂₈N₂O₆S: 424.1699

15

INTERMEDIATE 55**1-[4-(4-Oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid ethyl ester**

The title compound was prepared with 1-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid ethyl ester according to the procedure of
20 Intermediate 40 as a light orange oil; ¹H NMR (CDCl₃) δ 1.22-1.29 (t, 3H), 1.77-1.80 (m, 4H), 2.59 (t, J=6.18 Hz, 4H), 3.25-3.37 (m, 3H), 3.75 (t, J=6.09 Hz, 4H), 4.13-4.22 (m, 2H), 6.90-6.96 (m, 2H), 7.74-7.81 (m, 2H); MS (ES) m/z 381.2 (MH⁺); HRMS for C₁₈H₂₄N₂O₅S: 380.9760

25

INTERMEDIATE 56**1-[4-(4-Oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-(2S)-2-carboxylic acid ethyl ester**

The title compound was prepared with 1-[4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-(2S)-2-carboxylic acid ethyl ester according to the procedure
30 of Intermediate 40 as an orange oil; ¹H NMR (CDCl₃) δ 1.27 (t, J=7.11 Hz, 3H), 1.92-2.01 (m, 3H), 2.61 (t, J=6.42 Hz, 4H), 3.24 (t, J=5.91 Hz, 3H), 3.75 (t, J=6.12 Hz, 4H), 4.14-4.23 (m, 2H), 6.91-6.96 (m, 2H), 7.75-7.83 (m, 2H); MS (ES) m/z 381.3 (MH⁺); HRMS for C₁₈H₂₄N₂O₅S: 380.9760

INTERMEDIATE 57**(2S)-2-(4-Fluoro-benzenesulfonylamino)-4-methyl-pentanoic acid ethyl ester**

The title compound was prepared with L-leucine ethyl ester hydrochloride and 2.5 equivalents of triethylamine according to the procedure of Intermediate 33 as a colorless oil; ¹H NMR (CDCl₃) δ 0.88-0.93 (m, 6H), 1.11 (t, J=7.14 Hz, 4H), 1.51 (t, J=7.53 Hz, 1H), 1.73-1.87 (m, 1H), 3.84-3.99 (m, 2H), 5.10 (d, J=9.99 Hz, 1H), 7.12-7.20 (m, 2H), 7.80-7.89 (m, 2H); MS (ES) m/z 318.2 (MH⁺); HRMS for C₁₄H₂₀FNO₄S: 317.109

INTERMEDIATE 58**(2S)-2-(4-Fluoro-benzenesulfonylamino)-3-methyl-butyric acid ethyl ester**

The title compound was prepared with L-valine ethyl ester hydrochloride and 2.5 equivalents of triethylamine according to the procedure of Intermediate 33 as a white solid; ¹H NMR (CDCl₃) δ 0.87 (d, J=6.87 Hz, 3H), 0.97 (d, J=6.78 Hz, 3H), 1.10 (t, J=7.14 Hz, 4H), 1.97-2.13 (m, 1H), 3.71 (q, J=4.92 Hz, 1H), 3.74-4.01 (m, 2H), 5.10 (d, J=10.02 Hz, 1H), 7.12-7.20 (m, 2H), 7.81-7.88 (m, 2H); MS (ES) m/z 304.1 (MH⁺); HRMS for C₁₃H₁₈FNO₄S: 303.0953

INTERMEDIATE 59**ethyl(2S)-2-([4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl)amino)-4-methylpentanoate**

The title compound was prepared with (2S)-2-(4-fluoro-benzenesulfonylamino)-4-methyl-pentanoic acid ethyl ester according to the procedure of Intermediate 37 as a yellow oil; ¹H NMR (CDCl₃) δ 0.87-0.91 (m, 3H), 1.07-1.13 (m, 4H), 1.48 (t, J=7.23 Hz, 4H), 3.49 (t, J=5.67, 4H), 3.81-3.92 (m, 8H), 4.00 (s, 4H), 4.96 (d, J=10.08 Hz, 1H), 6.86-6.91 (m, 2H), 7.62-7.67 (m, 2H); MS (ES) m/z 441.3 (MH⁺); HRMS for C₂₁H₃₂N₂O₆S: 440.1984

INTERMEDIATE 60**ethyl(2S)-2-([4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl)amino)-3-methylbutanoate**

The title compound was prepared with (2S)-2-(4-fluoro-benzenesulfonylamino)-3-methyl-butyric acid ethyl ester according to the procedure of Intermediate 37 as a dark

orange oil; ^1H NMR (CDCl_3) δ 0.87 (d, $J=6.81$ Hz, 3H), 0.97 (d, $J=6.72$ Hz, 3H), 1.06-1.13 (m, 3H), 1.79 (t, $J=5.67$ Hz, 4H), 3.44-3.49 (m, 4H), 3.89-3.92 (m, 2H), 4.00 (s, 4H), 5.03 (d, $J=10.05$ Hz, 1H), 6.90 (m, $J=8.76$ Hz, 2H), 7.62-7.68 (m, 2H); MS (ES) m/z 427.2 (MH^+); HRMS for $\text{C}_{20}\text{H}_{30}\text{N}_2\text{O}_6\text{S}$: 426.1822

5

INTERMEDIATE 61**ethyl(2S)-4-methyl-2-({[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl}amino)pentanoate**

The title compound was prepared with ethyl(2S)-2-({[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl}amino)-4-methylpentanoate according to the procedure of Intermediate 40 as an orange oil; ^1H NMR (CDCl_3) δ 0.87-0.93 (m, 6H), 1.11 (t, $J=7.14$ Hz, 3H), 1.45-1.51 (m, 2H), 1.75-1.86 (m, 2H), 2.57 (t, $J=6.15$ Hz, 4H), 3.73 (t, $J=6.09$ Hz, 4H), 3.84-4.00 (m, 2H), 5.04 (d, $J=10.02$ Hz, 1H), 6.88-6.94 (m, 2H), 7.69-7.76 (m, 2H); MS (ES) m/z 397.2 (MH^+); HRMS for $\text{C}_{19}\text{H}_{28}\text{N}_2\text{O}_5\text{S}$: 396.1685

15

INTERMEDIATE 62**ethyl(2S)-3-methyl-2-({[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl}amino)butanoate**

The title compound was prepared with ethyl(2S)-2-({[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl}amino)-3-methylbutanoate according to the procedure of Intermediate 40 as an orange solid; mp 77-80 $^{\circ}\text{C}$; ^1H NMR (CDCl_3) δ 0.87 (d, $J=6.81$ Hz, 3H), 0.98 (d, $J=6.78$ Hz, 3H), 1.10 (t, $J=7.14$ Hz, 3H), 2.00-2.10 (m, 2H), 2.57 (t, $J=6.15$ Hz, 4H), 3.73 (t, $J=6.09$ Hz, 4H), 3.88-4.00 (m, 2H), 5.04 (d, $J=10.02$ Hz, 1H), 6.87-6.92 (m, 2H), 7.60-7.75 (m, 2H); MS (ES) m/z 383.3 (MH^+); HRMS for $\text{C}_{18}\text{H}_{26}\text{N}_2\text{O}_5\text{S}$: 383.1633

25

INTERMEDIATE 63**ethyl 1-({[4-(4-fluorophenyl)sulfonyl]amino}cyclohexanecarboxylate**

The title compound was prepared with 1-aminocyclohexanecarboxylic acid, with gentle warming to get the mixture homogenous, according to the procedure of Intermediate 48 as a white solid; mp 96-98 $^{\circ}\text{C}$; ^1H NMR (CDCl_3) δ 1.23 (t, $J=7.17$ Hz, 3H), 1.26-1.46 (m, 6H), 1.82-1.87 (m, 4H), 4.00 (q, $J=7.11$ Hz, 2H), 4.79 (s, 1H), 7.12-7.21 (m, 2H), 7.85-7.92 (m, 2H); MS (ES) m/z 330.2 (MH^+); HRMS for $\text{C}_{15}\text{H}_{20}\text{FNO}_4\text{S}$: 329.1082

INTERMEDIATE 64**ethyl 1-([(4-fluorophenyl)sulfonyl]amino)cyclopentanecarboxylate**

The title compound was prepared with 1-aminocyclopentanecarboxylic acid, with gentle warming to get the mixture homogenous, according to the procedure of Intermediate 48 as a white solid; ¹H NMR (CDCl₃) δ 1.23 (t, J=7.14 Hz, 3H), 1.62-1.71 (m, 4H), 1.90-1.98 (m, 2H), 2.03-2.11 (m, 2H), 4.04 (q, J=7.14 Hz, 2H), 5.09 (s, 1H), 7.12-7.21 (m, 2H), 7.85-7.92 (m, 2H); MS (ES) m/z 316.2 (MH⁺); HRMS for C₁₄H₁₈FNO₄S: 315.0932

INTERMEDIATE 65**ethyl 1-([(4-(1,4-dioxo-8-azaspiro[4.5]dec-8)phenyl)sulfonyl]amino)-cyclopentanecarboxylate**

The title compound was prepared with ethyl 1-([(4-fluorophenyl)sulfonyl]amino)cyclopentanecarboxylate according to the procedure of Intermediate 37 as a light yellow solid; ¹H NMR (CDCl₃) δ 1.21 (t, J=7.14 Hz, 3H), 1.64-1.69 (m, 4H), 1.79 (t, J=5.7 Hz, 4H), 1.90-2.10 (m, 6H), 3.48 (t, J=5.79 Hz, 4H), 3.97-4.04 (m, 2H), 4.00 (s, 4H), 4.99 (s, 1H), 6.85-6.91 (m, 2H), 7.60-7.71 (m, 2H); MS (ES) m/z 439.2 (MH⁺); HRMS for C₂₁H₃₀N₂O₆S: 438.1812

INTERMEDIATE 66**ethyl 1-([(4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]amino)cyclopentanecarboxylate**

The title compound was prepared with ethyl 1-([(4-(1,4-dioxo-8-azaspiro[4.5]dec-8)phenyl)sulfonyl]amino)cyclopentanecarboxylate according to the procedure of Intermediate 40 as a yellow gum; ¹H NMR (CDCl₃) δ 1.24 (t, J=7.14 Hz, 3H), 1.57-1.69 (m, 4H), 1.90-1.96 (m, 2H), 1.97-2.11 (m, 2H), 2.58 (t, J=6.09 Hz, 4H), 3.74 (t, J=6.06 Hz, 4H), 4.04 (q, J=7.14 Hz, 2H), 5.03 (s, 1H), 6.86-6.93 (m, 2H), 7.72-7.78 (m, 2H); MS (ES) m/z 395.2 (MH⁺); HRMS for C₁₉H₂₆N₂O₅S: 395.1631

INTERMEDIATE 67**ethyl 1-([(4-(1,4-dioxo-8-azaspiro[4.5]dec-8-l)phenyl)sulfonyl]amino)cyclohexanecarboxylate**

The title compound was prepared with ethyl 1-([(4-fluorophenyl)sulfonyl]amino)-cyclohexanecarboxylate according to the procedure of Intermediate 37 as a yellow

gum; ^1H NMR (CDCl_3) δ 1.20-1.29 (m, 3H), 1.44-1.47 (m, 8H), 1.77-1.85 (m, 6H), 3.48 (t, $J=5.7$ Hz, 4H), 3.98 (q, $J=7.59$ Hz, 2H), 4.00 (s, 4H), 4.72 (s, 1H), 6.85-6.91 (m, 2H), 7.65-7.71 (m, 2H); MS (ES) m/z 453.2 (MH^+); HRMS for $\text{C}_{22}\text{H}_{32}\text{N}_2\text{O}_6\text{S}$: 453.2054

5

INTERMEDIATE 68**ethyl 1-([4-(4-oxo-1-piperidinyl)phenyl]sulfonyl)amino)cyclohexanecarboxylate**

The title compound was prepared with ethyl 1-([4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl)amino)cyclohexanecarboxylate according to the procedure of Intermediate 40 as a white solid; ^1H NMR (CDCl_3) δ 1.23 (t, $J=7.11$ Hz, 3H), 1.26-1.47 (m, 6H), 1.83-1.87 (m, 4H), 2.58 (t, $J=6.12$ Hz, 4H), 3.74 (t, $J=6.03$ Hz, 4H), 4.01 (q, $J=7.14$ Hz, 2H), 4.75 (s, 1H), 7.12-7.21 (m, 2H), 7.85-7.92 (m, 2H); MS (ES) m/z 409.3 (MH^+); HRMS for $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_5\text{S}$: 409.1788

10

INTERMEDIATE 69**ethyl (isopropyl[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl)amino)acetate**

The title compound was prepared with N-isopropyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide according to the procedure of Intermediate 2 as a yellow oil; ^1H NMR (CDCl_3) δ 1.02-1.10 (m, 6H), 1.25-1.33 (m, 3H), 2.56-2.61 (m, 4H), 3.38-3.50 (m, 1H), 3.74 (t, $J=6.06$ Hz, 4H), 3.89-3.97 (m, 2H), 4.16-4.28 (m, 2H), 6.89-7.18 (m, 2H), 7.71-7.79 (m, 1H), 7.86-7.91 (m, 1H); MS (ES) m/z 383.3 (MH^+); HRMS for $\text{C}_{18}\text{H}_{26}\text{N}_2\text{O}_5\text{S}$: 383.1630

20

INTERMEDIATE 70**N-Benzyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide**

The title compound was prepared from Intermediate 8, N-Benzyl-N-(tert-butylcarbonyl)-4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)benzenesulfonamide, according to the procedure of Intermediate 5 as a white solid; mp 136-140 °C; MS (ES) m/z 345.0 (MH^+); HRMS (EI) for $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}_3\text{S}$: 344.1166.

25

INTERMEDIATE 71**(3,4-Dimethoxyphenyl)[(4-fluorophenyl)sulfonyl]carbamic acid, tert-butyl ester**

The title compound was prepared from Intermediate 1, N-(3,4-dimethoxy-phenyl)-4-fluoro-benzenesulfonamide, according to the procedure of Intermediate 6 as a tan solid; mp 99-102 °C; MS (ES) m/z 412.0 (MH⁺); HRMS (EI) for C₁₉H₂₂FNO₆S: 344.1166.

INTERMEDIATE 72**(3,4-Dimethoxyphenyl)[[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl]carbamic acid, tert-butyl ester**

The title compound was prepared from Intermediate 71, (3,4-dimethoxy-phenyl)[(4-fluorophenyl)sulfonyl]carbamic acid, tert-butyl ester, according to the procedure of Intermediate 3 as a gum; MS (ES) m/z 434.9 (M-BOC+H⁺).

INTERMEDIATE 73**N-(3,4-Dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide**

The title compound was prepared from Intermediate 72, (3,4-dimethoxyphenyl)-[[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl]carbamic acid, tert-butyl ester, according to the procedure of Intermediate 5 as a yellow solid; mp 50-56 °C; MS (ES) m/z 391.0 (MH⁺); HRMS (EI) for C₁₉H₂₂N₂O₅S: 390.1246.

The following procedures describe the preparation of representative examples of this invention.

EXAMPLE 1**N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-{4-[2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide**

Sodium Triacetoxyborohydride (0.015g, 0.72mM) was added to a solution of 4-((2S)-3-Amino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one (0.08g, 0.36mM), N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide (0.19g, 0.39mM), and acetic acid (0.025ml, 0.43mM) in anhydrous dimethylformamide (5ml). The reaction was stirred overnight. The reaction was quenched with 50% H₂O/sat. NaHCO₃aq. (20ml). The solids were captured on a filter and washed with ethyl acetate, diethyl ether, and hexanes to afford 0.075g of the desired product as a brown solid. ¹H NMR (DMSO) δ 1.31 (m, 2H), 1.89 (m, 2H), 2.71 (m, 2H), 2.87 (m, 3H), 3.53(s, 3H), 3.67

(s, 3H), 3.87 (m, 4H), 3.98 (m, 1H), 4.67(s, 2H), 4.95(bs, 1H), 6.44 (s, 1H), 6.59(m, 2H), 6.79 (m, 2H), 7.05 (d, 2H, J=8.7 Hz), 7.25 (m, 6H), 7.41(d, 2H, J=8.4Hz), 10.59 (bs, 1H), 10.72 (bs, 1H); MS (ES) m/z: 688.1 (MH⁺); HRMS for C₃₆H₄₁N₅O₇S: 688.2799 (MH⁺)

5

EXAMPLE 2**N-Benzyl-N-butyl-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yl-oxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from 4-((2S)-3-Amino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one and Intermediate 9 according to the procedure of Example 1 as a brown solid. ¹H NMR (DMSO) δ 0.67(t, 3H, J=7.17Hz), 1.04(m, 2H), 1.24(m, 2H), 1.37 (m, 2H), 1.90 (m, 2H), 2.73 (m, 2H), 2.84(m, 2H), 2.99(m, 4H), 3.87(m, 3H), 4.03(M, 1H), 4.21(s, 2H), 5.07(bs, 1H), 6.61 (m, 1H), 6.84(t, 1H, J=8.1Hz), 7.07(d, 2H, J=9.0Hz), 7.32 (m, 6H), 7.59 (d, 2H, J=8.7Hz), 10.59 (bs, 1H), 10.72 (bs, 1H); MS (ES) m/z: 608.3 (MH⁺); HRMS for C₃₂H₄₁N₅O₅S: 608.2915 (MH⁺)

15

EXAMPLE 3**N-Benzyl-N-butyl-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from N-[5-(2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide and Intermediate 9 according to the procedure of Example 1 as an off-white solid. ¹H NMR (DMSO) δ 0.67(t, 3H, J=7.08Hz), 1.06(m, 2H), 1.22(m, 2H), 1.36 (m, 2H), 1.89 (m, 2H), 2.69 (m, 3H), 2.92(s, 3H), 2.99(m, 2H), 3.69(m, 2H), 3.85(m, 2H), 4.21(s, 2H), 4.52(m, 1H), 6.82 (d, 1H, J=11.52Hz), 7.03(d, 2H, J=8.1Hz), 7.19 (s, 1H), 7.32 (m, 6H), 7.61 (d, 2H, J=8.7Hz); MS (ES) m/z 631.2 (MH⁺); HRMS for C₃₁H₄₂N₄O₆S₂: 631.2626 (MH⁺)

25

EXAMPLE 4**N-Benzyl-4-{4-[2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from 4-((2S)-3-Amino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one and Intermediate 70, N-benzyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as a grey solid. ¹H NMR (DMSO) δ 1.37 (m, 2H), 1.90 (m, 2H), 2.73 (m, 2H), 2.84(m, 2H), 2.99(m, 4H), 3.87(m, 3H), 4.03(m, 1H), 5.07(bs, 1H), 6.67 (m, 1H), 6.85(t, 1H, J=8.1Hz), 7.07(d, 2H, J=9.0Hz),

30

7.32 (m, 6H), 7.59 (d, 2H, J=8.7Hz), 10.59 (bs, 1H), 10.72 (bs, 1H); MS (ES) m/z: 552.1 (MH⁺); HRMS for C₂₈H₃₃N₅O₅S: 552.2267 (MH⁺)

EXAMPLE 5

5 **N-Benzyl-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethyl-amino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from N-[5-(2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide and Intermediate 70, N-benzyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as an off-white solid. ¹H
10 NMR (DMSO) δ 1.33 (m, 2H), 1.86 (m, 2H), 2.67(m, 3H), 2.89(s, 3H), 2.99(m, 2H), 3.69(m, 2H), 3.85(s, 2H), 4.49(m, 1H), 6.83 (d, 1H, J=6.0Hz), 7.00(m, 2H), 7.19 (s, 1H), 7.24 (m, 6H), 7.56 (d, 2H, J=6.6Hz); MS (ES) m/z: 575.1 (MH⁺); HRMS for C₂₇H₃₄N₄O₆S₂: 575.2015 (MH⁺)

15 **EXAMPLE 6**

N-Benzyl-4-{4-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide

The title compound was prepared from 4-((2S)-3-Amino-2-hydroxy-propoxy)-phenol and Intermediate 70, N-benzyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide,
20 according to the procedure of Example 1 as a tan solid. ¹H NMR (DMSO) δ 1.27 (m, 2H), 1.86 (m, 2H), 2.75(m, 3H), 2.91(t, 2H, J=8.4Hz), 3.82(m, 5H), 3.89(s, 2H), 4.89(m, 1H), 6.67 (d, 2H, J=6.6Hz), 6.76(d, 2H, J=6.6Hz), 7.02 (d, 2H, J=6.6Hz), 7.26 (m, 5H), 7.57 (d, 2H, J=6.6Hz), 7.78(bs, 1H), 8.87(bs, 1H); MS (ES) m/z: 512.1 (MH⁺); HRMS for C₂₇H₃₃N₃O₅S: 511.2215 (MH⁺)

25

EXAMPLE 7

N-(3,4-Dimethoxy-phenyl)-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide

The title compound was prepared from 4-((2S)-3-Amino-2-hydroxy-propoxy)-1,3-
30 dihydro-benzimidazol-2-one and Intermediate 73, N-(3,4-dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as a grey solid. ¹H NMR (DMSO) δ 1.28 (m, 2H), 1.84 (m, 2H), 2.65(m, 1H), 2.81 (m, 4H), 3.62(s, 3H), 3.64(s, 3H), 3.77(m, 2H), 3.89(m, 2H), 4.03(m, 1H), 4.87(bs, 1H), 6.59 (m, 4H), 6.74(d, 1H, J=8.7Hz), 6.83(d, 1H, J=8.1Hz), 6.91 (d, 2H, J=9.0Hz), 7.45(d, 2H, J=9.0Hz),

10.57 (bs, 1H), 10.69 (bs, 1H); MS (ES) m/z: 598.1 (MH⁺); HRMS for C₂₉H₃₅N₅O₇S: 598.2296 (MH⁺)

EXAMPLE 8

5 **N-(3,4-Dimethoxy-phenyl)-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from N-[5-(2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamid, and Intermediate 73, N-(3,4-dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as a yellow
10 solid; mp 205-218 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.15-1.30 (m, 2 H), 1.70-1.90 (m, 2 H), 2.50-3.00 (m, 5 H), 2.89 (s, 3 H), 3.62 (s, 3 H), 3.65 (s, 3 H), 3.65-3.85 (m 2 H), 4.40-4.50 (m, 1 H), 6.50-7.10 (m, 8 H), 7.45 (d, 2 H), 9.11 (s, 1 H); MS (ES) m/z : 621.0 (MH⁺); HRMS Calcd. for C₂₈H₃₇N₄O₈S₂ (MH⁺): 621.2053. Found: 621.2058.

EXAMPLE 9

15 **4-{4-[(2S)-3-(4-Benzyloxy-phenoxy)-2-hydroxy-propylamino]-piperidin-1-yl}-N-(3,4-dimethoxy-phenyl)-benzenesulfonamide**

The title compound was prepared from 1-Amino-3-(4-benzyloxy-phenoxy)-propan-2-ol and Intermediate 73, N-(3,4-dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzene-sulfonamide, according to the procedure of Example 1 as an off-white solid; mp 113-
20 121°C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.15-1.35 (m, 2 H), 1.75-1.90 (m, 2 H), 2.50-2.90 (m, 5 H), 2.89 (s, 3 H), 3.61 (s, 3 H), 3.64 (s, 3 H), 3.64-3.80 (m, 5 H), 5.02 (s, 2 H), 6.70-7.00 (m, 9 H), 7.30-7.70 (m, 7 H); MS (ES) m/z : 648.1 (MH⁺); HRMS Calcd. for C₃₅H₄₂N₃O₇S (MH⁺): 648.2743. Found: 648.2710.

EXAMPLE 10

25 **4-{4-[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxy-propylamino]-piperidin-1-yl}-N-(3,4-dimethoxy-phenyl)-benzenesulfonamide**

The title compound was prepared from 1-Amino-3-(9H-carbazol-4-yloxy)-propan-2-ol and Intermediate 73, N-(3,4-dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzene-sulfonamide, according to the procedure of Example 1 as an off-white solid; mp 58-64°C;
30 ¹H NMR (300 MHz, DMSO-d₆) δ 1.20-1.40 (m, 2 H), 1.80-1.95 (m, 2 H), 2.60-2.90 (m, 5 H), 3.62 (s, 3 H), 3.64 (s, 3 H), 3.60-3.80 (m, 2 H), 4.00-4.20 (m, 3 H), 6.40-7.50 (m,

12 H), 7.95 (s, 1 H), 8.20 (d, 1 H), 11.30 (s, 1 H); MS (ES) m/z : 631.1 (MH⁺); HRMS Calcd. for C₃₄H₃₉N₄O₆S (MH⁺): 631.2590. Found: 631.2595.

EXAMPLE 11

5 **N-(3,4-Dimethoxy-phenyl)-4-{4-[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from 4-((2S)-3-Amino-2-hydroxy-propoxy)-phenol and Intermediate 73, N-(3,4-dimethoxy-phenyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as an off-white solid; mp 101-106°C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.15-1.30 (m, 2 H), 1.70-1.90 (m, 2 H), 2.50-2.90 (m, 5 H), 3.61 (s, 3 H), 3.63 (s, 3 H), 3.60-3.90 (m, 5 H), 6.45 (dd, 1 H), 6.60-6.80 (m, 8 H), 6.90 (d, 1 H), 7.45 (d, 1 H); MS (ES) m/z : 557.9 (MH⁺); HRMS Calcd. for C₂₈H₃₆N₃O₇S (MH⁺): 558.2274. Found: 558.2293.

EXAMPLE 12

15 **N-Butyl-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from 4-((2S)-3-amino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one and Intermediate 11, N-butyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as an off-white solid; mp 69-75 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 0.79 (t, 3 H), 1.10-1.40 (m, 6 H), 1.75-1.90 (m, 2 H), 2.67 (t, 2 H), 2.10-3.00 (m, 5 H), 3.70-4.10 (m, 5 H), 6.55 (d, 3 H), 6.62 (d, 1 H), 6.83 (t, 1 H), 7.00 (d, 2 H), 7.52 (d, 2 H), 10.45-10.80 (m, 2 H); MS (ES) m/z : 518.1 (MH⁺); HRMS Calcd. for C₂₅H₃₆N₅O₅S (MH⁺): 518.2437. Found: 518.2446.

EXAMPLE 13

25 **N-Butyl-4-{4-[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxy-propylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from 1-amino-3-(9H-carbazol-4-yloxy)-propan-2-ol and Intermediate 11, N-butyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as an off-white solid; mp 166-179 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 0.79 (t, 3 H), 1.15-1.40 (m, 6 H), 1.75-1.90 (m, 2 H), 2.64 (t, 2 H), 2.60-3.00 (m, 5 H), 3.60-4.20 (m, 5 H), 6.69 (d, 1 H), 6.80-7.60 (m, 7 H), 7.90 (s, 1 H), 8.20 (d,

2 H), 11.35 (s, 1 H); MS (ES) m/z : 551.1 (MH^+); HRMS Calcd. for $C_{30}H_{39}N_4O_4S$ (MH^+): 551.2692. Found: 551.2664.

EXAMPLE 14

5 **N-Butyl-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from N-[5-((1R)-2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide and Intermediate 11, N-butyl-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, according to the procedure of Example 1 as a white solid; mp

10 71-75 °C; 1H NMR (300 MHz, DMSO- d_6) δ 0.80 (t, 3 H), 1.10-1.40 (m, 6 H), 1.80-1.95 (m, 2 H), 2.50-2.90 (m, 5 H), 2.92 (s, 3 H), 3.70-3.90 (m, 2 H), 4.45-4.55 (m, 1 H), 6.82 (d, 1 H), 7.02 (d, 3 H), 7.19 (d, 1 H), 7.54 (d, 2 H); MS (ES) m/z : 541.0 (MH^+); HRMS Calcd. for $C_{24}H_{37}N_4O_6S_2$ (MH^+): 541.2155. Found: 541.2136.

EXAMPLE 15

15 **1-(4-{4-[2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester**

The title compound was prepared from N-[5-((1R)-2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide and Intermediate 14, 1-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid isopropyl ester, according to the procedure

20 of Example 1 as an off-white solid; mp 52-58 °C; 1H NMR (300 MHz, DMSO- d_6) δ 1.10-1.20 (m, 6 H), 1.20-1.35 (m, 2 H), 1.50-2.00 (m, 6 H), 2.91 (s, 3 H), 2.50-3.00 (m, 7 H), 3.70-3.90 (m, 2 H), 4.00 (m, 1 H), 4.40-4.50 (m, 1 H), 4.85-5.00 (m, 1 H), 6.77 (d, 1 H), 6.98 (d, 1 H), 7.03 (d, 2 H), 7.18 (d, 1 H), 7.57 (d, 2 H); MS (ES) m/z : 625.1 (MH^+);

25 HRMS Calcd. for $C_{28}H_{40}N_4O_8S_2$ (MH^+): 625.2360. Found: 625.2366.

EXAMPLE 16

30 **1-(4-{4-[2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester**

The title compound was prepared from 4-((2S)-3-Amino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one and Intermediate 14, 1-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid isopropyl ester, according to the procedure of Example 1 as an off-white solid; mp 74-83 °C; 1H NMR (300 MHz, DMSO- d_6) δ 1.10-1.20 (m, 6 H), 1.20-1.90 (m, 8 H), 2.60-3.40 (m, 6 H), 3.80-4.10 (m, 6 H), 4.85-4.95 (m, 1

H), 6.65 (d, 1 H), 6.75 (d, 1 H), 6.84 (t, 2 H), 7.00 (d, 2 H), 7.57 (d, 2 H), 10.57 (br s, 1 H), 10.70 (br s, 1 H); MS (ES) m/z : 602.1 (MH^+); HRMS Calcd. for $C_{29}H_{40}N_5O_7S$ (MH^+): 602.2634. Found: 602.2642.

5

EXAMPLE 17

1-(4-{4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid methylamide
Intermediate 20, 1-[4-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid methylamide, was hydrolyzed to the corresponding ketone according to the procedure of Intermediate 5, and then reacted with 4-((2S)-3-amino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one according to the procedure of Example 1 to give the title compound as a tan solid; mp 36-39 °C; 1H NMR (300 MHz, DMSO- d_6) δ 1.20-2.00 (m, 8 H), 2.55 (d, 3 H), 2.50-3.40 (m, 6 H), 3.70-4.10 (m, 6 H), 4.85-4.95 (m, 1 H), 6.55 (d, 1 H), 6.60 (d, 1 H), 6.80 (t, 2 H), 7.35 (d, 2 H), 7.60 (d, 2 H), 7.90 (q, 1 H), 10.60 (br s, 1 H), 10.70 (br s, 1 H); MS (ES) m/z : 573.1 (MH^+); HRMS Calcd. for $C_{27}H_{37}N_6O_6S$ (MH^+): 573.2490. Found: 573.2495.

10

15

EXAMPLE 18

1-(4-{4-[2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid

20

The title compound was prepared from Example 15 according to the procedure of Example 31 as gum; MS (ES) m/z : 583.1 (MH^+).

EXAMPLE 19

[Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid benzyl ester

25

The title compound was prepared from N-[5-((1R)-2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide and Intermediate 18, {butyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid benzyl ester, according to the procedure of Example 1 as a white solid; mp 59-64 °C; 1H NMR (300 MHz, DMSO- d_6) δ 0.78 (t, 3 H), 1.10-1.40 (m, 6 H), 1.80-1.95 (m, 2 H), 2.60-3.00 (m, 5 H), 2.91 (s, 3 H), 3.05 (t, 2 H), 3.70-3.80 (m, 2 H), 4.04 (s, 2 H), 4.40-4.50 (m, 1 H), 5.20 (s, 2 H), 6.80 (d, 1 H), 6.95 (d, 2 H), 7.00 (d, 2 H), 7.18 (d, 1 H), 7.30-7.45 (m, 5 H), 7.50 (d, 2 H); MS (ES) m/z : 689.1 (MH^+).

30

EXAMPLE 20

[Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid

5 Example 19 (0.20 g, 0.29 mmol) and a catalytic amount of 10% Pd/C in methanol (10 ml) was hydrogenated at 37 psi for 18h. The mixture was filtered through Celite and evaporated to give 0.10 g of the title compound as an off-white solid; mp 125-138°C; MS (ES) m/z : 599.3 (MH⁺).

EXAMPLE 21

(2R)-1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester

10 The title compound was prepared from N-[5-((1R)-2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide and Intermediate 23, (2R)-1-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester, according to the
15 procedure of Example 1 as a white solid; mp 62-69 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.20-1.40 (m, 2 H), 1.40-1.90 (m, 6 H), 2.50-3.20 (m, 5 H), 3.75-3.85 (m, 2 H), 4.15 (dd, 1 H), 4.40-4.50 (m, 1 H), 5.19 (s, 2 H), 6.80 (d, 1 H), 6.92 (d, 3 H), 7.15 (d, 1 H), 7.40-7.50(m, 5 H), 7.52 (d, 2 H); MS (ES) m/z : 673.1.1 (MH⁺).

20

EXAMPLE 22

(2S)-1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester

25 The title compound was prepared from N-[5-((1R)-2-Amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide and Intermediate 22, (2S)-1-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-pyrrolidine-2-carboxylic acid benzyl ester, according to the
30 procedure of Example 1 as a white solid; mp 65-71 °C; ¹H NMR (300 MHz, DMSO-d₆) δ 1.20-1.40 (m, 2 H), 1.40-1.90 (m, 6 H), 2.50-3.20 (m, 5 H), 3.75-3.85 (m, 2 H), 4.15 (dd, 1 H), 4.40-4.50 (m, 1 H), 5.19 (s, 2 H), 6.80 (d, 1 H), 6.92 (d, 3 H), 7.15 (d, 1 H), 7.40-7.50(m, 5 H), 7.52 (d, 2 H); MS (ES) m/z : 673.1 (MH⁺).

EXAMPLE 23

[Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester

The title compound was prepared according to the procedure of Example 1 from 1.03 g (2.6 mmol) of Intermediate 43, {butyl-[4-(4-oxo-piperidin-1-yl)-benzenesulfonyl]-amino}-acetic acid ethyl ester, and 0.77 g (3.1 mmol) of (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide, yielding 1.05 g of a light yellow solid; m.p. 94-95 °C; MS (ES) m/z 627.2 (MH⁺); HRMS (ES) Calcd. for C₂₈H₄₃N₄O₈S₂ (MH⁺): 627.2517, Found: 627.2505.

EXAMPLE 24

N-(2-Hydroxyethyl)-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide

The title compound was prepared according to the procedure of Example 1 from 0.12 g (0.4 mmol) of Intermediate 30, N-(2-hydroxyethyl)-4-(4-oxo-piperidin-1-yl)-benzenesulfonamide, and 0.12 g (0.5 mmol) of (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide, yielding 0.22 g of an off-white solid; m.p. 78-81°C; MS (ES) m/z 529.2 (MH⁺); HRMS (ES) Calcd. for C₂₂H₃₃N₄O₇S₂ (MH⁺): 529.1785, Found: 529.1779.

EXAMPLE 25

[(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-methyl-amino]-acetic acid ethyl ester

The title compound was prepared from Intermediate 42 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a light brown solid; ¹H NMR (DMSO) δ 1.15 (t, J=3.3 Hz, 3H), 1.23-1.35 (m, 2H), 1.83-1.91 (m, 2H), 2.60-2.71 (m, 5H), 2.87-2.96 (m, 3H), 2.92 (s, 3H), 3.38-3.48 (m, 2H), 3.80-3.89 (m, 5H), 4.06 (q, J=3.03 Hz, 2H), 4.48-4.52 (m, 1H), 5.37 (bs, 1H), 6.83 (d, J=8.25 Hz, 1H), 6.98-7.04 (m, 3H), 7.18 (d, J=1.98 Hz, 1H), 7.52 (d, J=9.0 Hz, 2H); MS (ES) m/z 585.2 (MH⁺); HRMS for C₂₅H₃₆N₄O₈S₂: 585.2034

EXAMPLE 26**N-Cyclopropylmethyl-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide**

The title compound was prepared from Intermediate 40 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a beige solid; ¹H NMR (DMSO) δ 0.02-0.1 (m, 2H), 0.3-0.4 (m, 2H), 0.73-0.82 (m, 1H), 1.23-1.33 (m, 2H), 1.81-1.90 (m, 2H), 2.56 (d, J=6.81 Hz, 2H), 2.60-2.71 (m, 4H), 2.83-2.88 (m, 3H), 2.92 (s, 3H), 3.17 (s, 2H), 3.76-3.80 (m, 2H), 4.46-4.50 (m, 1H), 5.5 (bs, 1H), 6.82 (d, J=8.22 Hz, 1H), 6.98-7.02 (m, 3H), 7.18 (d, J=1.98 Hz, 1H), 7.53 (d, J=9.0 Hz, 2H); MS (ES) m/z 539.2 (MH⁺); HRMS for C₂₄H₃₄N₄O₆S₂: 539.1985

EXAMPLE 27**4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-N-isobutyl-benzenesulfonamide**

The title compound was prepared from Intermediate 39 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a beige solid; ¹H NMR (DMSO) δ 0.79 (d, J=6.66 Hz, 6H), 1.23-1.35 (m, 2H), 1.53-1.67 (m, 1H), 1.82-1.90 (m, 2H), 2.45 (d, J=6.81 Hz, 2H), 2.59-2.72 (m, 4H), 2.84-2.88 (m, 3H), 2.92 (s, 3H), 3.17 (s, 2H), 3.77-3.81 (m, 2H), 4.47-4.51 (m, 1H), 5.4 (bs, 1H), 6.82 (d, J=8.25 Hz, 1H), 6.99-7.03 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.53 (d, J=9.0 Hz, 2H); MS (ES) m/z 541.3 (MH⁺); HRMS for C₂₄H₃₆N₄O₆S₂: 541.2138

EXAMPLE 28**[Cyclopropylmethyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester**

The title compound was prepared from Intermediate 45 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a tan solid; ¹H NMR (DMSO) δ 0.76-0.83 (m, 2H), 1.14 (t, J=7.11 Hz, 3H), 1.23-1.33 (m, 2H), 1.82-1.90 (m, 2H), 2.58-2.71 (m, 5H), 2.86-2.97 (m, 4H), 2.92 (s, 3H), 2.98 (d, J=6.9 Hz, 2H), 3.16 (s, 2H), 3.78-3.83 (m, 2H), 4.00-4.07 (m, 4H), 4.46-4.51 (m, 1H), 5.3 (bs, 1H), 6.82 (d, J=8.22 Hz, 1H), 6.97-7.03 (m, 3H), 7.18 (d, J=1.98 Hz, 1H), 7.54 (d, J=9.03 Hz, 2H); MS (ES) m/z 625.3 (MH⁺); HRMS for C₂₈H₄₀N₄O₈S₂: 625.2350

EXAMPLE 29**4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-N-isopropyl-benzenesulfonamide**

The title compound was prepared from Intermediate 44 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as an off-white solid; ¹H NMR (DMSO) δ 0.92 (d, J=6.57 Hz, 6H), 1.28-1.32 (m, 2H), 1.76-1.90 (m, 2H), 2.58-2.68 (m, 5H), 2.83-2.88 (m, 3H), 2.92 (s, 3H), 3.13-3.17 (m, 2H), 3.76-3.80 (m, 2H), 4.47-4.51 (m, 1H), 5.2 (bs, 1H), 6.82 (d, J=8.22 Hz, 1H), 6.99-7.03 (m, 3H), 7.18 (d, J=1.98 Hz, 1H), 7.54 (d, J=8.97 Hz, 2H); MS (ES) m/z 527.2 (MH⁺); HRMS for C₂₃H₃₄N₄O₆S₂: 527.1987

EXAMPLE 30**1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid ethyl ester**

The title compound was prepared from Intermediate 53 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a light brown solid; ¹H NMR (DMSO) δ 1.18 (t, J=7.11 Hz, 3H), 1.27-1.32 (m, 2H), 1.55-1.60 (m, 2H), 1.74-1.92 (m, 6H), 2.63-2.75 (m, 2H), 2.87-2.96 (m, 3H), 2.92 (s, 3H), 3.07-3.17 (m, 2H), 3.80-3.84 (m, 2H), 4.03-4.13 (m, 4H), 4.48 (m, 1H), 5.2 (bs, 1H), 6.82 (d, J=8.22 Hz, 1H), 6.99-7.05 (m, 3H), 7.18 (d, J=1.98 Hz, 1H), 7.56 (d, J=9.03 Hz, 2H); MS (ES) m/z 611.1 (MH⁺); HRMS for C₂₈H₄₀N₄O₈S₂: 611.2195

EXAMPLE 31**[Cyclopropylmethyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid**

To a stirred solution of 0.15 g (.24 mmol) of [cyclopropylmethyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester in 2 mL of ethanol, 0.1 g (2.4 mmol) of lithium hydroxide monohydrate in 2 ml of water was added dropwise over 10 minutes. After 20 minutes, the reaction mixture was quenched with .13 ml (2.4 mmol) of glacial acetic acid. The solvent was removed in vacuo and the pink aqueous residue was pipetted out of the flask. The solid was then washed with water and ethyl acetate and then dried via vacuum line to give 0.134 g of the title compound as a tan solid; ¹H NMR (DMSO) δ 0.82 (m, 1H), 1.41 (m, 2H), 1.85-1.97 (m, 2H), 2.68-2.82 (m, 8H), 2.92 (s, 3H),

3.04 (d, J=6.84 Hz, 2H), 3.30 (m, 5H), 3.76 (m, 4H), 4.58 (m, 1H), 6.83 (d, J=8.25 Hz, 1H), 6.94-7.05 (m, 3H), 7.18 (d, J=1.86 Hz, 1H), 7.60 (d, J=8.88 Hz, 2H); MS (ES) m/z 597.1 (MH⁺); HRMS (MH⁺) for C₂₆H₃₆N₄O₈S₂: 595.1904

5

EXAMPLE 32

[(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-isobutyl-amino]-acetic acid ethyl ester

The title compound was prepared from Intermediate 46 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a light brown solid; ¹H NMR (DMSO) δ 0.82 (d, J=6.54 Hz, 6H), 1.13 (t, J=7.11 Hz, 4H), 1.23-1.33 (m, 2H), 1.68-1.90 (m, 4H), 2.58-2.75 (m, 2H), 2.84-2.87 (m, 3H), 2.92 (s, 3H), 3.79-3.83 (m, 4H), 3.89 (s, 2H), 4.00 (q, J=7.05 Hz, 2H), 4.46-4.51 (m, 2H), 5.2 (bs, 1H), 6.82 (d, J=8.22 Hz, 1H), 6.98-7.03 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.52 (d, J=9.0 Hz, 2H); MS (ES) m/z 627.2 (MH⁺); HRMS for C₂₈H₄₂N₄O₈S₂: 627.2509

15

EXAMPLE 33

[(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-methyl-amino]-acetic acid

The title compound was prepared from [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}benzenesulfonyl)methyl-amino]-acetic acid ethyl ester according to the procedure of Example 31 as a brown solid; ¹H NMR (DMSO) δ 1.06 (t, J=7.11 Hz, 4H), 1.43-1.47 (m, 2H), 1.90-1.95 (m, 3H), 2.64 (s, 3H), 2.72-2.87 (m, 4H), 2.92 (s, 3H), 3.41-3.47 (m, 4H), 3.84-3.88 (m, 4H), 4.64-4.66 (m, 1H), 6.85 (d, J=8.25 Hz, 1H), 6.99-7.06 (m, 3H), 7.21 (d, J=1.89 Hz, 1H), 7.52 (d, J=8.88 Hz, 2H); MS (ES) m/z 557.2 (MH⁺); HRMS (MH⁺) for C₂₃H₃₂N₄O₈S₂: 555.1580

25

EXAMPLE 34

[(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-isobutyl-amino]-acetic acid

The title compound was prepared from [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}benzenesulfonyl)isobutylamino]-acetic acid ethyl ester according to the procedure of Example 31 as an off white solid; ¹H NMR (DMSO) δ 0.81 (d, J=6.6 Hz, 6H), 1.37-1.41 (m, 2H), 1.75-1.91 (m, 4H), 2.69-2.85

30

(m, 8H), 2.92 (s, 3H), 3.45 (m, 3H), 3.73 (m, 4H), 4.60-4.62 (m, 1H), 6.83 (d, J=8.25 Hz, 1H), 6.95-7.05 (m, 3H), 7.19 (d, J=2.01 Hz, 1H), 7.57 (d, J=8.94 Hz, 2H); MS (ES) m/z 597.2 (MH⁺); HRMS for C₂₆H₃₈N₄O₈S₂: 597.2052

5

EXAMPLE 35

1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid

The title compound was prepared from 1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid ethyl ester according to the procedure of Example 31 as a tan solid; ¹H NMR (DMSO) δ 1.32-1.36 (m, 2H), 1.51 (m, 2H), 1.77 (m, 2H), 1.90 (s, 1H), 2.63-2.78 (m, 6H), 2.92 (s, 3H), 3.12-3.15 (m, 4H), 3.27 (m, 2H), 3.79 (m, 2H), 3.93-3.98 (m, 2H), 4.52-4.56 (m, 1H), 6.83 (d, J=8.25 Hz, 1H), 6.98-7.04 (m, 3H), 7.19 (d, J=1.92 Hz, 1H), 7.57 (d, J=8.97 Hz, 2H); MS (ES) m/z 581.1 (MH⁺); HRMS for C₂₅H₃₄N₄O₈S₂: 581.1747

15

EXAMPLE 36

ethyl(2S)-1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethylamino]-1-piperidinyl}phenyl)sulfonyl]-2-pyrrolidinecarboxylate

The title compound was prepared from Intermediate 56 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a tan foam; ¹H NMR (DMSO) δ 1.16 (t, J=7.08 Hz, 3H), 1.24-1.32 (m, 2H), 1.55-1.60 (m, 2H), 1.77-1.94 (m, 5H), 2.63-2.75 (m, 3H), 2.87-2.96 (m, 2H), 2.92 (s, 3H), 3.09-3.13 (m, 1H), 3.28-3.39 (m, 3H), 3.80-3.85 (m, 2H), 4.03-4.14 (m, 4H), 4.47-4.52 (m, 1H), 6.83 (d, J=8.25 Hz, 1H), 6.99-7.05 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.56 (d, J=9.0 Hz, 2H); MS (ES) m/z 611.1 (MH⁺); HRMS for C₂₇H₃₈N₄O₈S₂: 611.2194

25

EXAMPLE 37

ethyl(2S)-2-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethylamino]-1-piperidinyl}phenyl)sulfonyl]amino]-4-methylpentanoate

30

The title compound was prepared from Intermediate 61 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a tan foam; ¹H NMR (DMSO) δ 0.70 (d, J=6.51 Hz, 3H), 0.80 (d, J=6.6 Hz, 3H), 1.02 (t, J=7.08 Hz, 3H), 1.23-1.40 (m, 5H), 1.51-1.70 (m, 2H), 1.85-1.90 (m, 3H),

2.59-2.76 (m, 3H), 2.84-2.89 (m, 2H), 2.92 (s, 3H), 3.63 (m, 2H), 3.77-3.85 (m, 4H), 4.47-4.52 (m, 1H), 5.25 (bs, 1H), 6.82 (d, J=8.22 Hz, 1H), 6.99-7.03 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.48 (d, J=9.0 Hz, 2H); MS (ES) m/z 627.2 (MH⁺); HRMS for C₂₈H₄₂N₄O₈S₂: 627.2509

5

EXAMPLE 38

ethyl(2S)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}-ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino)-3-methylbutanoate

The title compound was prepared from Intermediate 62 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a brown foam; ¹H NMR (DMSO) δ 0.80 (t, J=6.96 Hz, 3H), 1.00 (t, J=7.14 Hz, 3H), 1.23-1.34 (m, 2H), 1.76-1.90 (m, 4H), 2.60-2.72 (m, 4H), 2.83-2.88 (m, 2H), 2.92 (s, 3H), 3.39-3.41 (m, 2H), 3.74-3.83 (m, 5H), 4.48-4.52 (m, 1H), 5.3 (bs, 1H), 6.82 (d, J=8.25 Hz, 1H), 6.95-7.03 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.49 (d, J=9.0 Hz, 2H); MS (ES) m/z 613.2 (MH⁺); HRMS for C₂₇H₄₀N₄O₈S₂: 613.2350

15

EXAMPLE 39

(2S)-1-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)-amino]-1-piperidinyl}phenyl)sulfonyl]-2-pyrrolidinecarboxylic acid

The title compound was prepared from ethyl(2S)-1-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-2-pyrrolidinecarboxylate according to the procedure of Example 31 as a brown solid; ¹H NMR (DMSO) δ 1.37 (m, 2H), 1.46-1.50 (m, 1H), 1.68-1.79 (m, 3H), 1.85-1.96 (m, 2H), 1.90 (s, 1H), 2.65-2.72 (m, 3H), 2.77-2.89 (m, 3H), 2.92 (s, 3H), 3.06-3.12 (m, 2H), 3.21-3.23 (m, 3H), 3.80-3.85 (m, 2H), 3.92-3.96 (m, 1H), 4.56-4.58 (m, 1H), 6.84 (d, J=8.28 Hz, 1H), 6.99-7.05 (m, 3H), 7.20 (d, J=1.95 Hz, 1H), 7.57 (d, J=8.97 Hz, 2H); MS (ES) m/z 583.1 (MH⁺); HRMS for C₂₅H₃₄N₄O₈S₂: 583.1883

25

EXAMPLE 40

ethyl 1-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-nyl}phenyl)sulfonyl]amino)-cyclopentanecarboxylate

30

The title compound was prepared from Intermediate 66 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a beige solid; ¹H NMR (DMSO) δ 1.11 (t, J=7.11 Hz, 3H), 1.27-1.30 (m,

4H), 1.49 (m, 4H), 1.88 (m, 8H), 2.63-2.73 (m, 3H), 2.83-2.88 (m, 2H), 2.92 (s, 3H), 3.77-3.82 (m, 2H), 3.89 (q, J=708 Hz, 2H), 4.48 (m, 1H), 5.2 (bs, 1H), 6.82 (d, J=8.25 Hz, 1H), 6.95-7.03 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.50 (d, J=9.0 Hz, 2H); MS (ES) m/z 625.2 (MH⁺); HRMS for C₂₈H₄₀N₄O₈S₂: 625.2361

5

EXAMPLE 41

N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({1-[4-(1-pyrrolidinylsulfonyl)phenyl]piperidinyl)-4-amino)ethyl]phenyl}methanesulfonamide

The title compound was prepared from Intermediate 34 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a beige solid; ¹H NMR (DMSO) δ 1.23-1.35 (m, 2H), 1.60-1.65 (m, 4H), 1.83-1.91 (m, 2H), 2.59-2.76 (m, 5H), 2.86-2.95 (m, 2H), 2.92 (s, 3H), 3.03-3.08 (m, 4H), 3.16 (s, 1H), 3.79-3.84 (m, 2H), 4.47-4.52 (m, 1H), 5.3 (bs, 1H), 6.82 (d, J=8.25 Hz, 1H), 6.99-7.05 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.54 (d, J=8.97 Hz, 2H); MS (ES) m/z 539.2 (MH⁺); HRMS for C₂₄H₃₄N₄O₆S₂: 539.1990

15

EXAMPLE 42

N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({1-[4-(1-piperidinylsulfonyl)phenyl]-piperidinyl)-4-amino)ethyl]phenyl}methanesulfonamide

The title compound was prepared from Intermediate 35 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as an off white solid; ¹H NMR (DMSO) δ 1.24-1.35 (m, 4H), 1.50-1.53 (m, 4H), 1.83-1.90 (m, 2H), 2.59-2.71 (m, 4H), 2.75-2.82 (m, 4H), 2.87-2.95 (m, 2H), 2.92 (s, 3H), 3.17 (s, 2H), 3.79-3.84 (m, 2H), 4.47-4.51 (m, 1H), 5.3 (bs, 1H), 6.82 (d, J=8.25 Hz, 1H), 6.99-7.05 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.46 (d, J=9.0 Hz, 2H); MS (ES) m/z 553.2 (MH⁺); HRMS for C₂₅H₃₆N₄O₆S₂: 553.2149

25

EXAMPLE 43

Ethyl 1-[(4-{4-(((2R)-2-hydroxy-2-{4-hydroxy-3-ynyl}phenyl)sulfonyl)amino}-cyclohexanecarboxylate

30

The title compound was prepared from Intermediate 68 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a beige solid; ¹H NMR (DMSO) δ 1.10 (t, J=7.14 Hz, 3H), 1.23-1.33 (m, 8H), 1.63-1.90 (m, 6H), 2.59-2.76 (m, 4H), 2.83-2.88 (m, 2H), 3.17 (s, 3H), 3.77-3.86 (m,

2H), 4.47-4.52 (m, 1H), 5.3 (bs, 1H), 6.82 (d, J=8.22 Hz, 1H), 6.96-7.03 (m, 3H), 7.18 (d, J=1.98 Hz, 1H), 7.51 (d, J=8.97 Hz, 2H); MS (ES) m/z 639.2 (MH⁺); HRMS for C₂₉H₄₂N₄O₈S₂: 639.2517

5

EXAMPLE 44**Ethyl [[[4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-idinyl}phenyl)sulfonyl]-(isopropyl)-amino]acetate**

The title compound was prepared from Intermediate 69 and (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide according to the procedure of Example 1 as a beige solid; ¹H NMR (DMSO) δ 0.91 (d, J=6.69 Hz, 6H), 1.19 (t, J=7.08 Hz, 3H), 1.28-1.35 (m, 2H), 1.83-1.90 (m, 2H), 2.59-2.76 (m, 5H), 2.86 (m, 2H), 2.92 (s, 3H), 3.74-3.84 (m, 4H), 3.91 (s, 2H), 4.10 (q, J=7.05 Hz, 2H), 4.47-4.52 (m, 1H), 5.3 (bs, 1H), 6.82 (d, J=8.25 Hz, 1H), 6.99-7.03 (m, 3H), 7.18 (d, J=2.01 Hz, 1H), 7.62 (d, J=9.03 Hz, 2H); MS (ES) m/z 613.2 (MH⁺); HRMS for C₂₉H₄₂N₄O₈S₂: 613.2362

15

EXAMPLE 45**N-[2-Hydroxy-5-(1-hydroxy-2-{1-[4-(toluene-4-sulfonyl)-phenyl]piperidin-4-ylamino}-ethyl)-phenyl]-methanesulfonamide**

The title compound was prepared according to the procedure of Example 1 from 0.13 g (0.4 mmol) of Intermediate 25, 1-[4-(Toluene-4-sulfonyl)-phenyl]-piperidin-4-one, and 0.12 g (0.5 mmol) of (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide, yielding 0.18 g of a white solid; m.p. 115–118 °C; MS (ES) m/z 560.0 (MH⁺); HRMS (FAB) Calcd. for C₂₇H₃₄N₃O₆S₂ (MH⁺): 560.1889, Found: 560.1886.

25

EXAMPLE 46**4-((2S)-2-Hydroxy-3-{1-[4-(toluene-4-sulfonyl)-phenyl]-piperidin-4-ylamino}-propoxy)-1,3-dihydro-benzoimidazol-2-one**

The title compound was prepared according to the procedure of Example 1 from 0.13 g (0.4 mmol) of Intermediate 25, 1-[4-(toluene-4-sulfonyl)-phenyl]-piperidin-4-one, and 0.13 g (0.6 mmol) of 4-((2S)-3-Amino-2-hydroxy-propoxy)-1,3-dihydro-benzoimidazol-2-one, yielding 0.18 g of a white solid; m.p. 130–132 °C; MS (ES) m/z 537.0 (MH⁺); HRMS (FAB) Calcd. for C₂₈H₃₃N₄O₅S (MH⁺): 537.2166, Found: 537.2169.

EXAMPLE 47**2-(2-butynyl)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-4-hexynoicacid tert-butyl ester**

The title compound was prepared according to the procedure of Example 1 from 0.37 g (0.8 mmol) of Intermediate 27, 2-But-2-ynyl-2-[4-(4-oxo-piperidin-1-yl)-benzene-sulfonyl]-hex-4-ynoic acid tert-butyl ester, and 0.24 g (1.0 mmol) of (R)-N-[5-(2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide, yielding 0.54 g of an off-white solid; m.p. 93–95 °C; MS (ES) m/z 688.2 (MH^+); HRMS (ES) Calcd. for $C_{34}H_{46}N_3O_8S_2$ (MH^+): 688.2721, Found: 688.2722.

EXAMPLE 48**2-(2-butynyl)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-4-hexynoicacid**

To a solution of 2-(2-butynyl)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-4-hexynoic acid tert-butyl ester 0.21 g (0.3 mmol) in dichloromethane (3 ml) was added trifluoroacetic acid (0.23 ml, 3 mmol), and the mixture was stirred at room temperature for 2 days. It was then evaporated and treated with 10% sodium bicarbonate solution until pH 6. The resulting suspension was filtered and the precipitate washed with water, and dried in vacuo to give 85 mg of a beige solid; m.p. 175–177 °C; MS (ES) m/z 630.6 ($M-H^-$); HRMS (EI) Calcd. for $C_{30}H_{36}N_3O_8S_2$ ($M-H^-$): 630.1949, Found: 630.1943.

EXAMPLE 49**1-(4-{4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)propyl]-amino]-piperidin-1-yl}-benzenesulfonyl)-imidazolidine-2,4-dione****Step a) N-[(4-fluorophenyl)sulfonyl]-glycine**

A saturated sodium carbonate solution was added dropwise into a mixture of 4-fluorobenzenesulfonyl chloride (30.0 g, 154 mmol), glycine (11.5 g, 154 mmol), and dioxane (200 mL), until a basic (pH about 9) solution was achieved. After 30 minutes the mixture was neutralized with HCl (2 N), and the volatiles were removed in vacuo. The residue was recrystallized from cold (0 °C) to yield a white solid (23.6 g, 66% yield): mp 144–146 °C; 1H NMR (400 MHz, DMSO- d_6): δ 3.58 (s, 2 H), 7.39–7.42 (m, 2 H), 7.81–7.86 (m, 2H), 8.06 (brs, 1H), 12.5 (brs, 1H); MS m/e 232 ($M-H^+$);

Analysis for: $C_8H_8FNO_4S$ Calc'd: C, 41.20; H, 3.46; N, 6.01 Found: C, 41.14; H, 3.51; N, 5.85

Step b) 1-[(4-Fluorophenyl)sulfonyl]-2-thioxo-4-imidazolidinone

- 5 A mixture of *N*-[(4-fluorophenyl)sulfonyl]-glycine (17.0 g, 72.9 mmol), ammonium thiocyanate (7.2 g, 94.8 mmol), acetic anhydride (17.2 mL, 182.2 mmol), and pyridine (70 mL) was stirred at 100 °C for 24 hours. Then, the mixture was into water and extracted with ethyl acetate. The organic extracts were dried over $MgSO_4$. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 2/1) gave a yellow solid
- 10 (19.6 g, 98% yield): mp 208-210 °C; 1H NMR (400 MHz, $DMSO-d_6$): δ 4.78 (s, 2H), 7.47-7.51 (m, 2H), 8.14-8.18 (m, 2H), 12.6 (s, 1H); MS *m/e* 274 M^+ ;
Analysis for: $C_9H_7FN_2O_3S_2$ Calc'd: C, 39.41; H, 2.57; N, 10.21 Found: C, 39.90; H, 2.71; N, 10.09

15 **Step c) 1-[(4-Fluorophenyl)sulfonyl]-2,4-imidazolidinedione**

- A mixture of 1-[(4-fluorophenyl)sulfonyl]-2-thioxo-4-imidazolidinone (14.5 g, 52.9 mmol), and chloroacetic acid (100 g) was stirred at 120 °C for 2 days. Then, the mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over $MgSO_4$. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 1/1) gave a white solid (12.6 g, 92% yield): mp 232-234 °C; 1H NMR (400 MHz, $DMSO-d_6$): δ 4.48 (s, 2H), 7.47-7.52 (m, 2H), 8.06-8.09 (m, 2H), 11.61 (s, 1H); MS *m/e* 257 ($M-H$) $^+$;
- 20 Analysis for: $C_9H_7FN_2O_4S$ Calc'd: C, 41.86; H, 2.73; N, 10.85 Found: C, 42.24; H, 2.72; N, 10.6

25

Step d) 1-[[4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl]-2,4-imidazolidinedione

- A mixture of 1-[(4-fluorophenyl)sulfonyl]-2,4-imidazolidinedione (3.6 g, 13.9 mmol), 1,4-dioxo-8-azaspiro[4.5]-decane (3.56 mL, 27.8 mmol), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone (30 mL), acetonitrile (15 mL), and potassium carbonate (3.84 g, 27.8 mmol) was stirred at 65 °C for 2 days. Then, the mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over $MgSO_4$. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 1/1) gave a white solid (4.15 g, 78% yield): mp 222-224 °C; 1H NMR (400 MHz, $DMSO-d_6$): δ 1.63-
- 30

1.66 (m, 4H), 3.47-3.9 (m, 4H), 3.9 (s, 4H), 4.41 (s, 2H), 7.03-7.07 (m, 2H), 7.71-7.74 (m, 2H), 11.46 (brs, 1H); MS *m/e* 382 (M+H)⁺;

Analysis for: C₁₆H₁₉N₃O₆S Calc'd: C, 50.39; H, 5.02; N, 11.02 Found: C, 50.22; H, 4.92; N, 10.89

5

Step e) 1-[[4-(4-Oxo-1-piperidiny)phenyl]sulfonyl]-2,4-imidazolidinedione

A mixture of 1-[[4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)phenyl]sulfonyl]-2,4-imidazolidinedione (4.1 g, 10.76 mmol), HCl (concentrated, 10 mL), and dioxane (15 mL) was stirred at room temperature for 5 days. Then, the mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO₄.

10

Evaporation and purification by flash chromatography (hexanes/ethyl acetate 1/1) gave a white solid (3.2 g, 88% yield): mp 210-212 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 2.48 (m, 2H), 3.78 (m, 4H), 4.44 (s, 2H), 7.06-7.08 (m, 2H), 7.76-7.79 (m, 2H), 11.48 (s, 1H); MS *m/e* 338 (M+H)⁺;

15

Analysis for: C₁₄H₁₅N₃O₅S Calc'd: C, 49.85; H, 4.48; N, 12.46 Found: C, 49.51; H, 4.51; N, 11.84

Step f) 1-(4-{4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonyl)-imidazolidine-2,4-dione

20

Acetic acid (0.14 mL, 2.38 mmol) was added dropwise into a mixture of 4-[(2S)-3-amino-2-hydroxypropyl]oxy-1,3-dihydro-2H-benzimidazol-2-one (265 mg, 1.19 mmol), 1-[[4-(4-oxo-1-piperidiny)phenyl]sulfonyl]-2,4-imidazolidinedione (400 mg, 1.19 mmol) and N,N-dimethylformamide (5 mL). The mixture was stirred for 20 minutes and then, sodium triacetoxyborohydride (303 mg, 1.43 mmol) was added, and the new mixture was stirred at room temperature for 24 hours. The volatiles were removed in vacuo and the residue was purified by flash chromatography (dichloromethane/methyl alcohol 3/1) to produce a brown solid (256 mg, 40% yield): mp 230 °C (decomposed); ¹H NMR (400 MHz, DMSO-d₆): δ 1.52-1.63 (m, 2H), 2.04-2.15 (m, 2H), 2.48 (m, 2H), 2.9-3.0 (m, 2H), 3.13-3.15 (m, 1H), 3.2-3.4 (m, 3H), 4.0-4.1 (m, 5 H), 4.42 (s, 2H), 6.6-6.63 (m, 2H), 6.8-6.85 (m, 1H), 7.03-7.05 (m, 2H), 7.78-7.8 (m, 2H), 10.6 (s, 1H), 10.7 (s, 1H); MS *m/e* 543 (M-H)⁺;

25

30

Analysis for: C₂₄H₂₈N₆O₇S Calc'd: C, 45.24; H, 5.38; N, 12.88 Found: C, 45.88; H, 5.36; N, 13.88

EXAMPLE 50

N-[5-((1R)-2-{1-[4-(2,4-Dioxo-imidazolidine-1-sulfonyl)-phenyl]piperidin-4-ylamino}-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide

Acetic acid (0.15 mL, 2.6 mmol) was added dropwise into a mixture N-[5-[(1R)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide (320 mg, 1.3 mmol), 1-[[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl]-2,4-imidazolidinedione (440 mg, 1.3 mmol) and N,N-dimethylformamide (5 mL). The mixture was stirred for 20 minutes and then, sodium triacetoxyborohydride (331 mg, 1.56 mmol) was added, and the new mixture was stirred at room temperature for 24 hours. The volatiles were removed in vacuo and the residue was purified by flash chromatography (dichloromethane/methyl alcohol 4/1) to produce a white solid (496 mg, 67% yield): mp 200-202 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 1.35-1.42 (m, 2H), 1.81-1.97 (m, 2H), 2.7-2.82 (m, 2H), 2.83-2.97 (m, 6H), 3.95-3.97 (m, 2H), 4.22 (s, 2H), 4.57-4.6 (m, 1H), 6.82 (m, 1H), 7.1 (m, 3H), 7.2 (m, 1H), 7.75 (m, 2H), 8.4 (brs, 2H); MS *m/e* 566 (M-H)⁺; Analysis for: C₂₃H₂₉N₅O₈S₂ Calc'd: C, 48.67; H, 5.11; N, 12.34 Found: C, 47.64; H, 5.2; N, 11.26

EXAMPLE 51

1-(4-{4-[(2S)-2-Hydroxy-2-(2-trifluoromethyl-thiazol-4-yl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-imidazolidine-2,4-dione

Acetic acid (0.09 mL, 1.6 mmol) was added dropwise into a (1S)-2-amino-1-[2-(trifluoromethyl)-1,3-thiazol-4-yl]-1-ethanol (152 mg, 0.71 mmol), 1-[[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl]-2,4-imidazolidinedione (220 mg, 0.65 mmol) and N,N-dimethylformamide (3 mL). The mixture was stirred for 20 minutes and then, sodium triacetoxyborohydride (276 mg, 1.3 mmol) was added, and the new mixture was stirred at room temperature for 24 hours. The volatiles were removed in vacuo and the residue was purified by flash chromatography (dichloromethane/methyl alcohol 4/1) to produce an off-white solid (265 mg, 68% yield): mp 185-187 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 1.22-1.35 (m, 2H), 1.8-1.9 (m, 1H), 2.7-2.83 (m, 2H), 2.9-3.01 (m, 3H), 3.8 (m, 2H), 4.2 (s, 2H), 4.81 (m, 1H), 7.1 (m, 2H), 7.8 (m, 2H), 7.95 (s, 1H); MS *m/e* 534 (M+H)⁺; Analysis for: C₂₀H₂₂F₃N₅O₅S₂ Calc'd: C, 45.02; H, 4.16; N, 13.13 Found: C, 42.79; H, 4.27; N, 11.95

EXAMPLE 52

***tert*-Butyl 2-[[[4-{4-[[[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl]-ethyl]amino]-1-piperidinyl]phenyl)sulfonyl]amino}acetate**

Step a) *tert*-Butyl 2-[[[4-(4-fluorophenyl)sulfonyl]amino}acetate

5 N,N-Diisopropylethylamine (41.4 mL, 238.8 mmol) was added into a mixture of 4-fluorobenzenesulfonyl chloride (23.2 g, 119.4 mmol), glycine *tert*-butyl ester hydrochloride (20 g, 119.4 mmol) and tetrahydrofuran (200 mL). The mixture was stirred for 24 hours. The volatiles were then removed in vacuo, and the residue was taken in water (2000 mL) and stirred for 30 minutes. The precipitated solid was filtered and dried
10 to give a white solid (32.1 g, 93% yield): mp 105-107 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.28 (s, 9H), 3.6 (7.4 (m, 2H), 7.83 (m, 2H), 8.17 (t, J = 6.37 Hz, 1H); d, J = 6.37 Hz, 2H), MS *m/e* 289 M⁺;
Analysis for: C₁₂H₁₆FNO₄S Calc'd: C, 49.82; H, 5.57; N, 4.84 Found: C, 50.06; H, 5.72; N, 4.79

15

step b) *tert*-Butyl 2-[[[4-(4-hydroxy-1-piperidinyl)phenyl)sulfonyl]amino}acetate

A mixture of *tert*-butyl 2-[[[4-(4-fluorophenyl)sulfonyl]amino}acetate (22.5 g, 77.8 mmol), 4-hydroxypiperidine (11.8 g, 116.8 mmol), potassium carbonate (16.1 g, 116.8 mmol), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone (90 mL), and acetonitrile (60
20 mL) was stirred at 75 °C for 2 days. The mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 1/1) gave a white solid (22.1 g, 77 % yield): mp 125-127 °C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.29 (s, 9H), 1.4 (m, 2H), 2.79 (m, 2H), 3.0 (m, 2H), 3.46 (m, 2H), 3.68 (m, 3H), 4.72 (m, 1H), 7.0 (m, 2H),
25 7.56 (m, 2H), 7.68 (m, 1H); MS *m/e* 371 (M+H)⁺;
Analysis for: C₁₇H₂₆N₂O₅S Calc'd: C, 55.12; H, 7.07; N, 7.56 Found: C, 55.45; H, 7.24; N, 7.52

Step c) *tert*-Butyl 2-[[[4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]amino}acetate

30 Trifluoroacetic acid (0.21 mL, 2.7 mmol) was added dropwise into a cold (0 °C) mixture of *tert*-butyl 2-[[[4-(4-hydroxy-1-piperidinyl)phenyl)sulfonyl]amino}acetate (2.0 g, 5.4 mmol), dimethyl sulfoxide (15 mL), benzene (15 mL), pyridine (0.43 mL, 5.44 mmol), and 1,3-dicyclohexylcarbodiimide (3.34 g, 16.2 mmol). The mixture was allowed to come to room temperature, stirred for 20 hours, and then diluted with ethyl acetate. The
35 precipitated solid was filtered and discarded. The filtrate was washed with water, and

dried over MgSO_4 . Evaporation and purification by flash chromatography (hexanes/ethyl acetate 1/1) gave a white solid (1.85 g, 93 % yield): mp 130-132 °C; ^1H NMR (400 MHz, DMSO-d_6): δ 1.29 (s, 9H), 2.4 (m, 4H), 3.46 (d, $J = 6.15$ Hz, 2H), 3.73 (m, 4H), 7.07 (m, 2H), 7.58 (m, 2H), 7.69 (t, $J = 6.15$ Hz, 1H); MS m/e 368 M^+ ;

- 5 Analysis for: $\text{C}_{17}\text{H}_{26}\text{N}_2\text{O}_5\text{S}$ Calc'd: C, 55.42; H, 6.57; N, 7.60 Found: C, 55.56; H, 6.41; N, 7.57

Step d) *tert*-Butyl 2-[[[4-{4-[[[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl)sulfonyl]amino]acetate

- 10 Acetic acid (2.92 mL, 5.1 mmol) was added dropwise into a *N*-{5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide (627 mg, 2.55 mmol), *tert*-butyl 2-[[[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl]amino]acetate (940 mg, 2.55 mmol), and *N,N*-dimethylformamide (7 mL). The mixture was stirred for 20 minutes and then, sodium triacetoxyborohydride (649 mg, 3.06 mmol) was added, and the new mixture was stirred
15 at room temperature for 24 hours. The volatiles were removed in vacuo and the residue was purified by flash chromatography (dichloromethane/methyl alcohol 8/1) to produce a white solid (1.21 g, 80% yield): mp 113-115 °C; ^1H NMR (400 MHz, DMSO-d_6): δ 1.23-1.29 (m, 11 H), 1.8-1.83 (m, 2H), 2.6-2.7 (m, 3H), 2.81-28.3 (m, 2H), 2.91 (s, 3H), 3.45 (s, 2H), 3.79 (m, 2H), 4.47 (m, 1H), 6.95 (m, 1H), 7.0 (m, 3H), 7.18 (m, 1H), 7.5 (m, 2H);
20 MS m/e 599 ($\text{M}+\text{H}$) $^+$;
Analysis for: $\text{C}_{26}\text{H}_{38}\text{N}_4\text{O}_6\text{S}_2 \times 1 \text{ CH}_3\text{CO}_2\text{H}$ Calc'd: C, 51.05; H, 6.43; N, 8.50 Found: C, 51.08; H, 6.49; N, 8.70

EXAMPLE 53

- 25 **2-[[[4-{4-[[[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl]ethyl]-amino]-1-piperidinyl]phenyl)sulfonyl]amino]acetic acid**

- A mixture of *tert*-butyl 2-[[[4-{4-[[[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]phenyl]ethyl]amino]-1-piperidinyl]phenyl)sulfonyl]-amino]acetate (600mg, 1 mmol), dichloromethane (10 mL), and trifluoroacetic acid (2 mL) was stirred at room temperature
30 for 15 hours. The mixture was then poured into ethyl ether (50 mL) and the precipitated solid was filtered and dried. Purified by HPLC reverse phase chromatography (YMC C18 column, 85:15 water : 0.1% trifluoroacetic acid / acetonitrile) to yield a white solid (340 mg, 51%): mp 170-172 °C; MS m/e 541 ($\text{M}-\text{H}$) $^+$; ^1H NMR (400 MHz, DMSO-d_6): δ 1.4-1.5 (m, 2H), 1.9-2.0 (m, 2H), 2.75-3.1 (m, 8H), 3.2 (s, 2H), 3.84 (m, 2H), 4.65 (m, 1H), 6.83
35 (m, 2H), 7.0-7.06 (m, 3H), 7.2 (m, 1H), 7.6 (2H);

Analysis for: $C_{22}H_{30}N_4O_8S_2 \times 0.5 CF_3CO_2H$ Calc'd: C, 46.08; H, 5.09; N, 9.35 Found: C, 46.15; H, 4.99; N, 9.13

EXAMPLE 54

5 ***tert*-Butyl 2-([2-(*tert*-butoxy)-2-oxoethyl][4-{4-[(*2R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-1-piperidinyl}-phenyl)sulfonyl]amino)-acetate**

Step a) *tert*-Butyl 2-([2-(*tert*-butoxy)-2-oxoethyl][4-(4-oxo-1-piperidinyl)phenyl]-sulfonyl]amino)acetate

10 Sodium hydride (60% in mineral oil, 109 mg, 2.72 mmol) was added into a solution of *tert*-butyl 2-([4-(4-oxo-1-piperidinyl)phenyl]sulfonyl)amino)acetate 91 g, 2.72 mmol), and N,N-dimethylformamide (5 mL). The mixture was stirred at room temperature for 2 hours, and then *tert*-butyl bromoacetate (0.48 mL, 3.26 mmol) was added dropwise. The new mixture was stirred for 1 hour, poured into water and
15 extracted with ethyl acetate. The organic extracts were dried over $MgSO_4$. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 2/1) gave a yellow oil (670 mg, 52 % yield): MS m/e 482 (M^+); 1H NMR (400 MHz, $DMSO-d_6$): δ 1.31 (s, 18H), 2.4 (m, 4H), 3.75 (m, 4H), 3.95 (s, 4H), 7.05 (m, 2H), 7.58 (m, 2H);

Analysis for: $C_{23}H_{34}N_2O_7S$ Calc'd: C, 57.24; H, 7.10; N, 5.80 Found: C, 57.27; H, 7.22;
20 N, 5.84

Step b) *tert*-Butyl 2-([2-(*tert*-butoxy)-2-oxoethyl][4-{4-[(*2R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-1-piperidinyl}phenyl)-sulfonyl]amino)acetate

25 Acetic acid (0.95 mL, 1.66 mmol) was added dropwise into a *N*-{5-[(*1R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide (204 mg, 0.83 mmol), *tert*-butyl 2-([2-(*tert*-butoxy)-2-oxoethyl][4-(4-oxo-1-piperidinyl)phenyl]sulfonyl)amino)acetate (400 mg, 0.83 mmol), and N,N-dimethylformamide (4 mL). The mixture was stirred for 20 minutes and then, sodium triacetoxyborohydride (211 mg, 0.99 mmol) was added, and
30 the new mixture was stirred at room temperature for 24 hours. The volatiles were removed in vacuo and the residue was purified by flash chromatography (dichloromethane/methyl alcohol 8/1) to produce a white solid (520 mg, 88% yield): mp 164-166 °C; MS m/e 713 ($M+H^+$); 1H NMR (400 MHz, $DMSO-d_6$): δ 1.27 (m, 2H), 1.31 (s, 18H), 1.84 (m, 2H), 1.62-1.75 (m, 3H), 2.85-2.95 (m, 5H), 3.8 (m, 2H), 3.93 (s, 4H), 4.5
35 (m, 1H), 6.8 (m, 1H), 6.98-7.01 (m 2H), 7.17 (1H), 7.51 (m, 2H);

Analysis for: $C_{32}H_{48}N_4O_{10}S_2 \times 1 CH_3CO_2H$ Calc'd: C, 52.83; H, 6.78; N, 7.25 Found: C, 51.85; H, 6.61; N, 7.07

EXAMPLE 55

5 2-[(Carboxymethyl)[(4-{4-[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl)ethyl]amino}-1-piperidinyl)phenyl)sulfonyl]amino}acetic acid

A mixture of *tert*-butyl 2-[[2-(*tert*-butoxy)-2-oxoethyl][(4-{4-[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl]amino}-1-piperidinyl)phenyl)sulfonyl]-amino}acetate (400 mg, 0.56 mmol), dichloromethane (10 mL), and trifluoroacetic acid (3
10 mL) was stirred at room temperature for 15 hours. The mixture was then poured into ethyl ether (50 mL) and the precipitated solid was filtered and dried. The crude solid was dissolved in methyl alcohol (5 mL) and added slowly into ethyl ether (50 mL). The precipitated solid was filtered and dried to yield a white solid (465 mg, 67%): mp 163-166°C; MS *m/e* 599 (M-H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.5-1.6 (m, 2H), 2.0-2.1 (m, 2H), 2.8-3.2 (m, 8H), 3.8 (m, 2H), 4.0 (m, 2H), 4.8 (m, 1H), 6.9 (m, 1H), 7.05 (m, 3H), 7.2
15 (m, 1H), 7.6 (m, 2H);

Analysis for: $C_{24}H_{32}N_4O_{10}S_2 \times 0.5 CF_3CO_2H$ Calc'd: C, 44.97; H, 4.94; N, 8.52 Found: C, 44.74; H, 4.75; N, 8.19

20

EXAMPLE 56

Ethyl 2-[[[4-{4-[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethyl]amino}-1-piperidinyl)phenyl)sulfonyl]amino}acetate

Step a) Ethyl 2-[[[4-fluorophenyl)sulfonyl]amino}acetate

N,N-Diisopropylethylamine (26.8 mL, 154.2 mmol) was added into a mixture of 4-fluorobenzenesulfonyl chloride (15 g, 77.1 mmol), glycine ethyl ester hydrochloride (10.7
25 g, 77.1 mmol) and tetrahydrofuran (200 mL). The mixture was stirred for 24 hours. The volatiles were then removed in vacuo, and the residue was taken in water and extracted with ethyl acetate. The organic extracts were dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 4/1) gave a white solid (19.6
30 g, 93% yield): mp 90-92 °C; MS *m/e* 260 (M-H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.05 (t, J = 7.02 Hz, 3H), 3.7 (d, J = 7.25 Hz, 2H), 3.98 (q, J = 7.02 Hz, 2H), 7.4 (m, 2H), 7.83 (m, 2H), 8.23 (t, J = 7.25 Hz, 1H);

Analysis for: $C_{10}H_{12}FNO_4S$ Calc'd: C, 45.97; H, 4.63; N, 5.36 Found: C, 46.12; H, 4.50; N, 5.37

35

Step b) Ethyl 2-([4-(4-hydroxy-1-piperidinyl)phenyl]sulfonyl)amino)acetate

A mixture of ethyl 2-([4-(4-fluorophenyl)sulfonyl]amino)acetate (25 g, 95.8 mmol), 4-hydroxypiperidine (14.5 g, 143.7 mmol), potassium carbonate (19.8 g, 143.7 mmol), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone (90 mL), and acetonitrile (60 mL) was stirred at 75 °C for 2 days. The mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 1/1) gave a white solid (5.6 g, 33 % yield): mp 99-101 °C; MS *m/e* 343 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.09 (t, *J* = 7.01, 3H), 1.18-1.22 (m, 2H), 1.78-1.83 (m, 2H), 3.0-3.05 (m, 2H), 3.56 (d, *J* = 7.24 Hz, 2H), 3.68-3.72 (m, 3H), 3.97 (q, *J* = 7.01 Hz, 2H), 4.7 (m, 1H), 6.98 (m, 2H), 7.53 (m, 2H), 7.76 (t, *J* = 7.24 Hz, 1H); Analysis for: C₁₅H₂₂FN₂O₅S Calc'd: C, 52.62; H, 6.48; N, 8.18 Found: C, 52.64; H, 6.48; N, 8.17

Step c) Ethyl 2-([4-(4-oxo-1-piperidinyl)phenyl]sulfonyl)amino)acetate

Trifluoroacetic acid (0.11 mL, 1.45 mmol) was added dropwise into a cold (0 °C) mixture of ethyl 2-([4-(4-hydroxy-1-piperidinyl)phenyl]sulfonyl)amino)acetate (1.0 g, 2.9 mmol), dimethyl sulfoxide (7 mL), benzene (7 mL), pyridine (0.23 mL, 2.9 mmol), and 1,3-dicyclohexylcarbodiimide (1.79 g, 8.7 mmol). The mixture was allowed to come to room temperature, stirred for 20 hours, and then diluted with ethyl acetate. The precipitated solid was filtered and discarded. The filtrate was washed with water, and dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 2/1) gave a white solid (820 mg, 82 % yield): mp 90-92 °C; MS *m/e* 341 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.1 (t, *J* = 7.08 Hz, 3H), 2.41-2.44 (m, 2H), 3.6 (d, *J* = 7.23 Hz, 2H), 3.76 (m, 2H), 4.0 (q, *J* = 7.08 Hz, 2H), 7.05 (m, 2H), 7.58 (m, 2H), 7.8 (t, *J* = 7.23 Hz, 1H); Analysis for: C₁₆H₂₀FN₂O₅S Calc'd: C, 52.93; H, 2.92; N, 8.23 Found: C, 53.07; H, 5.93; N, 8.24

Step d) Ethyl 2-([4-(4-([2*R*]-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]-phenyl)ethyl)amino]-1-piperidinyl)phenyl)sulfonyl)amino)acetate

Acetic acid (0.61 mL, 10.7 mmol) was added dropwise into a *N*-{5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide (1.32 g, 5.35 mmol), ethyl 2-([4-(4-oxo-1-piperidinyl)phenyl]sulfonyl)amino)acetate (1.82, 5.35 mmol), and *N,N*-dimethyl-formamide (5 mL). The mixture was stirred for 20 minutes and then, sodium triacetox-

borohydride (1.36 g, 6.42 mmol) was added, and the new mixture was stirred at room temperature for 24 hours. The volatiles were removed in vacuo and the residue was purified by HPLC reverse phase (YMC C18 column, 17% MeOH: H₂O / 0.1 % AcOH) to produce a white solid (2.4 g, 90% yield): mp 105-107 °C; MS *m/e* 571 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆): δ 1.09 (t, J = 7.08, 3H), 1.25-1.35 (m, 2H), 1.8-1.85 (m, 2H), 2.6-2.7 (m, 3H), 2.82-2.91 (m, 5H), 3.56 (s, 3H), 3.8 (m, 2H), 3.97 (q, J = 7.08 Hz, 2H), 4.5 (m, 1H), 6.8 (, m, 2H), 7.0 (m, 3H), 7.18 (m, 1H), 7.56 (m, 2H);
 Analysis for: C₂₄H₃₄N₄O₈S₂ x 1 CH₃CO₂H Calc'd: C, 49.51; H, 6.07; N, 8.88 Found: C, 49.62; H, 6.23; N, 8.77

10

EXAMPLE 57

Methyl 2-[[[4-{4-[[[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl]-ethyl]amino]-1-piperidinyl]phenyl)sulfonyl]amino}acetate

Step a) Methyl 2-[[[4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]amino]acetate

15 A mixture of *tert*-butyl 2-[[[4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]amino]acetate (1.0, 2.72 mmol) and formic acid (95%, 10 mL) was stirred at 60 °C for 3 hours. The volatiles were then removed in vacuo and the residue (847 mg) was taken in tetrahydrofuran (10 mL) and water (0.2 mL). The mixture was cooled to 0 °C and (trimethylsilyl) diazomethane (2 M, 2 mL) was added dropwise. The mixture was allowed
 20 to come to room temperature, stirred for 30 minutes, and then poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 2/1) gave a white solid (780 mg, 92% yield): mp 118-120 °C; MS *m/e* 327 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆): δ 2.43 (m, 4H), 3.53 (s, 3H), 3.59 (d, J = 6.37 Hz, 2H), 3.76 (m, 2H), 7.05 9m, 2H),
 25 7.59 (m, 2H), 7.82 (t, J = 6.37 Hz, 1H);
 Analysis for: C₁₄H₁₈N₂O₅S Calc'd: C, 51.52; H, 5.56; N, 8.58 Found: C, 51.52; H, 5.57; N, 8.51

Step b) Methyl 2-[[[4-{4-[[[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]-phenyl]ethyl]amino]-1-piperidinyl]phenyl)sulfonyl]amino}acetate

30 Acetic acid (0.26 mL, 4.12 mmol) was added dropwise into a *N*-[5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide (566 mg, 2.3 mmol), methyl 2-[[[4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]amino]acetate (750 mg, 0.23 mmol), and *N,N*-dimethylformamide (5 mL). The mixture was stirred for 20 minutes and then, sodium triacetoxyborohydride (585 mg, 2.76 mmol) was added, and the new mixture was stirred
 35

at room temperature for 24 hours. The volatiles were removed in vacuo and the residue was purified by flash chromatography (dichloromethane/methyl alcohol 8/1) to produce a white solid (1.15 mg, 90% yield): mp 123-125 °C; MS *m/e* 571 (M+H)⁺; ¹H NMR (400 MHz, DMSO-*d*₆): δ 1.2-1.3 (m, 2H), 1.8-1.87 (m, 2H), 2.6-2.75 (m, 3H), 2.9-2.97 (m, 5H), 3.51 (, 3H), 3.57 (s, 2H), 3.8 (m, 2H), 4.5 (m, 1H), 6.8 (m, 1H), 7.0 (m, 3H), 7.2 (m, 1H), 7.57 (m, 2H);

Analysis for: C₂₄H₃₄N₄O₈S₂ x 1 CH₃CO₂H Calc'd: C, 48.69; H, 5.88; N, 9.08 Found: C, 49.02; H, 5.87; N, 9.29

10

EXAMPLE 58

Ethyl 2-([(4-{4-([(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl)-ethyl]amino]piperidin-1-yl}phenyl)sulfonyl]amino)acetylcarbamate.

Step a) tert-Butyl ([4-(4-oxopiperidin-1-yl)phenyl]sulfonyl)amino)acetate

Trifluoroacetic acid (0.62 ml, 8.09 mmol) was added dropwise into a cold (0 °C) mixture of tert-butyl-([(4-(4-hydroxypiperidin-1-yl)phenyl]sulfonylamino)acetate (6g, 16.2 mmol), 1,3-dicyclohexylcarbodiimide (10 g, 48.6 mmol), pyridine (1.31 mL, 16.2 mmol), methyl sulfoxide (45 mL) and benzene (45 mL). The new mixture was warmed up to room temperature and stirred for 18 hours, diluted with ethyl acetate (100 mL), and the precipitated solid was filtered and discarded. The organic filtrate was washed with water, and dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 6/4) gave a white solid (5.65 g, 90 % yield): MS *m/e* 369 (M+H)⁺; ¹H NMR (DMSO-*d*₆ 400 MHz) δ 1.29 (s, 9H), 2.42 (t, 4H), 3.46 (d, 2H), 3.72 (t, 4H), 7.07 (d, 2H), 7.56 (d, 2H), 7.58 (t, 1H).

25

Step b) 2-([(4-(4-oxo-1-piperidinyl)phenyl]sulfonyl)amino)acetic acid

A mixture of tert-butyl-([(4-(4-oxopiperidin-1-yl)phenyl]sulfonylamino)acetate (1.75 g, 4.75 mmol) and formic acid (96 %, 7 mL) was stirred at 60 °C for 4 hours. The volatiles were removed in vacuo to give a yellow solid (1.1 g, 74 % yield): MS *m/e* 311 (M-H)⁺; ¹H NMR (DMSO-*d*₆ 400 MHz) δ 2.45 (t, 4H), 3.58 (d, 2H), 3.80 (t, 4H), 7.17 (d, 2H), 7.64 (d, 2H), 7.72 (t, 1H), 12.7 (s, 1H).

30

Step c) Ethyl 2-([(4-(4-oxopiperidin-1-yl)phenyl]sulfonyl)amino)acetylcarbamate

A mixture of ([4-(4-oxopiperidin-1-yl)phenyl]sulfonyl)amino)acetic acid (0.312 g, 1.0 mmol), ethyl (*tert*-butylimino)methylenecarbamate (0.6 mL), and tetrahydrofuran (3mL) was reflux for 3 hours. The volatiles were removed in vacuo and the residue was purified

35

by flash chromatography (hexanes/ethyl acetate 6/4) to give a white solid (0.17 g, 45 % yield): MS m/e 382; (M-H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ 1.25(t, 3H), 2.50 (m, 4H), 3.4 (s, 2H), 3.81 (m, 4H), 4.18 (q, 2H), 7.15 (d, 2H), 7.65 (d, 2H), 10.65 (s, 1H).

5 Step d) Ethyl 2-(((4-(4-(((2R)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)-amino)phenyl)ethyl) amino)piperidin-1-yl)phenyl)sulfonyl)amino)-acetylcarbamate.

A mixture of ethyl 2-(((4-(4-oxopiperidin-1-yl)phenyl)sulfonyl)amino)acetylcarbamate (0.17 g, 0.453 mmol) and N-{5-[(1R)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl}methansulfonamide (0.115g, 0.4674 mmol), sodium triacetoxymethylborohydride (0.19 g, 0.90 mmol), acetic acid (0.1 mL) in N,N-dimethylformamide (2.2 mL) was stirred at room temperature for 18 hours. The solvent was removed in vacuo and the residue was purified by flash chromatography (methylene chloride/methanol/ammonium hydroxide 8/2/0.001) to give a white solid (0.17 g, 61 % yield): mp 98-105 °C, MS m/e 614 (M+H)⁺; ¹H NMR (DMSO-d₆ 400 MHz) δ 1.17 (t, 3H), 1.29 (m, 2H), 1.88 (m, 2H), 2.67 (m, 3H), 2.90 (m, 5H), 3.80 (m, 4H), 4.07 (q, 2H), 4.48 (m, 1H), 6.82 (d, 1H), 6.99 (m, 3H), 7.16 (s, 1H), 7.51 (d, 2H);

Analysis for C₂₅H₃₅N₅O₉S₂ x 1.0 CH₃COOH x 0.63 H₂O Calc'd: C, 47.40; H, 5.78; N, 10.21 Found: C, 47.35; H, 6.02; N, 10.00.

20

EXAMPLE 59

tert-Butyl (((4-(4-(((2R)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)-ethyl)amino) piperidin-1-yl)phenyl)sulfonyl)(methoxycarbonyl)-amino)acetate

Step a) tert-Butyl ((methoxycarbonyl)((4-(4-oxopiperidin-1-yl)phenyl)sulfonyl)-amino)acetate

25 Sodium hydride (60 % in mineral oil, 0.18 g, 4.6 mmol) was added portionwise to a cold (0 °C) mixture of tert-butyl-(((4-(4-oxopiperidin-1-yl)phenyl)sulfonyl)amino)acetate (1.5 g, 4.07 mmol) and N, N-dimethylformamide (8 mL). The mixture was stirred for 1 hour and then methyl chloroformate (0.36 mL, 4.6 mmol) in N, N-dimethylformamide (0.5 mL) was added dropwise. The new mixture was warmed up to room temperature and stirred for 5 hours, poured into water, neutralized to pH 7 with saturated aqueous bicarbonate solution, and extracted with ethyl acetate. The organic extracts were washed with brine, and dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 6/4) gave a white solid (0.64 g, 37 %): ¹H NMR (DMSO-d₆ 300 MHz) δ 1.41(s, 9H), 2.52 (m, 4H), 3.63 (s, 3H), 3.81 (m, 4H), 4.41(s, 2H), 7.12 (d, 2H), 7.79 (d, 2H).

Step b) *tert*-Butyl [[[4-{4-[[[(2*R*)-2-hydroxy-2-{4-hydroxy-3[(methylsulfonyl)amino]phenyl]ethyl]amino]piperidin-1-yl}phenyl)sulfonyl]-(methoxycarbonyl)-amino]acetate

- 5 This compound was prepared from *tert*-butyl ((methoxycarbonyl)[4-(4-oxopiperidin-1-yl)-phenyl]sulfonyl)amino)acetate and *N*-{5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl}-methanesulfonamide in substantially the same manner as described in Example 50, and was obtained as a white solid (0.3 g, 62 %): mp 110-115 °C; MS *m/e* 657 (*M*+*H*)⁺; ¹H NMR (DMSO-*d*₆ 400 MHz) δ 1.24 (m, 2H), 1.38 (s, 9H), 1.89 (m, 2H), 2.66 (m, 3H), 2.91 (s, 3H), 2.99 (m, 2H), 3.6 (s, 3H), 3.88 (m, 2H), 4.47 (s, 2H), 4.49 (m, 1H), 6.82 (s, 1H), 6.99 (m, 3H), 7.17 s, 1H), 7.67 (d, 2H);
- 10 Analysis for C₂₈H₄₀N₄O₁₀S₂ x 0.8 CH₃COOH x 0.41 H₂O Calc'd: C, 50.34; H, 6.05; N, 7.83 Found: C, 50.06; H, 6.40; N, 7.52.

15

EXAMPLE 60

[[[4-{4-[[[(2*R*)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl]-ethyl]-amino]piperidin-1-yl}phenyl)sulfonyl](methoxycarbonyl)amino]acetic acid

- This compound was prepared from *tert*-butyl [[[4-{4-[[[(2*R*)-2-hydroxy-2-{4-hydroxy-3[(methylsulfonyl)amino]phenyl]ethyl]amino]piperidin-1-yl}phenyl)sulfonyl]-(methoxycarbonyl)amino]acetate in substantially the same manner as described in
- 20 Example 53, with one change; the mixture was stirred at room temperature for 20 hours. The volatiles were removed and the product was purified by reverse phase chromatography to give a white solid (0.08 g, 45 % yield): mp 60 °C, MS *m/e* 601 (*M*+*H*)⁺; ¹H NMR (DMSO-*d*₆ 400 MHz) δ 1.60 (m, 2H), 2.08 (m, 2H), 2.86 (m, 2H), 2.93 (s, 3H), 2.94 (m, 2H), 3.08 (m, 1H), 3.59 (s, 3H), 4.06 (m, 2H), 4.42 (s, 3H), 4.76 (m, 1H), 6.89 (d, 1H), 7.04 (m, 3H), 7.23 s, 1H), 7.70 (d, 2H);
- 25 Analysis for C₂₄H₃₂N₄O₁₀S₂ x 2.0 CF₃COOH x 0.63 H₂O Calc'd: C, 40.00; H, 3.96; N, 6.66 Found: C, 37.84; H, 3.77; N, 5.87.

30

EXAMPLE 61

Ethyl {(2,5-difluorobenzyl)[(4-{4-[[[(2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methyl-sulfonyl)-amino]phenyl]ethyl]amino]piperidin-1-yl}phenyl)sulfonyl]amino}acetate

Step a) *N*-(2,5-Difluorobenzyl)-4-fluorobenzenesulfonamide

- A solution of 2,4-difluorobenzyl amine (9.5 g, 66.37 mmol) in methylene chloride
- 35 (15 mL) was added dropwise into a cold (-10 °C) mixture of 4-fluorobenzenesulfonyl

chloride (15.6 g, 80 mmol), diisopropylethyl amine (18.1 mL, 104 mmol) and methylene chloride (80 mL). The new mixture was warmed up to room temperature, stirred for 4 hours, poured into water, acidified with aqueous hydrochloric acid (2N), and extracted with methylene chloride. The organic extracts were washed with brine, and dried over
5 MgSO_4 . Evaporation and purification by flash chromatography (hexanes/ethyl acetate 8/2) gave an off white solid (12.5 g, 63 % yield): MS m/e 300 (M-H)⁺; ¹H NMR (DMSO- d_6 400 MHz) δ 4.13 (d, 2H), 7.19 (m, 3H), 7.41 (d, 2H), 7.84(d, 2H), 8.36 (t, 1H).

Step b) *N*-(2,5-Difluorobenzyl)-4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-benzene-sulfonamide

A mixture of *N*-(2,5-difluorobenzyl)-4-fluorobenzenesulfonamide (12.1 g, 40.16 mmol) and 1,4-dioxo-8-azaspiro[4.5]decane (9.9 ml) was heated at 65 °C for 6 days. The product was purified by flash chromatography (hexanes/ethyl acetate 7/3) to give a white solid 10.4g, 62 % yield), mp 135 °C; MS m/e 425 (M+H)⁺; ¹H NMR (DMSO- d_6 400 MHz) δ
15 1.6 (m,4H), 3.42 (m, 4H), 3.91 (s, 4H), 3.98(d, 2H), 6.99 (d, 2H), 7.04 (m, 3H), 7.50 (d, 2H), 7.89(t, 1H).

Step c) *N*-(2,5-Difluorobenzyl)-4-(4-oxopiperidin-1-yl)benzenesulfonamide

N-(2,5-difluorobenzyl)-4-fluorobenzenesulfonamide (4.5 g, 10.60 mmol) was
20 treated at -10 °C with concentrated hydrochloric acid (50 mL). The mixture was warmed up to room temperature, stirred for 24 hours, neutralized with ammonium hydroxide at 0°C and extracted with methylene chloride. The organic extracts were washed with brine, and dried over MgSO_4 . The solvent was removed in vacuo to give an off white solid (4.1 g, 94 % yield): mp 119 °C; MS m/e 379 (M-H)⁺; ¹H NMR (DMSO- d_6 400 MHz)
25 δ 2.47 (m,4H), 3.70 (m, 4H), 4.15 (d, 2H), 7.10 (d, 2H), 7.19 (m, 3H), 7.62 (d, 2H), 8.01 (t, 1H).

Step d) Ethyl ((2,5-difluorobenzyl){[4-(4-oxopiperidin-1-yl)phenyl]-sulfonyl}amino)-acetate

A mixture of *N*-(2,5-difluorobenzyl)-4-(4-oxopiperidin-1-yl)benzenesulfonamide (2g, 5.25 mmol), potassium carbonate (0.8 g, 5.78 mmol), ethyl bromoacetate (0.64 mL, 5.78 mmol) and acetonitrile (20 mL) was reflux for 18 hours. After cooling to room temperature the mixture was poured into aqueous ammonium chloride and extracted with ethyl acetate. The organic extracts were washed with brine, and dried over MgSO_4 .
35 Evaporation and purification by flash chromatography (hexanes/ethyl acetate 6/4) gave a

light yellow oil (1.49 g, 60 % yield): MS m/e 465 (M-H)⁺; ¹H NMR (DMSO-d₆ 400 MHz) δ 1.08 (t, 3H), 2.48 (m, 4H), 3.75 (m, 4H), 3.94 (q, 2H), 3.97 (s, 2H), 4.38 (s, 2H), 7.08 (d, 2H), 7.19 (m, 3H), 7.64 (d, 2H).

Step e) Ethyl {(2,5-difluorobenzyl)[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl]amino]piperidin-1-yl}phenyl)sulfonyl]amino}acetate

This compound was prepared from ethyl ((2,5-difluorobenzyl)[(4-(4-oxopiperidin-1-yl)phenyl)sulfonyl]amino)acetate, and N-{5-[(1R)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl}methanesulfonamide in substantially the same manner as described in example 7, with one change; the product was purified by reverse phase chromatography and was obtained as a white solid (1.25 g, 49 % yield): mp 85-90 °C; MS m/e 697 (M+H)⁺; ¹H NMR (DMSO-d₆ 400 MHz) δ 1.07, (t, 3H), 1.31 (m, 2H), 1.89 (m, 2H), 2.67 (m, 2H), 2.70 (m, 1H), 2.91 (s, 3H), 2.94, (m, 2H), 3.91 (m, 1H), 3.94 (q, 2H), 3.95 (s, 2H), 4.36, (s, 2H), 4.51 (m, 1H), 6.83 (d, 1H), 6.99 (m, 3H), 7.19 (m, 4H), 7.55 (d, 2H); Analysis for C₃₁H₃₈F₂N₄O₈S₂ x 2.0 CH₃COOH Calcd: C, 45.45, H, 4.36; N, 6.28 Found: C, 46.23; H, 4.38; N, 6.28.

EXAMPLE 62

1-[4-(((Butylamino)carbonyl)amino)sulfonyl]phenyl]-4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl]amino]piperidine

Step a) 1-(3-Bromoisoxazol-5-yl)ethanone

A solution of 4-fluorobenzenesulfonyl chloride (76 g, 0.39 mol) in tetrahydrofuran (200 mL) was added slowly into a cold (-40 °C) saturated tetrahydrofuran/ammonia solution (200 mL). The resulting suspension was allowed to come to room temperature and stirred for 20 hours. The suspension was filtered and the solid washed with ethyl acetate. The organic filtrate was concentrated in vacuo and the product was crystallized from ethyl acetate/hexanes to give a white solid (63 g, 92 % yield): MS m/e 174 (M-H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ 7.42, (m, 4H), 7.85 (m, 2H).

Step b) 4-(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)benzenesulfonamide

A mixture of 1-(3-bromoisoxazol-5-yl)ethanone (5.3 g, 30.28 mmol) and 1,4-dioxo-8-azaspiro[4.5]decane (7.4 mL) was warmed at 65 °C for 4 days. After cooling to room temperature, the mixture was triturated with methylene chloride to give a white solid (3.0 g, 33 % yield): MS m/e 297 (M-H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ 1.69 (m, 4H), 3.22 (m, 4H), 3.80 (s, 4H), 7.04 (d, 2H), 7.60 (d, 2H).

Step c) 1-[4-(((Butylamino)carbonyl)amino)sulfonyl]phenyl]-4-oxopiperidine

Sodium hydride (60 % in mineral oil, 0.1 g, 2.5 mmol) was added at room temperature into a mixture of 4-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)benzenesulfonamide (0.5 g, 1.67 mmol) and tetrahydro furan (10 mL). After stirring for 18 hours, n-butyl isocyanate (0.28 mL, 2.5 mmol) was added, and stirring was continued overnight. The mixture was cooled to 0 °C and acidified with concentrated hydrochloric acid (7 mL). The new mixture was allowed to come to room temperature, stirred for another 18 hours, neutralized with ammonium hydroxide at) °C, and extracted with ethyl acetate. The organic extracts were washed with brine, and dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/methylene chloride/isopropyl alcohol 5/4/1) gave a white solid

(0.34 g, 57 % yield): MS m/e 352 (M-H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ 0.96, (t, 3H), 1.23 (m, 2H), 1.38, (m, 2H), 2.46 (m, 2H), 2.98, (m, 4H), 3.84 (m, 4H), 6.40, (t, 1H), 7.15 (d, 2H), 7.78 (d, 2H), 10.21 (s, 1H).

Step d) 1-[4-(((Butylamino)carbonyl)amino)sulfonyl]phenyl]-4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)piperidine

This compound was prepared from 1-[4-(((butylamino)carbonyl)amino)sulfonyl]phenyl]-4-oxopiperidine, and N-{5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl}-methansulfonamide in substantially the same manner, as described in Example 50, with one change; the product was purified by reverse phase chromatography and was obtained as a white solid (0.16 g, 23 % yield): mp 100-102 °C, MS m/e 584 (M+H)⁺; ¹H NMR (DMSO-d₆ 400 MHz) δ 0.75, (t, 3H), 1.13 (m, 2H), 1.23 (m 2H), 1.44 (m, 2H), 1.93 (m, 2H), 2.79 (m, 2H), 2.85 (m, 2H), 2.87 (m, 2H), 2.90 (s, 3H), 3.04 (m, 1H), 3.86 (m, 2H), 4.66 (m, 1H), 6.85 (d, 1H), 6.93 (d, 2H), 7.04 (m, 1H), 7.18 (d, 1H), 7.56, (d, 2H); Analysis for C₂₅H₃₇N₅O₇S₂ x 2.0 CH₃COOH x 0.67 H₂O Calcd: C, 48.67; H, 6.48; N, 9.79 Found :C, 46.16; H, 6.62; N, 9.81.

EXAMPLE 63

2-((2,5-Difluorobenzyl)[(4-[4-(((2*R*)-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino]-1-piperidinyl)phenyl)sulfonyl]amino)acetic acid

Step a) *tert*-Butyl 2-((2,5-difluorobenzyl)[(4-(4-oxo-1-piperidinyl)phenyl)-sulfonyl]amino)acetate

Sodium hydride (60 % in mineral oil, 0.49 g, 12.27 mmol) was added portionwise to a cold (0 °C) mixture of *tert*-butyl([(4-(4-oxopiperidin-1-yl)phenyl)sulfonyl]amino)acetate

(4.0 g, 10.85 mmol) and N, N-dimethylformamide (60 mL). The mixture was stirred for 2 hours, and then 2,5-difluorobenzyl bromide (1.4 mL, 10.85 mmol) in N,N-dimethylformamide (5 mL) was added dropwise. The new mixture was stirred at 0 °C for 2 hours, poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic
5 extracts were washed with brine, and dried over MgSO₄. Evaporation and purification by flash chromatography (hexanes/ethyl acetate 6/4) gave a white solid (3.2 g, 60 % yield): MS m/e 495 (M+H)⁺; ¹H NMR (DMSO-d₆ 300 MHz) δ 1.38 (s, 9H), 2.45 (m, 4H), 3.78 (m, 4H), 3.85 (s, 2H), 4.2 (s, 2H), 7.15 (d, 2H), 7.20 (m, 3H), 7.74 (d, 2H).

10 **Step b) *tert*-Butyl 2-((2,5-difluorobenzyl)[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl)amino]-1-piperidinyl)phenyl)sulfonyl]amino)-acetate**

This compound was prepared from *tert*-butyl 2-((2,5-difluorobenzyl)[(4-{4-oxo-1-piperidinyl)phenyl)sulfonyl]amino)acetate and *N*-(5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide in substantially the same manner, as described in
15 Example 50, and was obtained as a white solid (2.9 g, 63 % yield): MS m/e 725 (M+H)⁺; ¹H NMR (DMSO-d₆ 400 MHz) δ 1.27, (s, 9H), 1.29 (m, 2H), 1.88 (m 2H), 2.68 (m, 2H), 2.72 (m, 1H), 2.88 (m, 2H), 2.91 (s, 3H), 3.83 (m, 4H), 4.35 (s, 2H), 4.50 (m, 1H), 6.83 (d, 1H), 7.01 (m, 3H), 7.18 (m, 4H), 7.56 (d, 2H).

20

Step c) 2-((2,5-Difluorobenzyl)[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl)amino]-1-piperidinyl)phenyl)sulfonyl]amino}acetic acid

This compound was prepared from *tert*-butyl 2-((2,5-difluorobenzyl)[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl)amino]-1-piperidinyl)phenyl)sulfonyl]amino)acetate in substantially the same manner, as described in Example 53,
25 with one change; the mixture was stirred at room temperature for 20 hours. The volatiles were removed and the product was purified by reverse phase chromatography to give a white solid (1.44 g, 42 % yield): mp 80-82 °C; MS m/e 669 (M+H)⁺; ¹H NMR (DMSO-d₆ 400 MHz) δ 1.62 (m, 2H), 2.11 (m, 2H), 2.85 (m, 2H), 2.94 (s, 3H), 2.96 (m, 1H), 3.11 (m, 1H), 3.34 (m, 1H), 3.88 (s, 2H), 3.99 (m, 2H), 4.37 (s, 2H), 4.79 (m, 1H), 6.01 (br, 1H), 6.90 (d, 1H), 7.05 (m, 3H), 7.18 (m, 3H), 7.21 (s, 1H), 7.59 (d, 2H), 8.58 (brs, 1H), 8.66 (brs, 1H), 8.74 (brs, 1H), 10.01 (brs, 1H);
30 Analysis for C₂₉H₃₄F₂N₄O₈S₂ x 2.0 CF₃COOH x 0.73 H₂O Calc'd: C, 43.52; H, 4.11; N, 6.15 Found: C, 42.95; H, 3.93; N, 6.08.
35

EXAMPLE 64

Ethyl {4-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl]-ethyl)amino]piperidin-1-yl}phenyl)sulfonyl]piperazin-1-yl}acetate

step a) Ethyl 2-{4-[(4-fluorophenyl)sulfonyl]-1-piperazinyl}acetate

4-Fluorobenzenesulfonyl chloride (10 g, 50.4 mmol) was added into a cold (0°C) solution of 1-(ethoxycarbonylmethyl-piperazine) (5.64 mL, 50.4 mmol) and N,N-diisopropylethylamine (9.13 mL, 55.4 mmol) in tetrahydrofuran (100 mL) over a period of 20 minutes. The mixture was then stirred at room temperature overnight. The mixture was concentrated and water was added. The aqueous mixture was extracted with ethyl acetate. The extracts were washed with water, dried with magnesium sulfate. The extracts were concentrated to give an oil (16.38 g, 97% yield): ¹H NMR (300 MHz, DMSO-d₆): δ 1.13-1.18 (t, 3 H), 2.55-2.60 (m, 4 H), 2.86-2.90 (m, 4 H), 3.22 (s, 2 H), 4.01-4.06 (q, 2 H), 7.46-7.51 (m, 2 H), 7.79-7.83 (m, 2 H); MS m/z 331 (M+H)⁺; Analysis for C₁₄H₁₉FN₂O₄S Calc'd: C, 50.90; H, 5.80; N, 8.48; Found: C, 50.97; H, 5.87; N, 8.56.

step b) ethyl 2-{4-[(4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]-1-piperazinyl}acetate

A mixture of ethyl 2-{4-[(4-fluorophenyl)sulfonyl]-1-piperazinyl}acetate (8 g, 24.2 mmol), 4-piperidone hydrochloride monohydrate (5.58 g, 36.3 mmol) and potassium carbonate (10.0 g, 72.66 mmol) in 1, 3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidine (25 mL) and acetonitrile was stirred at 75 °C for 3 days. The mixture was diluted with water and extracted with ethyl acetate. The extract were washed with water and dried with MgSO₄. Evaporation and purification by flash column chromatography (dichloromethane/ethyl acetate 1/1) gave a white solid (0.55 g, 6 % yield): mp: 81-83 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 1.13-1.17 (t, 3 H), 2.45-2.47 (m, 4 H), 2.48-2.50 (m, 4 H), 2.82-2.85 (m, 4 H), 3.21 (s, 2 H), 3.74-3.77 (m, 4 H), 4.01-4.07 (q, 2 H), 7.09-7.12 (d, 2 H), 7.50-7.54 (d, 2 H); MS m/z 409 M⁺.

step c) ethyl {4-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]-phenyl]ethyl)amino]piperidin-1-yl}phenyl)sulfonyl]piperazin-1-yl}acetate

The title compound was prepared from *N*-(5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide and ethyl 2-{4-[(4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]-1-piperazinyl}acetate in substantially the same manner, as described in

Example 50. The product was obtained as a light yellow solid; mp: 91-92 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 1.08-1.17 (t, 3 H), 1.49-1.56 (m, 2 H), 2.02-2.07 (m, 2 H), 2.45-2.50 (m, 4 H), 2.52-2.56 (m, 2 H), 2.74-2.80 (m, 2 H), 2.86-3.01 (m, 5 H), 3.20 (s, 2 H), 3.24-3.36 (m, 4 H), 3.96-3.99 (d, 2 H), 4.01-4.07 (q, 2 H), 4.69-4.71 (m, 1 H), 6.86-6.88 (d, 2 H), 7.05-7.09 (m, 3 H), 7.23-7.24 (m, 1 H), 7.47-7.50 (d, 2 H), 8.20 (brs, 4 H); MS m/z 640 (M+H)⁺; Analysis for C₂₈H₄₁N₅O₈S₂ x 1.0 F₃CCO₂H x 0.18 CH₂Cl₂ Calc'd: C, 47.13; H, 5.55; N, 9.11; Found: C, 47.02; H, 5.75; N, 8.67.

EXAMPLE 65

10 {4-[(4-{4-[(2R)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethyl]-amino]piperidin-1-yl}phenyl)sulfonyl]piperazin-1-yl}acetic acid, sodium salt

A solution of ethyl {4-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl]amino]piperidin-1-yl}phenyl)sulfonyl]-piperazin-1-yl}acetate (1.0 g, 1.02 mmol) and 1 N aqueous sodium hydroxy (4.1 mL, 4.1 mmol) in methyl alcohol-tetrahydrofuran (1/1) was stirred at room temperature overnight. The solvent was removed in vacuo and chased with benzene. Methyl alcohol (60 mL) was added and the solid was isolated by filtration. The filtrate was then concentrated to give a brown solid; mp 131 °C (decomposed): ¹H NMR (400 MHz, DMSO-d₆): δ 1.22-1.27 (m, 2 H), 1.80-1.87 (m, 2 H), 2.46-2.48 (m, 4 H), 2.57-2.67 (m, 6 H), 2.80-2.89 (m, 4 H), 2.90-2.98 (m, 2 H), 3.16 (s, 3 H), 3.78-3.82 (m, 2 H), 4.34-4.37 (m, 1 H), 6.45-6.51 (m, 2 H), 7.01-7.04 (d, 2 H), 7.44-7.46 (d, 2 H); MS m/z 612 (M+H)⁺; Analysis for C₂₆H₃₅N₅O₈S₂Na₂ x 3.0 F₃CCO₂Na x 0.47 H₂O x 1.0 CH₃OH Calc'd: C, 37.94; H, 4.04; N, 6.71; Found: C, 37.40; H, 3.98; N, 6.69.

EXAMPLE 66

25 N-(2-Hydroxy-5-[(1R)-1-hydroxy-2-[(1-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl)-piperidin-4-yl]amino]ethyl]phenyl)methanesulfonamide
step a) 1-[(4-fluorophenyl)sulfonyl]-4-methylpiperazine

The title compound was prepared from 4-fluorobenzenesulfonyl chloride, 1-methylpiperazine in substantially the same manner, as described in example 9, step a. The product was obtained as an oil; ¹H NMR (300 MHz, DMSO-d₆): δ 2.12 (s, 3 H), 2.31-2.37 (m, 4 H), 2.85-2.92 (m, 4 H), 7.46-7.52 (m, 2 H), 7.76-7.82 (m, 2 H); MS m/z 259 (M+H)⁺; Analysis for C₁₁H₁₅FN₂O₂S Calc'd: C, 51.15; H, 5.85; N, 10.84; Found: C, 51.18; H, 5.81; N, 10.90.

step b) 1-{4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl}-4-piperidinone

The title compound was prepared from 1-[(4-fluorophenyl)sulfonyl]-4-methylpiperazine and 4-piperidone hydrochloride monohydrate in substantially the same manner, as described in Example 64. The product was obtained as a semi-solid: ¹H NMR (300 MHz, DMSO-d₆): δ 2.12 (s, 3 H), 2.33-2.35 (m, 4 H), 2.45-2.50 (m, 4 H), 2.74-2.82 (m, 4 H), 3.73-3.76 (m, 4 H), 7.08-7.12 (d, 2 H), 7.50-7.53 (m, 2 H); MS m/z 338 (M+H)⁺; Analysis for C₁₆H₂₃N₃O₃S Calc'd: C, 56.95; H, 6.87; N, 12.45; Found: C, 57.03; H, 6.89; N, 12.38.

Step c) N-(2-hydroxy-5-[(1R)-1-hydroxy-2-[(1-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}piperidin-4-yl)amino]ethyl]phenyl)methanesulfonamide

The title compound was prepared from N-(5-[(1R)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide, and 1-{4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl}-4-piperidinone in substantially the same manner, as described in Example 50. The product was obtained as a brown solid; mp: 89-91 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 1.53-1.65 (m, 2 H), 2.06-2.16 (m, 2 H), 2.82-2.89 (m, 2 H), 2.94 (s, 3 H), 3.09-3.13 (m, 2 H), 3.70 (brs, 2 H), 4.01-4.05 (m, 2 H), 4.76-4.79 (d, 2 H), 6.11 (brs, 1 H), 6.88-6.90 (d, 2 H), 7.06-7.13 (m, 4 H), 7.25 (s, 1 H), 7.52-7.55 (d, 2 H), 8.60 (brs, 1 H); 8.58 (brs, 1 H); 8.75 (s, 1 H), 9.64 (brs, 1 H), 10.00 (s, 1 H); MS m/z 568 (M+H)⁺; Analysis for C₂₅H₃₇N₅O₆S₂ x 0.4 hexane x 0.52 H₂O Calc'd: C, 42.07; H, 4.93; N, 7.34; Found: C, 42.27; H, 4.60; N, 6.70.

EXAMPLE 67

tert-Butyl {(2,5-difluorobenzyl)[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)ethyl]amino]piperidin-1-yl}phenyl)sulfonyl]-amino}acetate
step a) tert-butyl 2-[(2,5-difluorobenzyl){[4-(4-oxo-1-piperidinyl)phenyl]sulfonyl}-amino]acetate

Sodium hydride (60% in mineral oil, 0.12 g, 8.13 mmol) was added portionwise to a cold (0°C) solution of *tert*-butyl 2-[(4-(4-oxo-1-piperidinyl)phenyl)sulfonyl]amino)acetate (1.0 g, 2.71 mmol) in N,N-dimethylformamide (15 mL) under a nitrogen atmosphere. After stirring for 1 hour *o*-bromo-2,5-difluorotoluene (0.36 mL, 2.71 mmol) was added dropwise over a period of 10 minutes. The mixture was then stirred at 0 °C for 2 hours. The reaction was quenched with aqueous ammonium chloride to pH 5 and extracted with

ethyl acetate. The extracts were washed with water and dried with magnesium sulfate. The extracts were concentrated to give a solid (1.3 g, 97% yield): ^1H NMR (400 MHz, DMSO- d_6): δ 1.28 (s, 9 H), 2.42-2.45 (m, 4 H), 3.73-3.77 (m, 4 H), 3.86 (s, 2 H), 4.37 (s, 2 H), 7.07-7.09 (d, 2 H), 7.16-7.21 (m, 3 H), 7.62-7.65 (d, 2 H); MS m/z 495 ($M+H$) $^+$;
5 Analysis for $C_{24}H_{28}F_2N_2O_5S$ x Calc'd: C, 58.29; H, 5.71; N, 5.66; Found: C, 58.55; H, 6.03; N, 5.44.


**step b) tert-butyl {(2,5-difluorobenzyl)[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-
[(methylsulfonyl)amino]phenyl]ethyl)amino]piperidin-1-yl}phenyl)sulfonyl]-amino}-
10 acetate**

The title compound was prepared from *N*-(5-[(1*R*)-2-amino-1-hydroxyethyl]-2-hydroxyphenyl)methanesulfonamide and ethyl 2-[(2,5-difluorobenzyl)[(4-{4-oxo-1-piperidinyl}phenyl)sulfonyl]amino)acetate in substantially the same manner, as described in Example 50. The product was obtained as a white solid: ^1H NMR (400 MHz, DMSO-
15 d_6): δ 1.28 (s, 9 H), 1.30-1.40 (m, 2 H), 1.89-1.96 (m, 2 H), 4.48-4.50 (m, 4 H), 2.69-2.92 (m, 4 H), 2.72 (s, 3 H), 3.84-3.89 (m, 3 H), 4.36 (s, 2 H), 4.56-4.59 (m, 1 H), 6.83-6.85 (m, 1 H), 7.00-7.04 (m, 3 H), 7.14-7.23 (m, 4 H), 7.57-7.60 (d, 2 H), 8.21 (s, 1 H); MS m/z 725 ($M+H$) $^+$; Analysis for $C_{33}H_{42}F_2N_4O_8S_2$ x 1.0 HCO_2H Calc'd: C, 52.98; H, 5.75; N, 7.27; Found: C, 51.24; H, 5.77; N, 7.14.

20

CLAIMS:

1. A compound of formula I having the structure:



5 wherein;

W is $(CH_2)_m$;

X is $(CH_2)_n$;

Y is OCH_2 , SCH_2 , or a bond;

R_1 is phenyl substituted with R_5 and R_6 , or Het substituted with R_5 and R_6 ;

- 10 R_2 is hydrogen, trifluoromethyl, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, or alkynyl of 2-7 carbon atoms;

R_4 is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, hydroxy, aryl substituted with R_5 and R_6 , Het substituted with R_5 and R_6 , aryloxy, $-NHCOR_7$, $-NR_8R_8$, $-CR_3R_5R_6$,
 15 arylamino, Het-amino, arylalkylamino having 1-6 carbon atoms in the alkyl chain, Het-alkylamino having 1-6 carbon atoms in the alkyl chain, alkoxyalkyl of 3-13 carbon atoms, carboxyalkyl of 2-7 carbon atoms, alkylcarbonylalkyl of 3-13 carbon atoms, arylcarbonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-carbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminocarbonylalkyl of 2-
 20 7 carbon atoms, alkylaminocarbonylalkyl of 3-13 carbon atoms, arylamino-carbonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-aminocarbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminosulfonylalkyl of 1-6 carbon atoms, alkylsulfonylalkyl of 2-12 carbon atoms, arylsulfonylalkyl having 1-6 carbon atoms in the alkyl chain, alkylaminosulfonylalkyl of 2-12 carbon atoms,
 25 arylaminosulfonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-aminosulfonylalkyl having 1-6 carbon atoms in the alkyl chain, phosphonylalkyl of 1-6 carbon atoms, or phosphorylalkyl of 1-6 carbon atoms;

R_3 , R_5 , and R_6 , are each, independently, hydrogen, trifluoromethyl, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl, Het, arylalkyl having 1-6 carbon atoms in the alkyl chain, Het-

30

- alkyl having 1-6 carbon atoms in the alkyl chain, halogen, cyano, nitro, hydroxy, alkoxy of 1-6 carbon atoms, aryloxy, arylalkyloxy having 1-6 carbon atoms in the alkyl chain, alkylthio 1-6 carbon atoms, arylthio, arylamino, Het-amino, arylalkyl-amino of 1-6 carbons in the alkyl chain, Het-alkylamino having 1-6 carbon atoms in the alkyl chain, hydroxyamino, -NHCOR₇, -NHSO₂R₇, -NHP(O)(R₇)₂, -COR₈, -SO₂R₈, -NR₈R₈, carboxy, alkylcarbonyl of 2-7 carbon atoms, formylalkyl of 2-7 carbon atoms, phosphoryl, alkoxycarbonylalkyl of 3-13 carbon atoms, carboxy-alkyl of 2-7 carbon atoms, alkylcarbonylalkyl of 2-13 carbon atoms, arylcarbonyl-alkyl having 1-6 carbon atoms in the alkyl chain, Het-carbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminocarbonylalkyl of 2-7 carbon atoms, alkyl-aminocarbonylalkyl of 3-13 carbon atoms, arylaminocarbonylalkyl having 1-6 carbon atoms in the alkyl chain, Het-aminocarbonylalkyl having 1-6 carbon atoms in the alkyl chain, aminosulfonylalkyl of 1-6 carbon atoms, alkylsulfonylalkyl of 2-12 carbon atoms, arylsulfonylalkyl having 1-6 carbon atoms in the alkyl chain, alkylaminosulfonylalkyl of 2-12 carbon atoms, arylaminosulfonylalkyl of 1-6 carbon atoms, Het-aminosulfonylalkyl of 1-6 carbon atoms, phosphonylalkyl of 1-6 carbon atoms, or phosphorylalkyl of 1-6 carbon atoms; or R₅ and R₆ may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R₅ and R₆ are attached to a common carbon atom;
- R₇ is hydrogen, trifluoromethyl, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, aryl, alkoxy of 1-6 carbon atoms, -NR₈R₉, or -NR₉(CH₂)_p-R₈
- R₈ is hydrogen, alkoxy of 1-6 carbon atoms, alkyl of 1-6 carbon atoms, hydroxy, aryl substituted with R₅ and R₆, arylalkoxy having 1-6 carbon atoms in the alkyl chain, -CR₃R₅R₆, -(CH₂)_p-COR₉, or -(CH₂)_p-R₉;
- R₉ is hydrogen, hydroxy, alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, alkoxy of 1-6 carbon atoms, aryl substituted with R₅ and R₆, Het substituted with R₅ and R₆, arylalkoxy having 1-6 carbon atoms in the alkyl chain, or -NR₁₀R₁₀;
- R₁₀ is hydrogen, alkyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, hydroxy, aryl substituted with R₅ and R₆, or Het substituted with R₅ and R₆;
- Het is a monocyclic or bicyclic heterocycle of 5-10 ring atoms, having 1-4 heteroatoms selected from oxygen, nitrogen, and sulfur; wherein the heterocycle may be saturated, unsaturated, or partially unsaturated; and may be optionally fused to a phenyl ring; wherein one or more of the ring carbon atoms of Het may be a

carbonyl moiety, where the ring does not contain a double bond in the position corresponding to that carbon atom;

m is 1-3;

n is 1-3;

5 p is 0-6;

or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1 wherein R₂ is hydrogen.

10 3. A compound according to Claim 1 or Claim 2 wherein R₃ is hydrogen or COR₈.

4. A compound according to Claim 1 or Claim 2 wherein R₃ is hydrogen.

5. A compound according to any of Claims 1 to 4 wherein m is 2 and n is 2.

15 6. A compound according to any of Claims 1 to 5 wherein R₄ is aryl substituted with R₅ and R₆, Het substituted with R₅ and R₆, -NHCOR₇, -NR₈R₈, or -CR₃R₅R₆.

7. A compound according to any of Claims 1 to 6 wherein R₅ and R₆ are each,
20 independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, alkoxy of 1-6 carbon atoms, arylalkoxy having 1-6 carbon atoms in the alkyl chain, -COR₈, alkoxycarbonylalkyl of 3-13 carbon atoms, or carboxyalkyl of 2-7 carbon atoms, or R₅ and R₆ may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R₅ and R₆ are attached to a
25 common carbon atom.

8. A compound according to any of Claims 1 to 7 wherein R₇ = NR₈R₈.

9. A compound according to any of Claims 1 to 8 wherein R₈ is hydrogen, alkoxy of
30 1-6 carbon atoms, alkyl of 1-6 carbon atoms, hydroxy, aryl substituted with R₅ and R₆, arylalkoxy having 1-6 carbon atoms in the alkyl chain, -CR₃R₅R₆, -(CH₂)_p-COR₉, or -(CH₂)_p-R₉.

10. A compound according to any of Claims 1 to 9 wherein R₉ is hydroxy, alkoxy of 1-
35 6 carbon atoms, aryl substituted with R₅ and R₆, or arylalkoxy having 1-6 carbon atoms in the alkyl chain.

11. A compound according to Claim 1, wherein;

R₂ is hydrogen;

R₄ is alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, cycloalkyl of 3-8 carbon atoms, aryl substituted with R₅ and R₆, Het substituted with R₅ and R₆, -NHCOR₇, -NR₈R₈, or -CR₃R₅R₆;

R₃, R₅, and R₆ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, hydroxy, alkoxy of 1-6 carbon atoms, arylalkoxy having 1-6 carbon atoms in the alkyl chain, hydroxyamino, arylalkyl having 1-6 carbon atoms in the alkyl chain, Het-alkyl having 1-6 carbon atoms in the alkyl chain, -NHCOR₇, -NHSO₂R₇, -NR₈R₈, -COR₈, formylalkyl of 2-7 carbon atoms, alkoxycarbonylalkyl of 3-13 carbon atoms, or carboxyalkyl of 2-7 carbon atoms, or R₅ and R₆ may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R₅ and R₆ are attached to a common carbon atom;

Het is (a) a 6-membered saturated, partially unsaturated, or unsaturated heterocycle containing 1-2 nitrogens, optionally fused to a phenyl ring; (b) a 5-membered saturated, partially saturated, or unsaturated heterocycle containing 1-3 nitrogen, oxygen, or sulfur atoms, optionally fused to a phenyl ring; (c) a saturated, partially unsaturated, or unsaturated bicyclic heterocycle containing 1-4 nitrogen, oxygen, or sulfur atoms; (d) carbazole, dibenzofuran, and dibenzothiophene; wherein one or more of the ring carbon atoms of Het as described in (a), (b), or (c) may be a carbonyl moiety, where the ring does not contain a double bond in the position corresponding to that carbon atom;

or a pharmaceutically acceptable salt thereof.

12. A compound according to Claim 1 wherein;

Y is OCH₂ or a bond;

R₂ is hydrogen;

R₄ is aryl substituted with R₅ and R₆, Het substituted with R₅ and R₆, -NHCOR₇, -NR₈R₈, or -CR₃R₅R₆;

R₃, R₅, and R₆ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, halogen, hydroxy, alkoxy of 1-6 carbon atoms, arylalkoxy having 1-6 carbon atoms in the alkyl chain,

hydroxyamino, -NHSO₂R₇, -NR₈R₈, -COR₈, formylalkyl of 2-7 carbon atoms, alkoxyalkyl of 3-13 carbon atoms, or carboxyalkyl of 2-7 carbon atoms, or R₅ and R₆ may be alkylene groups that are taken together to form a 3-8 membered cycloalkyl ring when R₅ and R₆ are attached to a common carbon atom;

Het is pyridine, pyrimidine, furan, imidazolyl, thiazole, oxazole, isoxazole, pyrazole, triazole, tetrazole, carbazole, pyrrole, thiophene, imidazole, imidazol-2-one, imidazole-2-thione, imidazolidine-2,4-dione, pyrazoline, triazole, tetrazole, oxazolone, oxadiazole, imidazolone, thiazole, thiazolone, thiadiazole, thiadiazolone, thiazoladine-2,4-dione, pyridine, pyrimidine, piperazine, pyrazine, pyrrolidine, piperidine, morpholine, benzofuran, dibenzofuran, dibenzothiophene, isobenzofuran, indole, isoindole, benzothiophene, 1,3-dihydrobenzoimidazol-2-one, benzo[1,2,5]thiadiazole, 2-oxo-2,3-dihydro-1H-benzoimidazole, quinoline, or isoquinoline;

or a pharmaceutically acceptable salt thereof.

13. A compound according to Claim 1 which is one of the following:

- a) N-Benzyl-N-(3,4-dimethoxy-phenyl)-4-{4-[2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- 20 b) N-Benzyl-N-butyl-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide ;
- c) N-Benzyl-N-butyl-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- d) N-Benzyl-4-{4-[2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- 25 e) N-Benzyl-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- f) N-Benzyl-4-{4-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- 30 g) N-(3,4-Dimethoxy-phenyl)-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- h) N-(3,4-Dimethoxy-phenyl)-4-{4-[2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- i) 4-{4-[(2S)-3-(4-Benzoyloxy-phenoxy)-2-hydroxy-propylamino]-piperidin-1-yl}-N-(3,4-dimethoxy-phenyl)-benzenesulfonamide;
- 35

- j) 4-{4-[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxy-propylamino]-piperidin-1-yl}-N-(3,4-dimethoxy-phenyl)-benzenesulfonamide;
- k) N-(3,4-Dimethoxy-phenyl)-4-{4-[(2S)-2-hydroxy-3-(4-hydroxy-phenoxy)-propyl-amino]-piperidin-1-yl}-benzenesulfonamide;
- 5 l) N-Butyl-4-{4-[(2S)-2-hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)-propylamino]-piperidin-1-yl}-benzenesulfonamide;
- m) N-Butyl-4-{4-[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxy-propylamino]piperidin-1-yl}-benzenesulfonamide;
- n) N-Butyl-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonamide;
- 10 o) 1-(4-{4-[2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester;
- p) 1-(4-{4-[2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)propylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid isopropyl ester;
- 15 q) 1-(4-{4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yloxy)propyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid methylamide;
- r) 1-(4-{4-[2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid;
- s) [Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid benzyl ester;
- 20 t) [Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid;
- u) (2R)-1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester;
- 25 v) (2S)-1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-2-carboxylic acid benzyl ester;
- w) [Butyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethyl-amino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester-1-yl)-phenyl)-amino]-acetic acid;
- 30 x) N-(2-Hydroxyethyl)-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;
- y) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-methyl-amino]-acetic acid ethyl ester;
- 35 z) N-Cyclopropylmethyl-4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonamide;

- aa) 4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-N-isobutyl-benzenesulfonamide;
- bb) [Cyclopropylmethyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid ethyl ester;
- 5 cc) 4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-N-isopropyl-benzenesulfonamide;
- dd) 1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid ethyl ester;
- ee) [Cyclopropylmethyl-(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)-ethylamino]-piperidin-1-yl}-benzenesulfonyl)-amino]-acetic acid;
- 10 ff) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-isobutyl-amino]-acetic acid ethyl ester;
- gg) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-methyl-amino]-acetic acid;
- 15 hh) [(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-isobutyl-amino]-acetic acid;
- ii) 1-(4-{4-[(2R)-2-Hydroxy-2-(4-hydroxy-3-methanesulfonylamino-phenyl)ethylamino]-piperidin-1-yl}-benzenesulfonyl)-pyrrolidine-(2R)-2-carboxylic acid;
- jj) ethyl(2S)-1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethylamino]-1-piperidinyl}phenyl)sulfonyl]-2-pyrrolidinecarboxylate;
- 20 kk) ethyl(2S)-2-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]-phenyl)ethylamino]-1-piperidinyl}phenyl)sulfonyl]amino)-4-methylpentanoate;
- ll) ethyl(2S)-2-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]-phenyl)ethylamino]-1-piperidinyl}phenyl)sulfonyl]amino)-3-methylbutanoate;
- 25 mm) (2S)-1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-[(methylsulfonyl)amino]phenyl)-ethylamino]-1-piperidinyl}phenyl)sulfonyl]-2-pyrrolidinecarboxylic acid;
- nn) ethyl 1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-nyl)phenyl)sulfonyl]amino}-cyclopentanecarboxylate;
- oo) N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({1-[4-(1-pyrrolidinylsulfonyl)phenyl]-4-piperidinyl}amino)ethyl]phenyl}methanesulfonamide;
- 30 pp) N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({1-[4-(1-piperidinylsulfonyl)phenyl]-4-piperidinyl}amino)ethyl]phenyl}methanesulfonamide;
- qq) Ethyl 1-[(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-nyl)phenyl)sulfonyl]amino}cyclohexanecarboxylate;
- 35 rr) Ethyl [(4-{4-[(2R)-2-hydroxy-2-(4-hydroxy-3-idinyl)phenyl)sulfonyl](isopropyl)-amino}acetate;

- ss) N-[2-Hydroxy-5-(1-hydroxy-2-{1-[4-(toluene-4-sulfonyl)-phenyl]-piperidin-4-yl-amino}-ethyl)-phenyl]-methanesulfonamide;
- tt) 4-((2S)-2-Hydroxy-3-{1-[4-(toluene-4-sulfonyl)-phenyl]-piperidin-4-ylamino}-propoxy)-1,3-dihydro-benzoimidazol-2-one;
- 5 uu) 2-(2-butynyl)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-4-hexynoic acid tert-butyl ester;
- vv) 2-(2-butynyl)-2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]-4-hexynoic acid;
- ww) 1-(4-{4-[(2S)-2-Hydroxy-3-(2-oxo-2,3-dihydro-1H-benzoimidazol-4-yl)oxy]propyl-amino]-piperidin-1-yl)-benzenesulfonyl)-imidazolidine-2,4-dione;
- 10 xx) N-[5-((1R)-2-{1-[4-(2,4-Dioxo-imidazolidine-1-sulfonyl)phenyl]piperidin-4-ylamino}-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide;
- yy) 1-(4-{4-[(2S)-2-Hydroxy-2-(2-trifluoromethyl-thiazol-4-yl)-ethylamino]-piperidin-1-yl)-benzenesulfonyl)-imidazolidine-2,4-dione;
- 15 zz) *tert*-Butyl 2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]-phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino)acetate;
- aaa) 2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)-amino]-1-piperidinyl}phenyl)sulfonyl]amino)acetic acid;
- bbb) *tert*-Butyl 2-[[2-(*tert*-butoxy)-2-oxoethyl][(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino)-acetate;
- 20 ccc) 2-[(Carboxymethyl)[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]phenyl}ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino)acetic acid;
- ddd) Ethyl 2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino)acetate;
- 25 eee) Methyl 2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino]-1-piperidinyl}phenyl)sulfonyl]amino)acetate;
- fff) Ethyl 2-[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino]piperidin-1-yl}phenyl)sulfonyl]amino)acetylcarbamate;
- 30 ggg) *tert*-Butyl [[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}-ethyl)amino]piperidin-1-yl}phenyl)sulfonyl](methoxycarbonyl)amino]acetate;
- hhh) [(4-{4-[(2R)-2-Hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)-amino]piperidin-1-yl}phenyl)sulfonyl](methoxycarbonyl)amino)acetic acid;
- iii) Ethyl [(2,5-difluorobenzyl)[(4-{4-[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)-amino]phenyl}ethyl)amino]piperidin-1-yl}phenyl)sulfonyl]amino)acetate;
- 35

- jij) 1-[4-(((Butylamino)carbonyl)amino)sulfonyl]phenyl]-4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino)piperidine ;
 kkk) 2-((2,5-Difluorobenzyl)[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino)-1-piperidinyl}phenyl)sulfonyl]amino)acetic acid;
 5 lll) Ethyl {4-[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino)piperidin-1-yl}phenyl)sulfonyl]piperazin-1-yl}acetate;
 mmm) {4-[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino)piperidin-1-yl}phenyl)sulfonyl]piperazin-1-yl}acetic acid;
 nnn) N-(2-Hydroxy-5-((1*R*)-1-hydroxy-2-[(1-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl)-piperidin-4-yl]amino)ethyl)phenyl)methanesulfonamide; or
 10 ooo) tert-Butyl ((2,5-difluorobenzyl)[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino)piperidin-1-yl}phenyl)sulfonyl]amino)acetate;
 or a pharmaceutically acceptable salt thereof; and
 {4-[(4-{4-(((2*R*)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino)-piperidin-1-yl}phenyl)sulfonyl]piperazin-1-yl}acetic acid, sodium salt.
 15

14. A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises providing to said mammal, an effective amount of a compound of formula I as defined in any of Claims 1 to 13.

20

15. A method of treating or inhibiting type II diabetes in a mammal in need thereof which comprises providing to said mammal, an effective amount of a compound of formula I as defined in any of Claims 1 to 13.

25 16. A method of modulating glucose levels in a mammal in need thereof which comprises providing to said mammal, an effective amount of a compound of formula I as defined in any of Claims 1 to 13.

30 17. A method of treating or inhibiting urinary incontinence in a mammal in need thereof which comprises providing to said mammal an effective amount of a compound of formula I as defined in any of Claims 1 to 13.

35 18. A method of treating or inhibiting atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, or ocular hypertension in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula I as defined in any of Claims 1 to 13.

19. A method of increasing the lean meat to fat ratio in a mammal in need thereof, which comprises providing to said mammal an effective amount of a compound of formula I as defined in any of Claims 1 to 13.

5 20. Use of a compound of formula I as claimed in any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal.

10 21. Use of a compound of formula I as claimed in any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or inhibiting type II diabetes in a mammal.

15 22. Use of a compound of formula I as claimed in any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for modulating glucose levels in a mammal.

20 23. Use of a compound of formula I as claimed in any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or inhibiting urinary incontinence in a mammal.


25 24. Use of a compound of formula I as claimed in any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or inhibiting atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, or ocular hypertension in a mammal.

25 25. Use of a compound of formula I as claimed in any one of Claims 1 to 13 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for increasing the lean meat to fat ratio in a mammal.


30 26. A pharmaceutical composition which comprises a compound of formula I as defined in any one of Claims 1 to 13 and a pharmaceutically acceptable carrier.

27. A process for preparing a compound of formula I as defined in Claim 1 which comprises one of the following:

35 a) reductively aminating a compound of formula




wherein W, X, R₃ and R₄ are as defined in Claim 1 with a compound of formula



wherein R₁ and Y are as defined in Claim 1 to give a compound of formula I as defined

5 in Claim 1 wherein R₂ is hydrogen;


or b) reacting a compound of formula




wherein R₁, Y, W, X, R₃ and R₄ are as defined in Claim 1 with an organometallic agent,

10 e.g. of formula R₂M where M is an alkali metal, MgBr, ZnCl₂ to give a compound of formula I wherein R₂ is trifluoromethyl, alkyl of 1-6 carbons, alkenyl of 2-7 carbons, alkynyl of 2-7 carbons or cycloalkyl of 4-8 carbons;

or c) reacting a compound of formula



15 wherein R₁ and Y are as defined in Claim 1 with a compound of formula



wherein W, X, Z and R₃ are as defined in Claim 1 to give a compound of formula I

wherein R₂ is hydrogen; or

20

- d) removing a protecting group from a compound of formula I in which at least one substituent carries a protecting group to give a compound of formula I;
- or e) converting a basic compound of formula I to a salt thereof by reaction with a pharmaceutically acceptable acid;
- 5 or f) converting a compound of formula I having one or more reactive substituent groups to a different compound of formula I;
- or g) isolating an isomer of a compound of formula I from a mixture thereof.

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 01/22379

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12 C07D211/58 C07D401/14 C07D417/14 A61P3/10
 A61P13/00 A61P29/00 A61K31/4545

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 65895 A (MARSAULT ERIC ; SANOFI SYNTHELABO (FR); CROCI TIZIANO (IT); GUZZI U) 23 December 1999 (1999-12-23) Examples 9-12, 15 and claims 1, 3, 7	1-26
P, X	WO 01 17989 A (SANOFI SYNTHELABO ; CECCHI ROBERTO (IT); OLIVA AMBROGIO (IT)) 15 March 2001 (2001-03-15) Examples 5-7, 10 and claims 1-2, 6-7, 12-13	1-7, 11, 14-27
P, X	WO 01 43744 A (SANOFI SYNTHELABO ; CECCHI ROBERTO (IT)) 21 June 2001 (2001-06-21) Examples 2-11, 13, 17-19 and claims 1, 3, 5-6, 8-9	1-7, 11, 12, 14-27
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

22 November 2001

Date of mailing of the international search report

07/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Diederens, J

INTERNATIONAL SEARCH REPORT

onal Application No
PCT/US 01/22379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	B. HU ET AL.: "(4-Piperidin-1-yl)phenyl Amides: Potent and selective human beta-3 agonists" J. MED. CHEM., vol. 44, no. 9, 26 April 2001 (2001-04-26), pages 1456-1466, XP002183767 compound 2 -----	1-7, 11, 14-27

INTERNATIONAL SEARCH REPORT

onal Application No
PCT/US 01/22379

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9965895	A	23-12-1999	FR 2780057 A1 AU 4048299 A EP 1087961 A1 WO 9965895 A1	24-12-1999 05-01-2000 04-04-2001 23-12-1999
WO 0117989	A	15-03-2001	FR 2798126 A1 AU 7425900 A WO 0117989 A2	09-03-2001 10-04-2001 15-03-2001
WO 0143744	A	21-06-2001	FR 2802531 A1 FR 2802529 A1 AU 2525801 A WO 0143744 A1	22-06-2001 22-06-2001 25-06-2001 21-06-2001